ClinicalTrials.gg
CompletedNCT03192176Updated Nov 26, 2024Results posted

A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

A Phase 2 interventional study of Fezolinetant and Placebo in Menopause and Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Completed at 51 sites in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
6th of 16
356 · median 249
Started
2017
the only one that year
Phase 2
5 of 16
1 open now
Registered
1st of 16
by date
Lead sponsor
6 of 16
Astellas Pharma Global Development, Inc.

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 1st registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.

Read the detailed description

This was a 12-week randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multi-center study to assess the efficacy of ESN364 in postmenopausal women suffering from vasomotor symptoms (hot flashes).

This study consisted of a screening period (Days -35 to -1, including the screening visit [Visit 1] and a minimum 7-day collection of baseline vasomotor symptom frequency and severity assessments), a 12 week treatment period (Day 1 [Visit 2] to Week 12 [Visit 5]), and a follow up visit (Week 15 [Visit 6]) 3 weeks after the last dose of study drug.

The study was performed on an ambulatory basis. The screening visit (Visit 1) occurred up to 35 days prior to randomization. Eligibility was assessed via physical examination, clinical laboratory testing, vital signs, ECG, Pap smear, mammography, and endometrial biopsy. Subjects received an electronic diary to record daily vasomotor symptoms during the duration of the screening period. Subjects who had ≥7 consecutive days of vasomotor symptom recordings participated in the study. Subjects are encouraged to continue recording for the duration of the whole screening period. The electronic diary was reviewed by study site staff on Day 1 (Visit 2) to confirm study eligibility. Subjects were rescreened 1 time upon approval of the medical monitor.

During the treatment period, subjects returned to the study site every 4 weeks for assessments.

The follow-up visit occurred approximately 3 weeks following the last dose of study drug.

03

Conditions studied

  • Menopause
  • Hot Flashes

Browse trials for

Keywords

  • Vasomotor symptoms
  • Menopause
  • Hot flashes
  • Perimenopause
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women >40 years and ≤65 years of age at the screening visit;
  • A between 18 kg/sqm to 38 kg/sqm (extremes included);
  • Spontaneous amenorrhea for ≥12 consecutive months; or spontaneous amenorrhea for ≥6 months with biochemical criteria of menopause (follicle-stimulating hormone [FSH] >40 IU/L); or having had bilateral oophorectomy ≥6 weeks prior to the screening visit (with or without hysterectomy);
  • At least 50 moderate to severe vasomotor symptoms per week (ie, 7 consecutive days), as recorded in the daily diary during the screening period;
  • In good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and within the reference range for the population studied, or showing no deviations, as judged by the Investigator;
  • Women >40 years of age who have documentation of a normal/negative or no clinically significant findings mammogram (obtained at Screening or within the prior 9 months of trial enrollment.) Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings;
  • Willing to undergo a transvaginal ultrasound to assess endometrial thickness at Screening and at Week 12 (end-of-treatment, - and subjects) who are withdrawn from the study prior to completion, at the Early Termination (ET) Visit. This is not required for subjects who have had a partial (supracervical) or full hysterectomy;
  • Willing to undergo an endometrial at Screening (in the event that the subject's transvaginal ultrasound shows endometrial thickness ≥4 mm) and at Week 12 (end--of--treatment) - all subjects), for subjects with uterine bleeding, and for subjects who are withdrawn from the study prior to completion, at the ET Visit if study drug exposure is ≥10 weeks. This is not required for subjects who have had a partial (supracervical) or full hysterectomy;
  • Negative alcohol breath test and negative urine test for selected drugs of abuse (amphetamines, tricyclic antidepressants, cocaine, or opiates) at the screening visit;
  • Negative urine pregnancy test;
  • Negative serology panel (including surface antigen, virus antibody, and antibody screens);
  • Form signed voluntarily before any study-related procedure is performed, indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study; and
  • Documentation of a normal Pap smear (or equivalent cervical cytology) or of no clinical significance in the opinion of the Investigator within the previous 9 months or at Screening.

Exclusion criteria

Exclusion Criteria:

  • Use of a prohibited therapy (hormone therapy, hormonal , or vasomotor symptom medication [prescription, over the counter, or herbal]) or not willing to wash out drugs
  • History (in the past year) or presence of drug or alcohol abuse;
  • Previous or current history of a malignant tumor, except for basal cell carcinoma;
  • Uncontrolled hypertension and a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg;
  • Judged by the Investigator to be unsuited to participate in the study based on findings observed during physical examination, vital sign assessment, or 12-lead (ECG);
  • History of severe allergy, , or intolerance to drugs in general, including the study drug and any of its ;
  • Exclusion criterion 7 has been removed in Amendment 1;
  • An unacceptable result from endometrial (performed when endometrial thickness is ≥ 4mm measured by transvaginal ultrasound) of endometrial hyperplasia, endometrial cancer, or inadequate specimen at Screening (1 repeat biopsy permitted if technically possible);
  • History of endometrial hyperplasia or uterine/endometrial cancer;
  • History of unexplained uterine bleeding;
  • History of seizures or other convulsive disorders;
  • Medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [eg, moderate asthma], endocrine, or gynecological disease) or that could confound interpretation of the study outcome;
  • Presence or sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion (ADME) mechanisms of drugs as judged by the Investigator;
  • Active liver disease or jaundice, or values of (ALT) and aspartate aminotransferase (AST) >1.5 x the (ULN); or total >1.5 x ULN; or creatinine >1.5 x ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease formula ≤59 mL/min/1.73 sqm at the screening visit;
  • Concurrent participation in another interventional study (or participation within 3 months prior to screening in this study);
  • Suicide attempt in the past 3 years;
  • Unable or unwilling to complete the study procedures; or
  • Subject is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof, who is directly involved in the conduct of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
356 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.

    Drug: Fezolinetant

  • Experimental
    Fezolinetant 15 mg

    Participants received fezolinetant 15 mg capsules orally, BID for a period of 12 weeks.

    Drug: Placebo

  • Experimental
    Fezolinetant 30 mg

    Participants received fezolinetant 30 mg capsules orally, BID for a period of 12 weeks.

    Drug: Fezolinetant

  • Experimental
    Fezolinetant 60 mg

    Participants received fezolinetant 60 mg capsules orally, BID for a period of 12 weeks.

    Drug: Fezolinetant

  • Experimental
    Fezolinetant 90 mg

    Participants received fezolinetant 90 mg capsules orally, BID for a period of 12 weeks.

    Drug: Fezolinetant

  • Experimental
    Fezolinetant 30 mg + Placebo

    Participants received fezolinetant 30 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.

    Drug: Fezolinetant

  • Experimental
    Fezolinetant 60 mg + Placebo

    Participants received fezolinetant 60 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.

    Drug: Fezolinetant

  • Experimental
    Fezolinetant 120 mg + Placebo

    Participants received fezolinetant 120 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.

    Drug: Fezolinetant

Interventions

  • Oral Capsule

    Also known as: ESN364

  • DrugPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Baseline and week 4

  2. Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Baseline and week 12

  3. Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4

    Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.

    Time frame: Baseline and week 4

  4. Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12

    Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher scores indicates greater severity.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  2. Change From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15

  3. Change From Baseline in The Mean Severity of Mild, Moderate, and Severe VMS to Each Study Week

    Severity of mild, moderate \& severe VMS per day was calculated as follows \[(number of mild VMS × 1) + (number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily mild/moderate/severe VMS Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot \& was sweating \& needed to take action Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  4. Change From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week

    Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for patients that had no moderate or severe VMS. Higher score indicates greater severity.

    Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15

  5. Change From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week

    The hot flash score per 24h (or 12 h day time or 12 h night time) of VMS (mild, moderate, and severe) is calculated as follows: (number of mild VMS x 1) + (number of moderate VMS x 2) + (number of severe VMS x 3). Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Higher score indicates greater severity.

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  6. Change From Baseline in The Hot Flash Score of Moderate and Severe VMS to Each Study Week

    The hot flash score per 24h of moderate and severe VMS is calculated as follows: (number of moderate VMS x 2) + (number of severe VMS x 3). Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). VMS. Baseline is the average frequency of 24h vasomotor symptom from 7 non-missing days prior to Day 1. Higher score indicates greater severity.

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  7. Mean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  8. Mean Percent Reduction of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  9. Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15

  10. Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  11. Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  12. Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  13. Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  14. Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  15. Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  16. Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  17. Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  18. Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  19. Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  20. Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  21. Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  22. Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  23. Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  24. Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  25. Change From Baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) at Weeks 4, 8, 12, and 15

    The HFRDIS is a 10-item scale that measures a woman's perceptions of the degree to which VMS interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, and enjoying life); the tenth item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory, which assess the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which VMS had interfered with each item during the previous 2-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score is the average of individual item scores (sum of items/10).

    Time frame: Baseline and weeks 4, 8, 12, and 15

  26. Leeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores at Weeks 4, 8, 12 and 15

    The LSEQ is a 10-item self-rated questionnaire that assesses a participants aspects of sleep and early morning behavior. The questions are grouped into 4 chronological areas: ease of getting to sleep, perceived quality of sleep, ease of awaking from sleep, and integrity of early morning behavior following wakefulness. The LSEQ is a visual analog scale that requires respondents to place marks on a group of 10 cm lines. Lines extend between extremes like "more difficult than usual" and "easier than usual." Responses are measured using a 100 mm scale and are averaged to a score for each domain. Higher scores indicates better sleep and better early morning behavior.

    Time frame: Weeks 4, 8, 12, and 15

  27. Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8, 12, and 15

    The GCS is a 21-item scale that provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item is rated by the participant according to its severity using a 4-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into 3 main independent symptom measures by summing up the individual item scores: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and VMS (items 19 to 20; score 0 to 6). Item 21 is a probe for sexual dysfunction. The total score can range from 0 to 63. Higher scores indicate worse symptoms.

    Time frame: Baseline and weeks 4, 8, 12, and 15

  28. Change From Baseline in Menopause-Specific Quality of Life (MENQoL) at Weeks 4, 8, 12, and 15

    The MENQoL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of 1 of 4 domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1 to 3), psychosocial (items 4 to 10), physical (items 11 to 26), and sexual (items 27 to 29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a 0 (not bothersome) to 6 (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a "1" and endorsement a "2," plus the number of the particular rating, so that the possible score on any item ranges from 1 to 8. Higher scores indicate that menopause symptoms are more bothersome.

    Time frame: Baseline and weeks 4, 8, 12, and 15

  29. Change Over Time From Baseline in Plasma Concentrations of Luteinizing Hormone (LH) at Week 12

    Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.

    Time frame: Baseline and week 12

  30. Change Over Time From Baseline in Plasma Concentrations of Follicle-Stimulating Hormone (FSH) at Week 12

    Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.

    Time frame: Baseline and week 12

  31. Change Over Time From Baseline in Plasma Concentrations of Estradiol (E2) at Week 12

    Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration. The analysis value for Estradiol was imputed as 73.4/2 = 36.7 when result was \< 73.4.

    Time frame: Baseline and week 12

  32. Change Over Time From Baseline in Plasma Concentrations of Sex Hormone-Binding Globulin (SHBG) at Week 12

    Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.

    Time frame: Baseline and week 12

07

Results

Posted Sep 29, 2021

Participant flow

Postmenopausal women participants 40 to 65 years of age who had at least 50 moderate to severe vasomotor symptoms (VMS) per week and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.

Participant flow — Overall Study
MilestonePlacebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Started4445444544454544
Treated4345434544434544
Completed3740383332343637
Not completed75612121197
Withdrew: Adverse event10453233
Withdrew: Lost to follow-up00123111
Withdrew: Physician decision10000210
Withdrew: Protocol deviation11002000
Withdrew: Withdrawal by subject34043442
Withdrew: Miscellaneous10111201

Outcome measures

PrimaryCo-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Baseline and week 4
Reported as:
Least squares mean · VMS per day
Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4
VMS per dayPlacebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4-4.2 ± 0.65-6.1 ± 0.65-7.2 ± 0.64-7.0 ± 0.62-7.7 ± 0.65-6.5 ± 0.65-7.2 ± 0.61-6.6 ± 0.63
Statistical analysis
  • Placebo BID vs Fezolinetant 15 mg BID · ANCOVA · p = 0.0240 (LS Means(LSM), standard errors(SE), confidence intervals(CI), \& p-values come from an ANCOVA model with CFB as the dependent variable \& treatment group, pooled center, smoking status as factors \& baseline measurement, baseline weight as covariates.) · Lsmean difference: -1.9 · 95% CI -3.56 to -0.25
  • Placebo BID vs Fezolinetant 30 mg BID · ANCOVA · p = 0.0004 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -3.0 · 95% CI -4.68 to -1.38
  • Placebo BID vs Fezolinetant 60 mg BID · ANCOVA · p = 0.0010 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.8 · 95% CI -4.44 to -1.14
  • Placebo BID vs Fezolinetant 90 mg BID · ANCOVA · p = <0.0001 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -3.5 · 95% CI -5.20 to -1.89
  • Placebo BID vs Fezolinetant 30 mg QD · ANCOVA · p = 0.0058 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.3 · 95% CI -4.00 to -0.68
  • Placebo BID vs Fezolinetant 60 mg QD · ANCOVA · p = 0.0003 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -3.0 · 95% CI -4.65 to -1.41
  • Placebo BID vs Fezolinetant 120 mg QD · ANCOVA · p = 0.0042 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.4 · 95% CI -4.06 to 0.76
PrimaryCo-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Baseline and week 12
Reported as:
Least squares mean · VMS per day
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12
VMS per dayPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12-5.3 ± 0.58-7.2 ± 0.54-7.5 ± 0.56-7.6 ± 0.55-8.0 ± 0.58-7.4 ± 0.58-7.9 ± 0.54-7.4 ± 0.57
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · ANCOVA · p = 0.0154 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -1.8 · 95% CI -3.30 to -0.35
  • Placebo vs Fezolinetant 30 mg BID · ANCOVA · p = 0.0043 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.1 · 95% CI -3.60 to -0.67
  • Placebo vs Fezolinetant 60 mg BID · ANCOVA · p = 0.0023 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.3 · 95% CI -3.76 to -0.83
  • Placebo vs Fezolinetant 90 mg BID · ANCOVA · p = 0.0005 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.6 · 95% CI -4.09 to -1.16
  • Placebo vs Fezolinetant 30 mg QD · ANCOVA · p = 0.0064 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.1 · 95% CI -3.52 to -0.58
  • Placebo vs Fezolinetant 60 mg QD · ANCOVA · p = 0.0005 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · -2.6: -2.6 · 95% CI -4.04 to -1.15
  • Placebo vs Fezolinetant 120 mg QD · ANCOVA · p = 0.0063 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -2.1 · 95% CI -3.52 to -0.59
PrimaryCo-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4

Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.

Time frame:
Baseline and week 4
Reported as:
Least squares mean · Score on a scale
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4-0.3 ± 0.15-0.8 ± 0.14-0.9 ± 0.15-1.2 ± 0.14-1.3 ± 0.15-0.7 ± 0.15-0.9 ± 0.14-1.0 ± 0.15
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · ANCOVA · p = 0.0215 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.5 · 95% CI -0.84 to -0.07
  • Placebo vs Fezolinetant 30 mg BID · ANCOVA · p = 0.0017 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.6 · 95% CI -1.01 to -0.24
  • Placebo vs Fezolinetant 60 mg BID · ANCOVA · p = <0.0001 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.8 · 95% CI -1.21 to -0.44
  • Placebo vs Fezolinetant 90 mg BID · ANCOVA · p = <0.0001 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -1.0 · 95% CI -1.37 to -0.59
  • Placebo vs Fezolinetant 30 mg QD · ANCOVA · p = 0.0322 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.4 · 95% CI -0.81 to -0.04
  • Placebo vs Fezolinetant 60 mg QD · ANCOVA · p = 0.0017 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.6 · 95% CI -0.99 to -0.23
  • Placebo vs Fezolinetant 120 mg QD · ANCOVA · p = 0.0004 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean differencce: -0.7 · 95% CI -1.08 to -0.31
PrimaryCo-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12

Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher scores indicates greater severity.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Score on a scale
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12-0.8 ± 0.16-1.0 ± 0.15-1.1 ± 0.16-1.3 ± 0.16-1.4 ± 0.17-0.9 ± 0.16-1.3 ± 0.15-1.1 ± 0.16
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · ANCOVA · p = 0.2324 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.3 · 95% CI -0.67 to -0.16
  • Placebo vs Fezolinetant 30 mg BID · ANCOVA · p = 0.0736 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.4 · 95% CI -0.80 to 0.04
  • Placebo vs Fezolinetant 60 mg BID · ANCOVA · p = 0.0080 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.6 · 95% CI -0.98 to -0.15
  • Placebo vs Fezolinetant 90 mg BID · ANCOVA · p = 0.0028 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.6 · 95% CI -1.07 to -0.22
  • Placebo vs Fezolinetant 30 mg QD · ANCOVA · p = 0.4647 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean differnce: -0.2 · 95% CI -0.58 to 0.26
  • Placebo vs Fezolinetant 60 mg QD · ANCOVA · p = 0.0160 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.5 · 95% CI -0.92 to -0.10
  • Placebo vs Fezolinetant 120 mg QD · ANCOVA · p = 0.0901 (LS Means, SE, CI, and p-values come from an ANCOVA model with change from baseline as the dependent variable and treatment group, pooled center, smoking status as factors and baseline measurement, baseline weight as covariates.) · Lsmean difference: -0.4 · 95% CI -0.78 to 0.06
SecondaryChange From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Least squares mean · VMS per day
Change From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week
VMS per dayPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1-2.0 ± 0.60-3.4 ± 0.56-4.7 ± 0.59-5.5 ± 0.58-6.1 ± 0.61-3.0 ± 0.61-4.4 ± 0.56-4.8 ± 0.59
Week 2-3.6 ± 0.62-4.9 ± 0.58-6.3 ± 0.61-6.8 ± 0.60-7.3 ± 0.63-5.1 ± 0.63-5.4 ± 0.59-6.0 ± 0.61
Week 3-3.8 ± 0.63-5.6 ± 0.60-6.8 ± 0.62-7.3 ± 0.617.7 ± 0.64-5.8 ± 0.64-6.1 ± 0.60-6.6 ± 0.62
Week 4-4.0 ± 0.63-5.7 ± 0.60-7.0 ± 0.62-7.2 ± 0.61-8.1 ± 0.64-6.0 ± 0.64-6.8 ± 0.60-7.1 ± 0.62
Week 5-4.6 ± 0.60-5.8 ± 0.57-7.2 ± 0.59-7.6 ± 0.58-8.5 ± 0.61-6.6 ± 0.61-6.8 ± 0.56-7.1 ± 0.59
Week 6-4.9 ± 0.60-6.2 ± 0.57-7.2 ± 0.59-8.0 ± 0.58-8.6 ± 0.62-6.6 ± 0.61-7.1 ± 0.57-7.6 ± 0.59
Week 7-4.9 ± 0.61-6.2 ± 0.58-7.4 ± 0.60-7.8 ± 0.59-8.7 ± 0.63-6.8 ± 0.62-7.2 ± 0.58-7.7 ± 0.60
Week 8-5.5 ± 0.61-6.2 ± 0.58-7.5 ± 0.60-8.1 ± 0.60-8.5 ± 0.63-6.8 ± 0.63-7.4 ± 0.58-7.8 ± 0.61
Week 9-5.8 ± 0.59-6.8 ± 0.55-7.5 ± 0.57-8.3 ± 0.57-8.7 ± 0.60-6.8 ± 0.60-7.7 ± 0.56-7.9 ± 0.58
Week 10-5.6 ± 0.60-7.0 ± 0.57-7.1 ± 0.59-8.3 ± 0.59-8.7 ± 0.62-7.2 ± 0.62-7.8 ± 0.58-8.0 ± 0.60
Week 11-5.7 ± 0.59-7.0 ± 0.56-7.5 ± 0.58-8.7 ± 0.58-8.6 ± 0.61-7.3 ± 0.60-8.0 ± 0.56-8.0 ± 0.59
Week 12-5.7 ± 0.58-7.1 ± 0.54-7.6 ± 0.57-8.5 ± 0.57-8.8 ± 0.59-7.4 ± 0.59-8.0 ± 0.55-8.1 ± 0.57
Week 13-4.7 ± 0.65-5.9 ± 0.58-5.1 ± 0.60-4.9 ± 0.63-5.7 ± 0.64-6.1 ± 0.65-5.9 ± 0.62-5.5 ± 0.61
Week 14-4.4 ± 0.65-5.2 ± 0.58-4.5 ± 0.60-4.5 ± 0.63-5.0 ± 0.64-5.6 ± 0.65-5.7 ± 0.63-5.1 ± 0.61
Week 15-4.9 ± 0.62-4.5 ± 0.56-4.7 ± 0.58-4.2 ± 0.62-4.5 ± 0.62-4.6 ± 0.64-5.6 ± 0.61-4.7 ± 0.59
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0865 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -2.92 to 0.20MMRM: Mixed Model Repeated Measures
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.22 to -1.10
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.00001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.5 · 95% CI -5.06 to -1.94
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.00001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.0 · 95% CI -5.63 to -2.47
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2360 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -2.55 to 0.63
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0032 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -3.92 to -0.80
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.29 to -1.19
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1318 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.86 to 0.38
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0014 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.30 to -1.04
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -3.2 · 95% CI -4.82 to -1.58
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.6 · 95% CI -5.30 to -2.00
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0752 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -3.15 to 0.15
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0343 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.38 to -0.13
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0049 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.95 to -0.71
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0285 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.50 to -0.20
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -4.69 to -1.37
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.5 · 95% CI -5.14 to -1.84
  • Placebo vs Fezolinetant 90 mg BID · MMRm · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.0 · 95% CI -5.65 to -2.28
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0169 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.74 to -0.37
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0049 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -4.04 to -0.73
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.48 to -1.18
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0428 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.36 to -0.06
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -4.65 to -1.34
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.00001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.2 · 95% CI -4.88 to -1.58
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.1 · 95% CI -5.73 to -2.37
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0225 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -3.64 to -0.28
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.49 to -1.19
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.70 to -1.42
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1168 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.80 to 0.31
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0012 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -4.15 to -1.03
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -4.54 to -1.42
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.9 · 95% CI -5.44 to -2.28
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0134 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -3.58 to -0.42
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0057 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.76 to -0.65
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0016 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -4.06 to -0.96
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0843 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -2.94 to 0.19
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0035 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.90 to -0.77
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.66 to -1.52
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.7 · 95% CI -5.28 to -2.10
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0315 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.33 to -0.16
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0063 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.75 to -0.62
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.25 to -1.14
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1090 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -2.89 to 0.29
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0018 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -4.14 to -0.95
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.9 · 95% CI -4.54 to -1.34
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.8 · 95% CI -5.40 to -2.15
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0231 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.9 · 95% CI -3.50 to -0.26
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0056 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.86 to -0.67
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.35 to -1.17
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3568 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -2.35 to 0.85
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0129 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -3.65 to -0.43
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0018 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -4.19 to -0.97
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.70 to -1.42
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -3.00 to 0.27
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0173 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -3.57 to -0.35
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0038 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -3.97 to -0.77
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1767 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -2.57 to 0.48
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0308 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.20 to -0.16
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0013 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -4.07 to -1.00
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.9 · 95% CI -4.47 to -1.36
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2109 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -2.55 to 0.56
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0152 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.9 · 95% CI -3.44 to -0.37
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0075 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.61 to -0.56
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0869 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -2.96 to 0.20
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0520 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.14 to 0.01
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.30 to -1.12
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.68 to -1.46
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0456 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.25 to -0.03
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0073 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.76 to -0.59
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0026 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -4.01 to -0.86
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0878 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -2.87 to 0.20
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0182 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.9 · 95% CI -3.39 to -0.32
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -4.55 to -1.44
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -4.53 to -1.40
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0387 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.22 to -0.09
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0031 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.89 to -0.80
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0029 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.88 to -0.81
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0653 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -2.90 to 0.09
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0102 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -3.46 to -0.47
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.9 · 95% CI -4.38 to -1.36
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.2 · 95% CI -4.72 to -1.67
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0231 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.30 to -0.25
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -3.88 to -0.87
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -3.88 to -0.87
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0013 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -3.96 to -0.97
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1460 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.89 to 0.43
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.6066 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -2.10 to 1.23
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.8422 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -1.88 to 1.54
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.2346 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -2.74 to 0.67
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1128 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -3.11 to 0.33
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1811 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.89 to 0.55
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3521 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -2.45 to 0.87
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3570 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -2.44 to 0.88
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.9227 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.1 · 95% CI -1.73 to 1.57
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.8894 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -1.84 to 1.60
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.5074 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -2.29 to 1.13
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1753 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -1.2 · 95% CI -2.91 to 0.53
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1212 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -3.09 to 0.36
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3702 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -2.41 to 0.90
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.6459 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.4 · 95% CI -1.22 to 1.96
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.8248 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -1.40 to 1.75
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.4226 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.7 · 95% CI -0.98 to 2.33
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.6469 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.4 · 95% CI -1.25 to 2.01
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.7642 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.3 · 95% CI -1.41 to 1.91
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4068 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -2.36 to 0.966
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.7974 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -1.37 to 1.78
SecondaryChange From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15
Reported as:
Least squares mean · VMS per day
Change From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week
VMS per dayPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1-2.1 ± 0.59-3.8 ± 0.56-5.3 ± 0.58-5.7 ± 0.57-6.4 ± 0.60-3.3 ± 0.60-4.7 ± 0.56-4.7 ± 0.58
Week 2-3.7 ± 0.60-5.3 ± 0.57-6.8 ± 0.59-6.8 ± 0.58-7.3 ± 0.61-5.4 ± 0.61-6.0 ± 0.57-5.7 ± 0.59
Week 3-3.7 ± 0.61-5.8 ± 0.58-7.3 ± 0.60-7.0 ± 0.59-7.7 ± 0.62-6.3 ± 0.62-6.9 ± 0.58-6.3 ± 0.60
Week 5-4.5 ± 0.58-6.3 ± 0.55-7.6 ± 0.57-7.3 ± 0.56-8.3 ± 0.59-6.9 ± 0.59-7.3 ± 0.55-6.7 ± 0.57
Week 6-4.8 ± 0.58-6.6 ± 0.55-7.5 ± 0.57-7.6 ± 0.57-8.3 ± 0.60-7.0 ± 0.60-7.5 ± 0.55-7.1 ± 0.58
Week 7-4.9 ± 0.59-6.5 ± 0.56-7.7 ± 0.58-7.5 ± 0.58-8.4 ± 0.61-7.1 ± 0.60-7.4 ± 0.56-7.2 ± 0.59
Week 8-5.5 ± 0.59-6.6 ± 0.56-7.6 ± 0.58-7.7 ± 0.58-8.3 ± 0.61-7.1 ± 0.61-7.7 ± 0.56-7.3 ± 0.59
Week 9-5.7 ± 0.57-7.1 ± 0.54-7.7 ± 0.56-8.0 ± 0.56-8.4 ± 0.59-7.1 ± 0.59-7.9 ± 0.54-7.3 ± 0.57
Week 10-5.4 ± 0.59-7.2 ± 0.56-7.5 ± 0.58-7.9 ± 0.58-8.3 ± 0.61-7.4 ± 0.60-7.8 ± 0.56-7.6 ± 0.59
Week 11-5.5 ± 0.57-7.3 ± 0.54-7.8 ± 0.56-8.3 ± 0.56-8.3 ± 0.59-7.6 ± 0.58-8.0 ± 0.54-7.6 ± 0.57
Week 13-4.4 ± 0.65-6.4 ± 0.58-5.4 ± 0.60-5.3 ± 0.63-5.7 ± 0.64-6.8 ± 0.65-6.0 ± 0.62-5.2 ± 0.61
Week 14-4.1 ± 0.66-5.7 ± 0.60-4.5 ± 0.61-4.8 ± 0.65-5.0 ± 0.66-6.2 ± 0.67-5.8 ± 0.65-4.8 ± 0.63
Week 15-4.6 ± 0.65-5.1 ± 0.59-4.5 ± 0.60-4.5 ± 0.65-4.4 ± 0.65-5.6 ± 0.67-5.5 ± 0.65-4.4 ± 0.61
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0297 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.23 to -0.17
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.66 to -1.58
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.00001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.6 · 95% CI -5.10 to -2.02
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.2 · 95% CI -5.78 to -2.66
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1318 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.76 to 0.36
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0010 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -4.13 to -1.05
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0011 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -4.10 to -1.04
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0405 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.20 to -0.07
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.70 to -1.55
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -3.1 · 95% CI -4.66 to -1.52
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.7 · 95% CI -5.26 to -2.07
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0325 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.34 to -0.15
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0035 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -3.92 to -0.78
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0102 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.61 to -0.49
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0098 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.69 to -0.51
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.6 · 95% CI -5.18 to -1.98
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.3 · 95% CI -4.89 to -1.70
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.0 · 95% CI -5.61 to -2.37
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -4.17 to -0.93
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.71 to -1.52
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0020 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -4.11 to -0.93
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0210 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.27 to -0.27
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.1 · 95% CI -4.59 to -1.58
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.88 · 95% CI -4.34 to -1.33
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.8 · 95% CI -5.29 to -2.23
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0023 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -3.91 to -0.86
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.25 to -1.24
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0036 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.73 to -0.74
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0195 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.33 to -0.29
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.21 to -1.17
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.32 to -1.27
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.5 · 95% CI -5.01 to -1.92
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0061 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.71 to -0.62
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.19 to -1.14
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0030 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.81 to -0.78
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0383 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.17 to -0.09
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.33 to -1.24
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0011 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -4.14 to -1.04
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.5 · 95% CI -5.07 to -1.93
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0055 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.80 to -0.66
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0014 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -4.09 to -0.99
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0040 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.80 to -0.73
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1502 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -2.68 to 0.41
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0057 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.74 to -0.64
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0054 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.76 to -0.66
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.38 to -1.22
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0412 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.21 to -0.07
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0054 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.76 to -0.66
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0167 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.9 · 95% CI -3.43 to -0.34
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0533 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.94 to 0.02
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0065 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.54 to -0.58
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0025 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.80 to -0.82
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0005 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.7 · 95% CI -4.22 to -1.20
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0541 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.99 to 0.03
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0039 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.69 to -0.71
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0245 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.18 to -0.22
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0187 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.36 to -0.31
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0060 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.68 to -0.62
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0014 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -4.06 to -0.98
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.9 · 95% CI -4.49 to -1.37
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0100 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.61 to -0.49
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0019 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -3.98 to -0.91
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0049 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -3.73 to -0.67
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0186 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.25 to -0.30
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0024 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -3.77 to -0.82
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.28 to -1.30
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -4.30 to -1.29
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0058 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.63 to -0.62
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -4.04 to -1.7
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0050 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.59 to -0.64
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0205 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -3.63 to -0.31
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.2818 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -2.58 to 0.75
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3102 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -2.60 to 0.83
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.1422 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -2.99 to 0.43
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0064 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -4.12 to -0.68
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0752 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.28 to 0.16
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3632 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -2.43 to 0.89
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0625 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -1.6 · 95% CI -3.32 to 0.09
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6613 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -2.07 to 1.32
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.4209 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -2.48 to 1.04
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.3288 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.9 · 95% CI -2.63 to 0.88
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0202 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.1 · 95% CI -3.86 to -0.33
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0682 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.42 to 0.12
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3912 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -2.44 to 0.96
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.4964 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -2.25 to 1.09
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.9830 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -1.64 to 1.68
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9715 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -1.71 to 1.78
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.8715 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -1.58 to 1.86
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2233 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -2.83 to 0.66
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.2882 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -2.69 to 0.80
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.8643 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -1.52 to 1.80
SecondaryChange From Baseline in The Mean Severity of Mild, Moderate, and Severe VMS to Each Study Week

Severity of mild, moderate \& severe VMS per day was calculated as follows \[(number of mild VMS × 1) + (number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily mild/moderate/severe VMS Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot \& was sweating \& needed to take action Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Mean Severity of Mild, Moderate, and Severe VMS to Each Study Week
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1-0.2 ± 0.09-0.5 ± 0.08-0.5 ± 0.09-0.6 ± 0.09-0.8 ± 0.09-0.2 ± 0.09-0.5 ± 0.08-0.5 ± 0.09
Week 2-0.2 ± 0.11-0.6 ± 0.11-0.7 ± 0.11-1.0 ± 0.11-1.1 ± 0.11-0.4 ± 0.11-0.7 ± 0.11-0.8 ± 0.11
Week 3-0.3 ± 0.13-0.8 ± 0.12-0.9 ± 0.13-1.1 ± 0.12-1.2 ± 0.13-0.6 ± 0.13-0.9 ± 0.12-1.0 ± 0.13
Week 4-0.3 ± 0.13-0.8 ± 0.12-1.0 ± 0.13-1.1 ± 0.13-1.4 ± 0.13-0.8 ± 0.13-0.9 ± 0.12-1.1 ± 0.13
Week 5-0.5 ± 0.13-0.8 ± 0.13-1.0 ± 0.13-1.3 ± 0.13-1.5 ± 0.14-0.8 ± 0.14-0.9 ± 0.13-1.0 ± 0.13
Week 6-0.5 ± 0.14-0.9 ± 0.13-1.0 ± 0.14-1.4 ± 0.14-1.6 ± 0.14-0.8 ± 0.14-1.0 ± 0.13-1.2 ± 0.14
Week 7-0.5 ± 0.14-0.9 ± 0.14-1.1 ± 0.14-1.4 ± 0.14-1.6 ± 0.15-1.0 ± 0.14-1.0 ± 0.14-1.2 ± 0.14
Week 8-0.7 ± 0.15-1.0 ± 0.14-1.2 ± 0.15-1.5 ± 0.15-1.6 ± 0.15-0.9 ± 0.15-1.1 ± 0.15-1.3 ± 0.15
Week 9-0.8 ± 0.15-1.1 ± 0.14-1.1 ± 0.15-1.6 ± 0.15-1.6 ± 0.15-0.9 ± 0.15-1.2 ± 0.15-1.3 ± 0.15
Week 10-0.7 ± 0.15-1.2 ± 0.14-1.1 ± 0.15-1.5 ± 0.15-1.7 ± 0.15-1.0 ± 0.15-1.2 ± 0.14-1.4 ± 0.15
Week 11-0.7 ± 0.15-1.1 ± 0.14-1.1 ± 0.15-1.6 ± 0.15-1.8 ± 0.15-1.0 ± 0.15-1.2 ± 0.15-1.4 ± 0.15
Week 12-0.8 ± 0.15-1.2 ± 0.15-1.3 ± 0.15-1.6 ± 0.15-1.6 ± 0.16-1.0 ± 0.15-1.3 ± 0.15-1.3 ± 0.15
Week 13-0.1 ± 0.10-0.5 ± 0.09-0.3 ± 0.09-0.4 ± 0.09-0.3 ± 0.09-0.5 ± 0.10-0.4 ± 0.09-0.2 ± 0.09
Week 14-0.1 ± 0.10-0.3 ± 0.08-0.2 ± 0.09-0.3 ± 0.09-0.1 ± 0.09-0.4 ± 0.09-0.3 ± 0.09-0.2 ± 0.09
Week 150.0 ± 0.10-0.2 ± 0.09-0.2 ± 0.09-0.4 ± 0.10-0.1 ± 0.09-0.5 ± 0.10-0.3 ± 0.10-0.1 ± 0.09
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0104 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.53 to -0.07
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0060 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.56 to -0.09
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.71 to -0.24
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.85 to -0.38
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.6977 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.28 to 0.19
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0121 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.53 to -0.07
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0086 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.54 to -0.08
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0138 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.66 to -0.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0014 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.78 to -0.19
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.7 · 95% CI -1.02 to -0.43
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.19 to -0.59
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2831 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.46 to 0.14
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0051 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.72 to -0.13
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.81 to -0.22
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0058 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.83 to -0.14
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.97 to -0.28
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.14 to -0.46
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.27 to -0.57
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0807 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.66 to 0.04
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0014 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.91 to -0.22
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.02 to -0.34
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0046 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.85 to -0.16
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.99 to -0.29
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.14 to -0.45
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.14 to -0.70
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0209 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.77 to -0.06
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0011 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.93 to -0.24
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.07 to -0.38
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0956 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.67 to 0.05
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0050 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.89 to -0.16
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.18 to -0.45
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.40 to -0.65
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0915 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.69 to 0.05
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0378 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.75 to -0.02
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0053 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.89 to -0.16
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0614 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.83 to -0.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0040 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.92 to -0.18
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.33 to -0.58
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.47 to -0.71
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0967 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.70 to 0.06
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0063 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.90 to -0.15
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.13 to -0.38
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0632 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.75 to 0.02
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0020 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.00 to -0.23
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.29 to -0.51
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.48 to -0.69
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0308 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.82 to -0.04
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0105 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.89 to -0.12
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0010 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.03 to -0.26
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1469 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.69 to 0.11
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0315 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.84 to -0.04
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.18 to -0.38
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.26 to -0.43
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4494 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.56 to 0.25
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0595 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.79 to 0.02
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0065 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.96 to -0.16
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0745 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.77 to 0.04
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0540 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.80 to 0.01
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.22 to -0.41
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.26 to -0.43
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5317 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.54 to 0.28
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0424 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.83 to -0.01
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0134 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.91 to -0.11
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0300 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.84 to -0.04
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0605 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.78 to 0.02
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.20 to -0.40
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.38 to -0.56
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1848 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.68 to 0.13
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0321 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.84 to -0.04
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0025 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.01 to -0.22
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0441 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.81 to -0.01
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0422 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.82 to -0.01
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.27 to -0.45
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.44 to -0.62
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1464 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.71 to 0.11
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0144 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.91 to -0.10
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0013 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.06 to -0.26
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0596 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.80 to 0.02
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0360 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.85 to -0.03
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.15 to -0.32
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.23 to -0.39
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3227 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.62 to 0.21
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0220 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.89 to -0.07
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0380 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.84 to -0.02
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0067 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.60 to -0.10
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.1227 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.45 to 0.05
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0208 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.57 to -0.05
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.2396 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.41 to 0.10
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0022 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.67 to -0.15
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0479 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.53 to -0.00
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4152 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.35 to 0.15
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0262 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.3 · 95% CI -0.52 to -0.03
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1210 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.43 to 0.05
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0369 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.52 to -0.02
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.5855 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.1 · 95% CI -0.32 to 0.18
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0041 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.62 to -0.12
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0614 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.50 to 0.01
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3391 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.36 to 0.12
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0515 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.49 to 0.00
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0667 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.47 to 0.02
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0047 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.63 to -0.12
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.5130 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.34 to 0.17
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.75 to -0.23
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0126 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.60 to -0.07
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3507 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.36 to 0.13
SecondaryChange From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week

Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for patients that had no moderate or severe VMS. Higher score indicates greater severity.

Time frame:
Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1-0.1 ± 0.10-0.4 ± 0.09-0.5 ± 0.10-0.6 ± 0.10-0.8 ± 0.10-0.1 ± 0.10-0.4 ± 0.09-0.4 ± 0.10
Week 2-0.2 ± 0.12-0.5 ± 0.12-0.7 ± 0.12-1.0 ± 0.12-1.2 ± 0.13-0.3 ± 0.13-0.6 ± 0.12-0.8 ± 0.12
Week 3-0.2 ± 0.14-0.7 ± 0.14-1.0 ± 0.14-1.2 ± 0.14-1.3 ± 0.15-0.6 ± 0.14-0.8 ± 0.14-1.0 ± 0.14
Week 5-0.5 ± 0.15-0.8 ± 0.14-1.1 ± 0.15-1.4 ± 0.15-1.6 ± 0.15-0.9 ± 0.15-0.8 ± 0.14-1.1 ± 0.15
Week 6-0.5 ± 0.15-0.9 ± 0.15-1.1 ± 0.15-1.5 ± 0.15-1.6 ± 0.16-0.9 ± 0.15-1.0 ± 0.15-1.3 ± 0.15
Week 7-0.5 ± 0.15-0.9 ± 0.15-1.2 ± 0.15-1.5 ± 0.15-1.7 ± 0.16-1.0 ± 0.16-1.0 ± 0.15-1.2 ± 0.15
Week 8-0.7 ± 0.16-1.0 ± 0.15-1.2 ± 0.16-1.6 ± 0.16-1.6 ± 0.17-0.9 ± 0.16-1.2 ± 0.16-1.3 ± 0.16
Week 9-0.8 ± 0.16-1.1 ± 0.15-1.2 ± 0.16-1.6 ± 0.16-1.7 ± 0.16-0.9 ± 0.16-1.2 ± 0.15-1.3 ± 0.16
Week 10-0.8 ± 0.16-1.2 ± 0.15-1.2 ± 0.16-1.7 ± 0.16-1.8 ± 0.16-1.1 ± 0.16-1.2 ± 0.15-1.4 ± 0.16
Week 11-0.8 ± 0.16-1.1 ± 0.15-1.2 ± 0.16-1.7 ± 0.16-1.8 ± 0.16-1.1 ± 0.16-1.3 ± 0.15-1.5 ± 0.16
Week 13-0.1 ± 0.13-0.5 ± 0.12-0.3 ± 0.12-0.6 ± 0.13-0.3 ± 0.13-0.6 ± 0.13-0.4 ± 0.13-0.2 ± 0.12
Week 14-0.1 ± 0.13-0.3 ± 0.11-0.3 ± 0.11-0.5 ± 0.12-0.1 ± 0.12-0.5 ± 0.13-0.3 ± 0.13-0.2 ± 0.12
Week 150.0 ± 0.13-0.2 ± 0.12-0.3 ± 0.12-0.6 ± 0.13-0.1 ± 0.13-0.5 ± 0.13-0.4 ± 0.13-0.1 ± 0.12
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0098 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.60 to -0.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0048 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.63 to -0.11
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.80 to -0.28
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.00 to -0.47
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.6761 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.32 to 0.21
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0188 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.57 to -0.05
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0067 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.61 to -0.10
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0335 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.68 to -0.03
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.91 to -0.25
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.8 · 95% CI -1.14 to -0.48
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.41 to -0.74
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3227 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.50 to 0.17
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0085 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.77 to -0.11
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.95 to -0.30
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0102 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.87 to -0.12
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.15 to -0.39
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.29 to -0.54
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.46 to -0.68
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0740 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.73 to 0.03
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0024 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.97 to -0.21
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.17 to -0.41
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1197 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.72 to 0.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0046 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.98 to -0.18
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.28 to -0.47
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.51 to -0.69
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0553 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.80 to 0.01
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0823 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.76 to 0.05
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0060 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.96 to -0.16
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0374 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.83 to -0.03
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0042 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.00 to -0.19
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.38 to -0.56
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.54 to -0.71
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0710 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.79 to 0.03
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0160 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.91 to -0.09
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.15 to -0.34
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1013 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.76 to 0.07
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0011 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.11 to -0.28
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.36 to -0.53
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.57 to -0.72
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0476 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.85 to -0.00
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0220 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.90 to -0.07
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0019 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.07 to -0.24
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1457 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.74 to 0.11
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0284 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.91 to -0.05
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.26 to -0.39
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.36 to -0.48
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4223 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.61 to 0.26
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0442 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.87 to -0.01
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0071 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.02 to -0.16
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0823 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.80 to 0.05
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0336 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.89 to -0.04
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.32 to -0.46
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.34 to -0.47
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4819 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.59 to 0.28
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0371 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.88 to -0.03
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0121 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.97 to -0.12
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0281 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.89 to -0.05
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0436 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.86 to -0.01
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.34 to -0.49
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.47 to -0.60
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1488 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.75 to 0.11
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0251 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.91 to -0.06
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0027 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.08 to -0.23
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1053 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.77 to 0.07
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0304 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.90 to -0.04
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.33 to -0.43
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.49 to -0.61
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0873 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.81 to 0.06
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0124 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.97 to -0.12
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0014 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.12 to -0.27
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0479 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.68 to -0.00
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.2342 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.54 to 0.13
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0070 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.84 to -0.13
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.4291 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.49 to 0.21
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0076 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.83 to -0.13
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1506 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.62 to 0.10
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.5479 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.44 to 0.24
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1427 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.2 · 95% CI -0.57 to 0.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1498 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.56 to 0.09
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0103 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.79 to -0.11
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.8984 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.0 · 95% CI -0.36 to 0.32
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0095 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.79 to -0.11
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1370 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.60 to 0.08
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4223 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.46 to 0.19
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3265 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.50 to 0.17
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0852 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.62 to 0.04
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.91 to -0.21
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.5717 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.45 to 0.25
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0084 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.82 to -0.12
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0277 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.75 to -0.04
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4627 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.46 to 0.21
SecondaryChange From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week

The hot flash score per 24h (or 12 h day time or 12 h night time) of VMS (mild, moderate, and severe) is calculated as follows: (number of mild VMS x 1) + (number of moderate VMS x 2) + (number of severe VMS x 3). Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Higher score indicates greater severity.

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1-5.0 ± 1.48-9.8 ± 1.39-12.9 ± 1.45-14.1 ± 1.42-15.5 ± 1.50-8.4 ± 1.50-11.9 ± 1.39-11.9 ± 1.45
Week 2-8.9 ± 1.50-13.0 ± 1.41-16.5 ± 1.47-17.0 ± 1.44-18.1 ± 1.52-13.5 ± 1.52-14.8 ± 1.41-14.5 ± 1.47
Week 3-8.9 ± 1.54-14.5 ± 1.45-17.6 ± 1.51-17.7 ± 1.48-19.1 ± 1.57-15.4 ± 1.56-16.6 ± 1.45-15.9 ± 1.51
Week 4-9.5 ± 1.53-14.9 ± 1.45-17.9 ± 1.51-17.6 ± 1.47-19.7 ± 1.57-15.9 ± 1.56-17.7 ± 1.45-17.1 ± 1.51
Week 5-10.6 ± 1.45-15.4 ± 1.37-18.4 ± 1.43-18.6 ± 1.40-20.5 ± 1.49-16.9 ± 1.48-17.8 ± 1.37-17.2 ± 1.44
Week 6-11.6 ± 1.44-16.4 ± 1.36-18.4 ± 1.42-19.4 ± 1.39-20.6 ± 1.48-16.9 ± 1.47-18.2 ± 1.36-18.1 ± 1.43
Week 7-11.8 ± 1.46-16.2 ± 1.38-18.9 ± 1.44-19.1 ± 1.41-20.9 ± 1.50-17.4 ± 1.49-18.2 ± 1.39-18.3 ± 1.45
Week 8-13.0 ± 1.46-16.3 ± 1.38-18.9 ± 1.44-19.5 ± 1.42-20.5 ± 1.51-17.4 ± 1.50-18.8 ± 1.39-18.7 ± 1.45
Week 9-13.6 ± 1.40-17.6 ± 1.32-19.0 ± 1.37-20.2 ± 1.36-20.9 ± 1.44-17.3 ± 1.43-19.3 ± 1.33-18.7 ± 1.39
Week 10-13.1 ± 1.44-17.9 ± 1.37-18.5 ± 1.42-20.1 ± 1.41-20.8 ± 1.49-18.2 ± 1.48-19.4 ± 1.38-19.1 ± 1.44
Week 11-13.2 ± 1.41-17.9 ± 1.33-19.2 ± 1.39-20.9 ± 1.38-20.8 ± 1.46-18.6 ± 1.45-19.9 ± 1.35-19.2 ± 1.41
Week 12-13.1 ± 1.38-18.2 ± 1.31-19.2 ± 1.36-20.7 ± 1.35-21.3 ± 1.43-18.7 ± 1.42-19.8 ± 1.32-19.4 ± 1.38
Week 13-10.7 ± 1.63-16.0 ± 1.46-13.6 ± 1.51-12.7 ± 1.57-14.4 ± 1.61-16.3 ± 1.62-15.3 ± 1.56-13.3 ± 1.54
Week 14-10.0 ± 1.66-14.1 ± 1.50-11.5 ± 1.53-11.5 ± 1.63-12.5 ± 1.66-15.3 ± 1.67-14.7 ± 1.62-12.3 ± 1.57
Week 15-11.0 ± 1.59-12.3 ± 1.46-11.7 ± 1.48-10.8 ± 1.61-11.0 ± 1.60-13.6 ± 1.65-14.2 ± 1.59-10.9 ± 1.51
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0142 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.8 · 95% CI -8.62 to -0.97
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.9 · 95% CI -11.73 to -4.05
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.1 · 95% CI -12.98 to -5.31
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -10.5 · 95% CI -14.39 to -6.61
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0819 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.5 · 95% CI -7.36 to 0.44
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.9 · 95% CI -10.78 to -3.09
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0005 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.9 · 95% CI -10.69 to -3.05
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0380 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.1 · 95% CI -8.01 to -0.23
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.6 · 95% CI -11.46 to -3.64
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -8.1 · 95% CI -11.96 to -4.17
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.2 · 95% CI -13.17 to -5.25
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0245 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.6 · 95% CI -8.52 to -0.59
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0031 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.9 · 95% CI -9.83 to -2.01
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0046 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.53 to -1.75
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0064 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.61 to -1.59
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.7 · 95% CI -12.72 to -4.65
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.8 · 95% CI -12.78 to -4.75
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -10.2 · 95% CI -14.27 to -6.09
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.4 · 95% CI -10.54 to -2.36
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.7 · 95% CI -11.71 to -3.66
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.0 · 95% CI -10.96 to -2.95
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0075 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.5 · 95% CI -9.46 to -1.47
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.4 · 95% CI -12.44 to -4.42
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.2 · 95% CI -12.15 to -4.16
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -10.2 · 95% CI -14.30 to -6.16
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.4 · 95% CI -10.46 to -2.34
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.3 · 95% CI -12.25 to -4.25
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.6 · 95% CI -11.58 to -3.62
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0123 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.8 · 95% CI -8.60 to -1.05
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.8 · 95% CI -11.63 to -4.07
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.0 · 95% CI -11.80 to -4.23
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.9 · 95% CI -13.73 to -6.03
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0013 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.3 · 95% CI -10.13 to -2.47
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.2 · 95% CI -10.97 to -3.41
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.7 · 95% CI -10.41 to -2.89
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0119 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.8 · 95% CI -8.54 to -1.07
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.8 · 95% CI -10.58 to -3.09
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.8 · 95% CI -11.57 to -4.06
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.1 · 95% CI -12.89 to -5.27
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0057 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.4 · 95% CI -9.18 to -1.58
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.7 · 95% CI -10.40 to -2.90
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.5 · 95% CI -10.27 to -2.81
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0210 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.5 · 95% CI -8.27 to -0.68
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.2 · 95% CI -10.98 to -3.38
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.3 · 95% CI -11.12 to -3.49
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.1 · 95% CI -12.99 to -5.25
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0047 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.45 to -1.73
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.5 · 95% CI -10.29 to -2.67
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.5 · 95% CI -10.28 to -2.71
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0889 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.3 · 95% CI -7.10 to 0.51
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0023 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.9 · 95% CI -9.76 to -2.13
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.5 · 95% CI -10.36 to -2.71
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.5 · 95% CI -11.36 to -3.58
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0255 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.4 · 95% CI -8.30 to -0.55
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0031 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.8 · 95% CI -9.63 to -1.98
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0037 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.7 · 95% CI -9.45 to -1.85
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0316 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.0 · 95% CI -7.59 to -0.35
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0036 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.4 · 95% CI -9.02 to -1.78
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.6 · 95% CI -10.23 to -2.94
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.2 · 95% CI -10.93 to -3.54
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0502 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.7 · 95% CI -7.37 to 0.00
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0025 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.28 to -1.99
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0063 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.1 · 95% CI -8.67 to -1.44
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0117 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.8 · 95% CI -8.58 to -1.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0047 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.4 · 95% CI -9.17 to -1.67
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.0 · 95% CI -10.80 to -3.23
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.7 · 95% CI -11.51 to -3.86
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0083 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.2 · 95% CI -8.97 to -1.34
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0011 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.3 · 95% CI -10.10 to -2.56
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0017 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.0 · 95% CI -9.77 to -2.29
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0119 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.7 · 95% CI -8.37 to -1.05
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0015 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.0 · 95% CI -9.61 to -2.29
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.7 · 95% CI -11.38 to -3.99
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.6 · 95% CI -11.33 to -3.87
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0051 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.3 · 95% CI -9.07 to -1.62
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.6 · 95% CI -10.33 to -2.96
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0014 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.0 · 95% CI -9.64 to -2.34
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0054 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.1 · 95% CI -8.67 to -1.51
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.1 · 95% CI -9.71 to -2.55
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.6 · 95% CI -11.20 to -3.97
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.2 · 95% CI -11.88 to -4.59
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0026 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.27 to -1.99
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.8 · 95% CI -10.35 to -3.16
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.3 · 95% CI -9.88 to -2.75
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0126 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.3 · 95% CI -9.48 to -1.15
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.1724 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.9 · 95% CI -7.06 to 1.27
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3548 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -6.31 to 2.27
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.0860 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.8 · 95% CI -8.04 to 0.53
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0111 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.89 to -1.28
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0349 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.6 · 95% CI -8.94 to -0.33
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2205 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -6.77 to 1.57
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0645 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -4.0 · 95% CI -8.29 to 0.24
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.5031 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -5.69 to 2.80
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.5263 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -5.84 to 2.99
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.2782 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -2.4 · 95% CI -6.83 to 1.97
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0198 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.3 · 95% CI -9.67 to -0.84
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0417 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.6 · 95% CI -9.05 to -0.18
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2963 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -6.52 to 2.00
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5408 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -5.39 to 2.83
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.7473 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -4.74 to 3.41
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9214 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -4.07 to 4.50
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9876 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -4.19 to 4.26
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2379 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -6.86 to 1.71
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1491 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.2 · 95% CI -7.45 to 1.14
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9560 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -3.96 to 4.19
SecondaryChange From Baseline in The Hot Flash Score of Moderate and Severe VMS to Each Study Week

The hot flash score per 24h of moderate and severe VMS is calculated as follows: (number of moderate VMS x 2) + (number of severe VMS x 3). Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). VMS. Baseline is the average frequency of 24h vasomotor symptom from 7 non-missing days prior to Day 1. Higher score indicates greater severity.

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Hot Flash Score of Moderate and Severe VMS to Each Study Week
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1-5.1 ± 1.49-10.2 ± 1.40-13.4 ± 1.46-14.3 ± 1.43-15.7 ± 1.51-8.8 ± 1.51-12.2 ± 1.40-11.8 ± 1.46
Week 2-8.9 ± 1.51-13.5 ± 1.41-17.0 ± 1.48-16.9 ± 1.44-18.2 ± 1.53-13.8 ± 1.53-15.5 ± 1.42-14.3 ± 1.48
Week 3-8.9 ± 1.54-14.8 ± 1.45-18.2 ± 1.52-17.5 ± 1.48-19.1 ± 1.57-15.9 ± 1.57-17.3 ± 1.46-15.6 ± 1.52
Week 4-9.5 ± 1.54-15.2 ± 1.46-18.3 ± 1.51-17.4 ± 1.48-19.6 ± 1.57-16.4 ± 1.56-18.0 ± 1.45-16.7 ± 1.51
Week 5-10.5 ± 1.46-15.8 ± 1.38-18.8 ± 1.44-18.3 ± 1.41-20.3 ± 1.50-17.2 ± 1.49-18.2 ± 1.38-16.8 ± 1.45
Week 6-11.5 ± 1.45-16.7 ± 1.37-18.7 ± 1.43-19.0 ± 1.40-20.3 ± 1.49-17.3 ± 1.48-18.6 ± 1.37-17.6 ± 1.44
Week 7-11.8 ± 1.47-16.6 ± 1.39-19.2 ± 1.45-18.7 ± 1.42-20.6 ± 1.51-17.7 ± 1.50-18.5 ± 1.39-17.8 ± 1.46
Week 8-13.0 ± 1.47-16.6 ± 1.38-19.1 ± 1.44-19.1 ± 1.42-20.2 ± 1.51-17.7 ± 1.50-19.0 ± 1.39-18.2 ± 1.46
Week 9-13.5 ± 1.41-17.9 ± 1.33-19.3 ± 1.38-19.8 ± 1.37-20.5 ± 1.45-17.7 ± 1.44-19.4 ± 1.34-18.2 ± 1.40
Week 10-12.9 ± 1.45-18.2 ± 1.37-18.9 ± 1.42-19.7 ± 1.41-20.4 ± 1.49-18.4 ± 1.48-19.5 ± 1.38-18.7 ± 1.44
Week 11-13.0 ± 1.42-18.2 ± 1.34-19.4 ± 1.39-20.5 ± 1.38-20.5 ± 1.46-18.9 ± 1.45-19.9 ± 1.35-18.8 ± 1.41
Week 12-12.8 ± 1.39-18.4 ± 1.31-19.3 ± 1.36-20.3 ± 1.36-21.0 ± 1.43-19.0 ± 1.42-19.8 ± 1.32-19.0 ± 1.38
Week 13-10.4 ± 1.65-16.4 ± 1.49-13.8 ± 1.54-13.1 ± 1.60-14.4 ± 1.64-17.0 ± 1.65-15.4 ± 1.59-13.0 ± 1.56
Week 14-9.7 ± 1.70-14.5 ± 1.53-11.5 ± 1.57-11.7 ± 1.66-12.5 ± 1.69-15.9 ± 1.70-14.6 ± 1.66-12.0 ± 1.60
Week 15-10.7 ± 1.65-12.9 ± 1.51-11.6 ± 1.53-11.1 ± 1.67-10.9 ± 1.66-14.7 ± 1.71-14.1 ± 1.65-10.6 ± 1.56
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0089 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.2 · 95% CI -9.01 to -1.30
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.4 · 95% CI -12.22 to -4.48
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.2 · 95% CI -13.06 to -5.34
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -10.7 · 95% CI -14.58 to -6.75
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0630 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.7 · 95% CI -7.65 to 0.20
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.2 · 95% CI -11.04 to -3.30
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.7 · 95% CI -10.53 to -2.84
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0231 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.5 · 95% CI -8.43 to -0.63
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.0 · 95% CI -11.94 to -4.09
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -8.0 · 95% CI -11.87 to -4.05
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.2 · 95% CI -13.21 to -5.26
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0177 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.8 · 95% CI -8.80 to -0.84
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0012 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.5 · 95% CI -10.45 to -2.60
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0072 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.6 · 95% CI -9.26 to -2.64
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0044 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.9 · 95% CI -9.86 to -1.84
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.2 · 95% CI -13.27 to -5.21
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.6 · 95% CI -12.57 to -4.55
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -10.2 · 95% CI -14.29 to -6.11
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.0 · 95% CI -11.04 to -2.87
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.4 · 95% CI -12.44 to -4.39
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0012 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.6 · 95% CI -10.65 to -2.64
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0053 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.7 · 95% CI -9.72 to -1.71
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.8 · 95% CI -12.77 to -4.73
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.8 · 95% CI -11.84 to -3.84
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -10.0 · 95% CI -14.12 to -5.96
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0010 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.9 · 95% CI -10.92 to -2.78
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.5 · 95% CI -12.49 to -4.46
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0005 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.1 · 95% CI -11.12 to -3.13
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0057 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.4 · 95% CI -9.15 to -1.58
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.4 · 95% CI -12.15 to -4.56
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.9 · 95% CI -11.68 to -4.08
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -9.8 · 95% CI -13.66 to -5.93
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.7 · 95% CI -10.54 to -2.85
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.7 · 95% CI -11.55 to -3.95
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0010 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.4 · 95% CI -10.16 to -2.60
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0064 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.2 · 95% CI -8.99 to -1.48
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.2 · 95% CI -10.94 to -3.42
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.5 · 95% CI -11.29 to -3.75
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.9 · 95% CI -12.69 to -5.03
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0030 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.8 · 95% CI -9.62 to -1.99
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.1 · 95% CI -10.92 to -3.37
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0013 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.2 · 95% CI -9.91 to -2.42
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0137 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.8 · 95% CI -8.61 to -0.99
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.4 · 95% CI -11.24 to -3.60
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.0 · 95% CI -10.79 to -3.13
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.9 · 95% CI -12.74 to -4.97
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0028 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.9 · 95% CI -9.82 to -2.07
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.8 · 95% CI -10.60 to -2.94
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0020 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.0 · 95% CI -9.82 to -2.21
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0588 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.7 · 95% CI -7.46 to 0.14
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0018 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.7 · 95% CI -9.90 to 0.14
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0017 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.2 · 95% CI -9.98 to -2.34
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.2 · 95% CI -11.09 to -3.32
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0810 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.7 · 95% CI -8.55 to -0.81
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0020 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.1 · 95% CI -9.88 to -2.23
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0076 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.2 · 95% CI -8.98 to -1.39
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0182 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.4 · 95% CI -8.01 to -0.75
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0019 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.8 · 95% CI -9.42 to -2.16
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.4 · 95% CI -10.02 to -2.71
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.1 · 95% CI -10.76 to -3.35
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0263 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.2 · 95% CI -7.89 to -0.50
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0015 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.0 · 95% CI -9.61 to -2.29
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0113 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.7 · 95% CI -8.32 to -1.07
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0059 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.3 · 95% CI -9.04 to -1.54
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0018 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.0 · 95% CI -9.76 to -2.25
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.8 · 95% CI -10.62 to -3.05
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.6 · 95% CI -11.39 to -3.73
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0044 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.40 to -1.75
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.6 · 95% CI -10.40 to -2.84
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0025 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.8 · 95% CI -9.57 to -2.07
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0059 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.2 · 95% CI -8.81 to -1.49
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.4 · 95% CI -10.06 to -2.74
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.5 · 95% CI -11.18 to -3.79
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.5 · 95% CI -11.18 to -3.72
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0022 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.8 · 95% CI -9.56 to -2.11
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.9 · 95% CI -10.56 to -3.19
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0020 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.8 · 95% CI -9.44 to -2.13
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0023 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.6 · 95% CI -9.18 to -2.01
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.5 · 95% CI -10.06 to -2.89
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -7.4 · 95% CI -11.05 to -3.81
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -8.1 · 95% CI -11.80 to -4.49
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0011 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.1 · 95% CI -9.77 to -2.47
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.9 · 95% CI -10.54 to -3.32
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.1 · 95% CI -9.71 to -2.56
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0054 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.0 · 95% CI -10.26 to -1.80
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.1145 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.4 · 95% CI -7.63 to 0.83
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2106 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -7.13 to 1.58
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.0685 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.0 · 95% CI -8.39 to 0.31
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0029 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.7 · 95% CI -11.02 to -2.29
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0239 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -5.0 · 95% CI -9.42 to -0.67
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2224 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -6.86 to 1.60
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0308 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -4.8 · 95% CI -9.17 to -0.45
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.4194 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -6.13 to 2.56
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3759 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -6.55 to 2.48
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.2285 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -2.8 · 95% CI -7.26 to 1.74
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0072 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -6.2 · 95% CI -10.71 to -1.70
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0338 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.9 · 95% CI -9.46 to -0.38
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3026 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -6.64 to 2.07
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3120 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -6.45 to 2.07
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6816 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -5.11 to 3.34
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.8599 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -4.85 to 4.05
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9093 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -4.64 to 4.13
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0788 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -4.0 · 95% CI -8.43 to 0.46
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1278 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -3.5 · 95% CI -7.92 to 1.00
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9848 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit and smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -4.19 to 4.27
SecondaryMean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Least squares mean · Percent Reduction
Mean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week
Percent ReductionPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 114.5 ± 5.3329.1 ± 5.0137.6 ± 5.2151.8 ± 5.1255.5 ± 5.3922.7 ± 5.4040.1 ± 5.0244.7 ± 5.22
Week 230.3 ± 5.3046.2 ± 4.9954.8 ± 5.2064.0 ± 5.0968.3 ± 5.3944.8 ± 5.3849.8 ± 5.0156.1 ± 5.21
Week 332.0 ± 5.6652.2 ± 5.3760.3 ± 5.5868.9 ± 5.4472.5 ± 5.7751.7 ± 5.7556.9 ± 5.3762.8 ± 5.56
Week 434.7 ± 5.5855.3 ± 5.3363.5 ± 5.5268.1 ± 5.3976.2 ± 5.7254.5 ± 5.6964.7 ± 5.3067.9 ± 5.50
Week 541.3 ± 5.3256.7 ± 5.0866.1 ± 5.2672.1 ± 5.1780.1 ± 5.4960.4 ± 5.4263.6 ± 5.0666.4 ± 5.28
Week 645.4 ± 5.0160.0 ± 4.7465.3 ± 4.9375.1 ± 4.8681.1 ± 5.1660.1 ± 5.1265.9 ± 4.7572.0 ± 4.97
Week 745.1 ± 5.1759.6 ± 4.9268.1 ± 5.1074.0 ± 5.0581.9 ± 5.3460.7 ± 5.2966.3 ± 4.9372.2 ± 5.14
Week 850.9 ± 5.1360.5 ± 4.8769.0 ± 5.0576.1 ± 5.0181.5 ± 5.3262.1 ± 5.2669.2 ± 4.9074.5 ± 5.11
Week 953.8 ± 4.9065.7 ± 4.6468.4 ± 4.8178.2 ± 4.7883.4 ± 5.0662.2 ± 5.0372.3 ± 4.6774.5 ± 4.88
Week 1051.8 ± 5.0367.6 ± 4.7864.6 ± 4.9577.6 ± 4.9583.4 ± 5.2066.1 ± 5.1773.0 ± 4.8276.2 ± 5.02
Week 1153.5 ± 4.8868.0 ± 4.6368.8 ± 4.8180.0 ± 4.8183.4 ± 5.0567.4 ± 5.0275.4 ± 4.6676.9 ± 4.87
Week 1253.2 ± 4.8768.0 ± 4.6270.2 ± 4.8079.6 ± 4.8084.2 ± 5.0468.0 ± 5.0175.1 ± 4.6576.4 ± 4.86
Week 1343.6 ± 5.6953.3 ± 5.0745.9 ± 5.2445.1 ± 5.4750.7 ± 5.5949.3 ± 5.6654.0 ± 5.4448.0 ± 5.32
Week 1439.9 ± 6.1242.0 ± 5.5041.2 ± 5.6039.6 ± 5.9943.8 ± 6.0841.5 ± 6.1452.9 ± 6.0147.0 ± 5.72
Week 1545.0 ± 5.9737.1 ± 5.4942.9 ± 5.5637.8 ± 6.0639.4 ± 6.0132.4 ± 6.2151.4 ± 6.0043.0 ± 5.64
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0388 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.6 · 95% CI 0.76 to 28.49MMRM: Mixed Model Repeated Measures
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0012 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.1 · 95% CI 9.17 to 37.02
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 37.3 · 95% CI 23.41 to 51.22
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 41.0 · 95% CI 26.88 to 55.05
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2569 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 8.2 · 95% CI -5.98 to 22.32
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.6 · 95% CI 11.65 to 39.47
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 30.2 · 95% CI 16.39 to 44.06
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0240 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 15.9 · 95% CI 2.11 to 29.71
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.5 · 95% CI 10.62 to 38.37
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean differencce: 33.7 · 95% CI 19.87 to 47.52
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 38.0 · 95% CI 23.93 to 52.04
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0441 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.5 · 95% CI 0.38 to 28.53
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0061 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.4 · 95% CI 5.58 to 33.28
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.7 · 95% CI 11.96 to 39.53
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0078 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.2 · 95% CI 5.36 to 35.07
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 28.3 · 95% CI 13.36 to 43.22
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 36.9 · 95% CI 22.07 to 51.77
  • Placebo vs Fezolinetant 90 mg BID · MMRm · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 40.5 · 95% CI 25.41 to 55.67
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0108 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.7 · 95% CI 4.59 to 34.88
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0011 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.0 · 95% CI 10.09 to 39.84
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 30.9 · 95% CI 16.03 to 45.67
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0063 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.5 · 95% CI 5.84 to 35.23
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 28.7 · 95% CI 13.98 to 43.46
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 33.3 · 95% CI 18.66 to 48.00
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 41.5 · 95% CI 26.52 to 56.41
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0098 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.7 · 95% CI 4.78 to 34.66
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.9 · 95% CI 15.26 to 44.61
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 33.1 · 95% CI 18.50 to 47.73
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0303 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 15.4 · 95% CI 1.48 to 29.40
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.8 · 95% CI 10.77 to 38.74
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 30.8 · 95% CI 16.77 to 44.75
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 38.8 · 95% CI 24.55 to 53.00
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0086 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.1 · 95% CI 4.88 to 33.23
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0018 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.3 · 95% CI 8.33 to 36.24
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.1 · 95% CI 11.24 to 39.05
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0282 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.6 · 95% CI 1.56 to 27.60
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0029 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.9 · 95% CI 6.85 to 32.92
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.7 · 95% CI 16.58 to 42.73
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 35.7 · 95% CI 22.42 to 48.99
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0304 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.6 · 95% CI 1.40 to 27.90
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0022 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.4 · 95% CI 7.38 to 33.50
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 26.5 · 95% CI 13.56 to 39.50
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0362 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.4 · 95% CI 0.93 to 27.95
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.9 · 95% CI 9.41 to 36.47
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 28.9 · 95% CI 15.27 to 42.46
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 36.8 · 95% CI 22.99 to 50.57
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0265 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 15.6 · 95% CI 1.83 to 29.34
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0023 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 21.2 · 95% CI 7.60 to 34.71
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 27.1 · 95% CI 13.64 to 40.59
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1580 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 9.6 · 95% CI -3.75 to 22.99
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0082 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 18.1 · 95% CI 4.72 to 31.50
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.2 · 95% CI 11.77 to 38.71
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 30.6 · 95% CI 16.93 to 44.31
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1074 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 11.2 · 95% CI -2.45 to 24.84
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0077 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 18.3 · 95% CI 4.87 to 31.76
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.6 · 95% CI 10.29 to 37.01
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0689 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 11.8 · 95% CI -0.92 to 24.53
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0250 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.6 · 95% CI 1.84 to 27.27
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.4 · 95% CI 11.54 to 37.17
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.6 · 95% CI 16.60 to 42.57
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2041 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 8.4 · 95% CI -4.58 to 21.36
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0049 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 18.4 · 95% CI 5.62 to 31.20
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0015 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.7 · 95% CI 8.00 to 33.37
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0184 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 15.8 · 95% CI 2.68 to 28.89
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0551 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 12.8 · 95% CI -0.28 to 25.93
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.8 · 95% CI 12.51 to 39.00
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 31.6 · 95% CI 18.17 to 44.93
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0367 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.3 · 95% CI 0.89 to 27.62
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0017 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 21.2 · 95% CI 7.99 to 34.34
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.4 · 95% CI 11.29 to 37.44
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0255 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.5 · 95% CI 1.78 to 27.15
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0186 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 15.3 · 95% CI 2.57 to 27.94
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 26.5 · 95% CI 13.71 to 39.36
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.9 · 95% CI 16.94 to 42.81
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0347 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 13.9 · 95% CI 1.01 to 26.85
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 21.9 · 95% CI 9.16 to 34.65
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.4 · 95% CI 10.75 to 36.04
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0221 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.8 · 95% CI 2.13 to 27.43
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0087 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 17.0 · 95% CI 4.32 to 29.62
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 26.4 · 95% CI 13.65 to 39.23
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 31.0 · 95% CI 18.13 to 43.94
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0244 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.8 · 95% CI 1.92 to 27.70
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 21.9 · 95% CI 9.21 to 34.62
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.2 · 95% CI 10.63 to 35.83
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1871 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 9.8 · 95% CI -4.77 to 24.30
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.7552 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 2.3 · 95% CI -12.23 to 16.83
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.8407 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 1.5 · 95% CI -13.44 to 16.50
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.3450 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 7.2 · 95% CI -7.77 to 22.14
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4550 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 5.7 · 95% CI -9.34 to 20.80
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1747 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 10.4 · 95% CI -4.64 to 25.44
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.5476 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 4.4 · 95% CI -10.08 to 18.97
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.7954 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 2.1 · 95% CI -13.69 to 17.84
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.8731 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean differencce: 1.3 · 95% CI -14.41 to 16.95
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9689 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -0.3 · 95% CI -16.68 to 16.03
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.6378 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 3.9 · 95% CI -12.40 to 20.21
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.8503 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean differencce: 1.6 · 95% CI -14.82 to 17.97
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1224 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 13.0 · 95% CI -3.51 to 29.44
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3743 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 7.1 · 95% CI -8.62 to 22.85
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3173 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -7.9 · 95% CI -23.44 to 7.63
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.7905 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -2.1 · 95% CI -17.48 to 13.32
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3804 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -7.2 · 95% CI -23.46 to 8.98
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.4905 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -5.6 · 95% CI -21.58 to 10.38
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1289 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -12.6 · 95% CI -28.83 to 3.68
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4398 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 6.4 · 95% CI -9.86 to 22.61
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.7921 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -2.1 · 95% CI -17.45 to 13.33
SecondaryMean Percent Reduction of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Least squares mean · Percent Reduction
Mean Percent Reduction of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week
Percent ReductionPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 117.5 ± 5.5136.6 ± 5.1844.5 ± 5.3957.0 ± 5.3062.3 ± 5.5729.6 ± 5.5945.3 ± 5.2047.0 ± 5.40
Week 233.8 ± 5.3453.7 ± 5.0162.4 ± 5.2367.6 ± 5.1273.3 ± 5.4251.4 ± 5.4157.9 ± 5.0357.7 ± 5.25
Week 334.8 ± 5.6158.1 ± 5.3169.2 ± 5.5370.5 ± 5.4077.8 ± 5.7360.3 ± 5.7166.0 ± 5.3263.7 ± 5.52
Week 438.6 ± 5.5761.7 ± 5.3170.7 ± 5.5070.0 ± 5.3780.5 ± 5.7164.2 ± 5.6870.0 ± 5.2868.1 ± 5.49
Week 543.6 ± 5.3163.8 ± 5.0674.2 ± 5.2572.7 ± 5.1783.7 ± 5.4968.0 ± 5.4270.3 ± 5.0467.0 ± 5.28
Week 648.5 ± 5.0267.7 ± 4.7572.4 ± 4.9475.7 ± 4.8784.1 ± 5.1968.5 ± 5.1472.6 ± 4.7671.7 ± 4.99
Week 749.1 ± 5.1666.7 ± 4.9074.9 ± 5.0974.9 ± 5.0485.4 ± 5.3469.7 ± 5.2872.0 ± 4.9171.9 ± 5.14
Week 854.5 ± 5.0968.3 ± 4.8174.5 ± 5.0176.6 ± 4.9684.5 ± 5.2869.4 ± 5.2374.1 ± 4.8574.1 ± 5.08
Week 956.4 ± 4.9172.4 ± 4.6474.5 ± 4.8279.0 ± 4.7885.7 ± 5.0870.1 ± 5.0576.5 ± 4.6873.8 ± 4.90
Week 1053.5 ± 5.0374.2 ± 4.7772.3 ± 4.9577.9 ± 4.9585.6 ± 5.2172.6 ± 5.1876.6 ± 4.8176.4 ± 5.03
Week 1155.6 ± 4.8274.1 ± 4.5575.8 ± 4.7580.6 ± 4.7385.4 ± 4.9975.1 ± 4.9679.0 ± 4.5977.3 ± 4.82
Week 1255.0 ± 4.8574.3 ± 4.5875.8 ± 4.7780.2 ± 4.7786.9 ± 5.0275.1 ± 4.9977.7 ± 4.6176.9 ± 4.84
Week 1344.9 ± 6.0261.9 ± 5.3751.7 ± 5.5552.5 ± 5.7855.8 ± 5.9261.3 ± 5.9856.6 ± 5.7648.8 ± 5.63
Week 1441.0 ± 6.4750.4 ± 5.8344.9 ± 5.9345.9 ± 6.3447.2 ± 6.4451.4 ± 6.4955.3 ± 6.3647.7 ± 6.06
Week 1545.6 ± 6.4944.7 ± 5.9845.6 ± 6.0446.0 ± 6.6141.7 ± 6.5445.5 ± 6.7653.2 ± 6.5742.9 ± 6.12
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0090 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.1 · 95% CI 4.82 to 33.46MMRM: Mixed Model Repeated Measures
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 27.0 · 95% CI 12.61 to 41.39
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 39.5 · 95% CI 25.14 to 53.90
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 44.8 · 95% CI 30.27 to 59.39
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1019 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 12.2 · 95% CI -2.43 to 26.79
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 27.8 · 95% CI 13.45 to 42.22
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.5 · 95% CI 15.21 to 43.82
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0049 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.9 · 95% CI 6.10 to 33.76
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 28.6 · 95% CI 14.64 to 42.46
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean differencce: 33.8 · 95% CI 19.96 to 47.69
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 39.5 · 95% CI 25.40 to 53.58
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0146 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 17.6 · 95% CI 3.50 to 31.70
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.1 · 95% CI 10.21 to 38.00
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.9 · 95% CI 10.05 to 37.70
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0020 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.2 · 95% CI 8.56 to 37.90
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 34.4 · 95% CI 19.60 to 49.11
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 35.6 · 95% CI 20.96 to 50.32
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 43.0 · 95% CI 28.03 to 57.93
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.4 · 95% CI 10.48 to 40.37
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 31.2 · 95% CI 16.49 to 45.90
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 28.9 · 95% CI 14.24 to 43.52
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.1 · 95% CI 8.46 to 37.66
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 32.1 · 95% CI 17.42 to 46.71
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 31.3 · 95% CI 16.73 to 45.91
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 41.8 · 95% CI 26.95 to 56.68
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0008 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.6 · 95% CI 10.77 to 40.43
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 31.3 · 95% CI 16.75 to 45.94
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.4 · 95% CI 14.91 to 43.97
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0045 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.2 · 95% CI 6.31 to 34.06
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 30.6 · 95% CI 16.68 to 44.49
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.1 · 95% CI 15.14 to 42.98
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 40.1 · 95% CI 25.96 to 54.26
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0007 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.4 · 95% CI 10.28 to 38.42
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 26.7 · 95% CI 1.78 to 40.55
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0010 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.4 · 95% CI 9.55 to 37.22
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0040 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.1 · 95% CI 6.13 to 32.11
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.8 · 95% CI 10.80 to 36.83
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 27.2 · 95% CI 14.10 to 40.24
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 35.6 · 95% CI 22.34 to 48.88
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0032 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.0 · 95% CI 6.76 to 33.19
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.1 · 95% CI 11.02 to 37.13
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0005 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.1 · 95% CI 10.17 to 36.08
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0102 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 17.6 · 95% CI 4.20 to 31.04
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.9 · 95% CI 12.42 to 39.29
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.8 · 95% CI 12.29 to 39.33
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 36.3 · 95% CI 22.58 to 49.98
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0031 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.6 · 95% CI 7.00 to 34.29
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.9 · 95% CI 9.43 to 36.38
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.8 · 95% CI 9.42 to 36.19
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0408 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 13.8 · 95% CI 0.58 to 26.97
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0031 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.0 · 95% CI 6.77 to 33.21
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0012 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.1 · 95% CI 8.80 to 35.40
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.9 · 95% CI 16.39 to 43.42
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0303 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.9 · 95% CI 1.42 to 28.32
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0040 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.6 · 95% CI 6.30 to 32.87
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0038 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.5 · 95% CI 6.34 to 32.73
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0137 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 16.0 · 95% CI 3.29 to 28.68
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0052 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 18.1 · 95% CI 5.44 to 30.82
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.6 · 95% CI 9.81 to 35.39
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.4 · 95% CI 16.41 to 42.32
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0378 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 13.7 · 95% CI 0.78 to 26.63
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.002 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.1 · 95% CI 7.31 to 32.85
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0071 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 17.4 · 95% CI 4.77 to 30.09
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0020 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.7 · 95% CI 7.61 to 33.71
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0050 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 18.7 · 95% CI 5.68 to 31.79
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 24.4 · 95% CI 11.20 to 37.60
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 32.1 · 95% CI 18.77 to 45.42
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0050 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.1 · 95% CI 5.79 to 32.38
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.1 · 95% CI 9.95 to 36.22
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.8 · 95% CI 9.79 to 35.85
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0036 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 18.5 · 95% CI 6.11 to 30.98
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0015 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.2 · 95% CI 7.77 to 32.65
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.0 · 95% CI 12.41 to 37.57
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 29.8 · 95% CI 17.12 to 42.49
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0026 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.6 · 95% CI 6.90 to 32.21
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0003 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 23.4 · 95% CI 10.92 to 35.94
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 21.7 · 95% CI 9.34 to 34.14
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0026 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 19.3 · 95% CI 6.78 to 31.83
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0012 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.8 · 95% CI 8.29 to 33.33
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 25.1 · 95% CI 12.48 to 37.82
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 31.9 · 95% CI 19.11 to 44.67
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 20.1 · 95% CI 7.32 to 32.81
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 22.7 · 95% CI 10.10 to 35.29
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0006 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 21.9 · 95% CI 9.42 to 34.38
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0304 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 17.0 · 95% CI 1.62 to 32.40
  • Placebo vs Fezolinetant 30 mg BID · MMMRM · p = 0.3857 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 6.8 · 95% CI -8.60 to 22.19
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3497 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 7.5 · 95% CI -8.31 to 23.40
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.1771 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 10.9 · 95% CI -4.95 to 26.75
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0444 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 16.3 · 95% CI 0.41 to 32.29
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1500 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 11.7 · 95% CI -4.25 to 27.63
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.6196 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 3.9 · 95% CI -11.51 to 19.29
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.2664 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 9.4 · 95% CI -7.25 to 26.15
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6388 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean differencce: 4.0 · 95% CI -12.66 to 20.59
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.5797 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 4.9 · 95% CI -12.43 to 22.19
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.4817 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 6.2 · 95% CI -11.10 to 23.47
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2358 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean differencce: 10.5 · 95% CI -6.87 to 27.79
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1070 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 14.3 · 95% CI -3.11 to 31.77
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4268 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 6.7 · 95% CI -9.94 to 23.43
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.9197 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -0.9 · 95% CI -17.81 to 16.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.9954 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 0.0 · 95% CI -16.77 to 16.87
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9607 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 0.4 · 95% CI -17.28 to 18.17
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.6625 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -3.9 · 95% CI -21.33 to 13.59
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.9952 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -0.1 · 95% CI -17.81 to 17.70
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4001 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& BM as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: 7.6 · 95% CI -10.16 to 25.36
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.7510 (LSM, SE, CI, \& p-values come from an MMRM model with PR from baseline as dependent variable \& TG, visit and smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& interaction of BM by week.) · Lsmean difference: -2.7 · 95% CI -19.52 to 14.10
SecondaryNumber of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1519222425102123
Week 21426293230222628
Week 31626293332262929
Week 41926293131253231
Week 52224313029283029
Week 62424303128243033
Week 72525322928283030
Week 82628323228253132
Week 92729333131253031
Week 102328262631263232
Week 112328302530273331
Week 122127272728243232
Week 131219171415161417
Week 141114151013151417
Week 151410126991213
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0018 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.02 · 95% CI 1.95 to 18.64
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.28 · 95% CI 2.70 to 25.42
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.92 · 95% CI 3.53 to 33.74
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.18 · 95% CI 3.91 to 37.89
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2244 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.10 · 95% CI 0.64 to 6.92
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.58 · 95% CI 2.77 to 26.53
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.25 · 95% CI 2.71 to 25.13
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0149 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.04 · 95% CI 1.24 to 7.45
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.65 · 95% CI 1.85 to 11.73
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.36 · 95% CI 2.46 to 16.45
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.87 · 95% CI 2.56 to 18.46
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0897 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.18 · 95% CI 0.89 to 5.34
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0070 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.46 · 95% CI 1.42 to 8.53
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0041 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.75 · 95% CI 1.52 to 9.23
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0254 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.77 · 95% CI 1.13 to 6.78
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0032 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.00 · 95% CI 1.59 to 10.04
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.25 · 95% CI 2.37 to 16.51
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.78 · 95% CI 3.00 to 25.70
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0214 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.90 · 95% CI 1.17 to 7.18
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0049 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.67 · 95% CI 1.48 to 9.09
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0078 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.36 · 95% CI 1.38 to 8.22
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0727 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.28 · 95% CI 0.93 to 5.63
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0199 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.94 · 95% CI 1.19 to 7.29
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.21 · 95% CI 1.61 to 11.01
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0007 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.26 · 95% CI 2.16 to 18.26
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1206 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.02 · 95% CI 0.83 to 4.92
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0070 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.58 · 95% CI 1.42 to 9.03
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0088 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.41 · 95% CI 1.36 to 8.54
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4485 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.41 · 95% CI 0.58 to 3.40
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0255 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.92 · 95% CI 1.14 to 7.47
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0066 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.18 · 95% CI 1.49 to 11.75
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0061 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.46 · 95% CI 1.53 to 13.01
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0879 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.89 to 5.57
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0389 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.68 · 95% CI 1.05 to 6.83
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0446 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.62 · 95% CI 1.02 to 6.73
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8196 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.11 · 95% CI 0.45 to 2.72
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1450 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.00 · 95% CI 0.79 to 5.10
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0114 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.08 · 95% CI 1.37 to 12.11
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0307 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.29 · 95% CI 1.12 to 9.71
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5921 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.29 · 95% CI 0.51 to 3.24
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0502 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.69 · 95% CI 1.00 to 7.26
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0224 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.31 · 95% CI 1.18 to 9.25
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7225 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.18 · 95% CI 0.47 to 2.93
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0762 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.43 · 95% CI 0.91 to 6.48
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0252 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.51 · 95% CI 1.17 to 10.53
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0490 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.98 · 95% CI 1.00 to 8.87
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1773 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.97 · 95% CI 0.74 to 5.30
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0609 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.62 · 95% CI 0.96 to 7.16
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1364 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.11 · 95% CI 0.79 to 5.61
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5268 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.36 · 95% CI 0.53 to 3.51
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1645 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.02 · 95% CI 0.75 to 5.46
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0215 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.92 · 95% CI 1.22 to 12.57
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0600 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.04 · 95% CI 0.95 to 9.69
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6503 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.25 · 95% CI 0.47 to 3.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0683 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.70 · 95% CI 0.93 to 7.88
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0618 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.83 · 95% CI 0.95 to 8.44
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5621 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.34 · 95% CI 0.50 to 3.63
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2182 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.92 · 95% CI 0.68 to 5.40
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0600 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.11 · 95% CI 0.95 to 10.15
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0290 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.60 · 95% CI 1.17 to 18.12
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8485 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.10 · 95% CI 0.40 to 3.04
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1652 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.16 · 95% CI 0.73 to 6.42
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2244 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.94 · 95% CI 0.67 to 5.65
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2097 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.85 · 95% CI 0.71 to 4.84
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3708 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.53 · 95% CI 0.60 to 3.92
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0704 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.66 · 95% CI 0.92 to 7.66
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0040 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.21 · 95% CI 1.88 to 27.73
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1625 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.04 · 95% CI 0.75 to 5.55
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0093 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.59 · 95% CI 1.46 to 14.50
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0103 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.44 · 95% CI 1.42 to 13.87
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1965 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.89 · 95% CI 0.72 to 4.95
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0549 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.69 · 95% CI 0.98 to 7.42
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0503 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.01 · 95% CI 1.00 to 9.09
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0046 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.03 · 95% CI 1.82 to 27.10
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0866 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.46 · 95% CI 0.88 to 6.88
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0045 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.96 · 95% CI 1.74 to 20.40
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0207 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.59 · 95% CI 1.22 to 10.62
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2127 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.86 · 95% CI 0.70 to 4.91
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1521 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.04 · 95% CI 0.77 to 5.43
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0098 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.12 · 95% CI 1.48 to 17.70
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0047 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.08 · 95% CI 1.82 to 27.50
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1817 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.00 · 95% CI 0.72 to 5.51
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0042 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.09 · 95% CI 1.77 to 20.95
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0039 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.09 · 95% CI 1.78 to 20.74
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7025 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.23 · 95% CI 0.42 to 3.57
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9599 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.03 · 95% CI 0.36 to 2.97
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.9671 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.34 to 3.10
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.6810 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.26 · 95% CI 0.42 to 3.83
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6346 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.31 · 95% CI 0.43 to 4.04
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.7929 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.16 · 95% CI 0.38 to 3.57
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.8188 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.13 · 95% CI 0.39 to 3.28
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8226 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.88 · 95% CI 0.30 to 2.60
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9088 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.94 · 95% CI 0.32 to 2.72
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.6189 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.75 · 95% CI 0.24 to 2.35
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.6463 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.30 · 95% CI 0.42 to 4.03
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5060 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.47 · 95% CI 0.47 to 4.54
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.3842 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.67 · 95% CI 0.53 to 5.31
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5021 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.44 · 95% CI 0.49 to 4.23
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1349 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.42 · 95% CI 0.14 to 1.31
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3191 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.57 · 95% CI 0.19 to 1.71
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0623 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.30 · 95% CI 0.09 to 1.06
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1958 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.47 · 95% CI 0.15 to 1.48
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4353 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.62 · 95% CI 0.19 to 2.05
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.9729 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.31 to 3.31
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.4211 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.64 · 95% CI 0.22 to 1.89
SecondaryNumber of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1261117186716
Week 2915192624131321
Week 31117202727171626
Week 41014222430192426
Week 51517212629222225
Week 61418212728192226
Week 71519242528202225
Week 81819252427192126
Week 91821222728192426
Week 101621202329212624
Week 111925232428202828
Week 121821222526222627
Week 1341279710511
Week 14865327710
Week 1584530257
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1938 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.05 · 95% CI 0.57 to 16.35
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0162 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.97 · 95% CI 1.43 to 33.91
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0008 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.37 · 95% CI 3.04 to 67.96
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0005 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 16.02 · 95% CI 3.39 to 75.68
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1971 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.02 · 95% CI 0.56 to 16.17
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0811 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.31 · 95% CI 0.83 to 22.27
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0021 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.44 · 95% CI 2.43 to 53.94
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1370 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.11 · 95% CI 0.79 to 5.64
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0181 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.20 · 95% CI 1.22 to 8.40
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.43 · 95% CI 2.43 to 17.05
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.08 · 95% CI 2.26 to 16.31
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3241 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.65 · 95% CI 0.61 to 4.49
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2249 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.85 · 95% CI 0.68 to 5.03
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0096 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.53 · 95% CI 1.36 to 9.18
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0768 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.35 · 95% CI 0.91 to 6.05
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.00251 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.91 · 95% CI 1.14 to 7.39
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.99 · 95% CI 2.30 to 15.57
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.29 · 95% CI 2.70 to 19.71
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1144 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.14 · 95% CI 0.83 to 5.50
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1341 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.06 · 95% CI 0.80 to 5.30
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0017 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.43 · 95% CI 1.75 to 11.22
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1488 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.06 · 95% CI 0.77 to 5.50
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0043 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.99 · 95% CI 1.54 to 10.30
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0005 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.53 · 95% CI 2.10 to 14.57
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.54 · 95% CI 4.85 to 43.58
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0262 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.96 · 95% CI 1.14 to 7.68
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.07 · 95% CI 1.95 to 13.19
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.33 · 95% CI 2.06 to 13.80
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3673 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.52 · 95% CI 0.61 to 3.75
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1207 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.02 · 95% CI 0.83 to 4.91
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.01 · 95% CI 1.90 to 13.21
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.19 · 95% CI 3.08 to 27.38
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0594 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.38 · 95% CI 0.97 to 5.86
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0500 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.47 · 95% CI 1.00 to 6.09
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0123 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.22 · 95% CI 1.29 to 8.03
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2243 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.76 · 95% CI 0.71 to 4.37
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0976 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.13 · 95% CI 0.87 to 5.24
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.09 · 95% CI 2.25 to 16.44
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.13 · 95% CI 3.04 to 27.40
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1237 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.06 · 95% CI 0.82 to 5.17
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0226 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.94 · 95% CI 1.16 to 7.41
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0069 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.55 · 95% CI 1.42 to 8.91
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1666 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.90 · 95% CI 0.76 to 4.75
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0317 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.70 · 95% CI 1.09 to 6.67
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.28 · 95% CI 1.94 to 14.39
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.45 · 95% CI 2.81 to 25.46
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1142 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.10 · 95% CI 0.84 to 5.27
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0250 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.91 · 95% CI 1.14 to 7.39
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0166 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.08 · 95% CI 1.23 to 7.75
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6033 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.27 · 95% CI 0.52 to 3.11
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1170 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.05 · 95% CI 0.84 to 5.02
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0400 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.69 · 95% CI 1.05 to 6.91
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0020 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.61 · 95% CI 1.88 to 16.72
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5177 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.35 · 95% CI 0.54 to 3.37
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2117 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.79 · 95% CI 0.72 to 4.48
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0426 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.62 · 95% CI 1.03 to 6.67
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3508 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.54 · 95% CI 0.62 to 3.82
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4431 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.42 · 95% CI 0.58 to 3.45
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0050 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.27 · 95% CI 1.55 to 11.78
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0023 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.47 · 95% CI 1.84 to 16.30
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5663 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.31 · 95% CI 0.52 to 3.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0461 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 1.02 to 6.83
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0552 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.50 · 95% CI 0.98 to 6.38
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1536 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.95 · 95% CI 0.78 to 4.88
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2575 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.69 · 95% CI 0.68 to 4.20
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0096 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.73 · 95% CI 1.38 to 10.11
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.48 · 95% CI 2.69 to 26.76
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1047 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.18 · 95% CI 1.48 to 10.35
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0060 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.91 · 95% CI 1.48 to 10.35
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0414 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 1.04 to 6.71
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0809 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.31 · 95% CI 0.90 to 5.89
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2377 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.69 to 4.34
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0087 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.21 · 95% CI 1.44 to 12.34
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0022 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.00 · 95% CI 1.90 to 18.94
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4788 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.40 · 95% CI 0.55 to 3.55
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0074 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.98 · 95% CI 1.45 to 10.94
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0187 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.26 · 95% CI 1.22 to 8.75
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3443 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.57 · 95% CI 0.62 to 4.00
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2867 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.66 · 95% CI 0.65 to 4.22
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0044 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.12 · 95% CI 1.66 to 15.78
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0038 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.58 · 95% CI 1.74 to 17.87
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1424 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.09 · 95% CI 0.78 to 5.60
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0191 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.32 · 95% CI 1.22 to 9.07
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0244 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.15 · 95% CI 1.16 to 8.56
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1462 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.63 · 95% CI 0.71 to 9.67
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7403 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.26 · 95% CI 0.32 to 4.97
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2144 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.35 · 95% CI 0.61 to 9.07
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.4321 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.44 to 6.96
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1778 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.53 · 95% CI 0.66 to 9.75
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.8016 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.21 · 95% CI 0.28 to 5.20
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1486 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.62 · 95% CI 0.71 to 9.64
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2881 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.51 · 95% CI 0.15 to 1.77
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1217 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.36 · 95% CI 0.10 to 1.31
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1027 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.36 · 95% CI 0.07 to 1.28
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0428 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.18 · 95% CI 0.03 to 0.94
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5943 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.72 · 95% CI 0.21 to 2.44
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.9280 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.94 · 95% CI 0.27 to 3.28
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.9160 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.94 · 95% CI 0.30 to 2.94
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2262 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.43 · 95% CI 0.11 to 1.69
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2682 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.48 · 95% CI 0.13 to 1.75
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2344 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.40 · 95% CI 0.09 to 1.81
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0835 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.22 · 95% CI 0.04 to 1.22
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.6322 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.72 · 95% CI 0.19 to 2.72
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.4845 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.65 · 95% CI 0.20 to 2.17
SecondaryNumber of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 111166032
Week 225615162512
Week 349919166917
Week 461012191771218
Week 56711182091018
Week 6991621239921
Week 768152024101220
Week 81311172223101422
Week 91311152125101420
Week 101312142026111520
Week 111413131925121820
Week 121315151722101620
Week 1310121312
Week 1410200001
Week 1500010010
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9587 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.08 · 95% CI 0.06 to 17.98
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9895 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.06 to 16.89
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0736 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.24 · 95% CI 0.83 to 63.32
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0767 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.08 · 95% CI 0.81 to 61.78
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2880 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.51 · 95% CI 0.35 to 35.49
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5894 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.96 · 95% CI 0.17 to 22.47
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3093 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.45 · 95% CI 0.44 to 13.78
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1606 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.31 · 95% CI 0.62 to 17.58
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.92 · 95% CI 2.50 to 56.87
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0008 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.40 · 95% CI 3.02 to 68.73
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8803 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.86 · 95% CI 0.11 to 6.55
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2096 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.98 · 95% CI 0.54 to 16.46
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0110 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.69 · 95% CI 1.60 to 37.11
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0845 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.09 · 95% CI 0.86 to 11.11
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1094 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.83 · 95% CI 0.79 to 10.13
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.97 · 95% CI 2.68 to 30.07
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0016 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.11 · 95% CI 2.10 to 24.09
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4375 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.44 to 6.64
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0898 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.02 · 95% CI 0.84 to 10.85
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0027 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.32 · 95% CI 1.90 to 21.06
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1242 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.44 · 95% CI 0.78 to 7.64
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0815 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.66 · 95% CI 0.88 to 8.03
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.21 · 95% CI 2.11 to 18.27
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0027 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.28 · 95% CI 1.78 to 15.64
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6267 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.35 · 95% CI 0.41 to 4.46
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0709 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.77 · 95% CI 0.92 to 8.38
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0049 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.62 · 95% CI 1.59 to 13.59
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5107 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.50 · 95% CI 0.45 to 4.98
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1297 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.78 to 7.22
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0005 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.04 · 95% CI 2.34 to 21.22
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.50 · 95% CI 2.82 to 25.63
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2990 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.84 · 95% CI 0.58 to 5.81
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1355 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.38 · 95% CI 0.76 to 7.42
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0028 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.17 · 95% CI 1.76 to 15.14
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7422 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.20 · 95% CI 0.41 to 3.47
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0750 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.44 · 95% CI 0.91 to 6.52
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.00 · 95% CI 2.16 to 16.67
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.63 · 95% CI 2.69 to 21.65
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8405 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.12 · 95% CI 0.38 to 3.23
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.6257 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.30 · 95% CI 0.45 to 3.79
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0060 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.92 · 95% CI 1.48 to 10.36
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3556 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.54 to 5.68
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0190 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.67 · 95% CI 1.24 to 10.90
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.90 · 95% CI 3.20 to 30.68
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.81 · 95% CI 4.67 to 47.05
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1936 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.13 · 95% CI 0.68 to 6.67
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0335 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.39 · 95% CI 1.10 to 10.47
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.18 · 95% CI 2.10 to 18.17
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8330 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.90 · 95% CI 0.34 to 2.39
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3410 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.56 · 95% CI 0.62 to 3.91
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0075 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.71 · 95% CI 1.42 to 9.69
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0020 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.86 · 95% CI 1.78 to 13.26
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6216 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.78 · 95% CI 0.29 to 2.10
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.4615 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.43 · 95% CI 0.55 to 3.71
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0281 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.84 · 95% CI 1.12 to 7.19
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8028 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.88 · 95% CI 0.33 to 2.35
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6846 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.21 · 95% CI 0.48 to 3.07
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0149 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.31 · 95% CI 1.26 to 8.67
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.64 · 95% CI 2.03 to 15.65
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6434 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.79 · 95% CI 0.29 to 2.15
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.4784 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.41 · 95% CI 0.54 to 3.69
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0955 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.20 · 95% CI 0.87 to 5.55
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9082 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.06 · 95% CI 0.40 to 2.79
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6478 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.25 · 95% CI 0.48 to 3.21
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0104 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.65 · 95% CI 1.35 to 9.82
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.66 · 95% CI 2.34 to 18.94
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8560 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.91 · 95% CI 0.34 to 2.45
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.3319 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.60 · 95% CI 0.62 to 4.17
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0747 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.34 · 95% CI 0.92 to 5.95
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8986 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.06 · 95% CI 0.41 to 2.76
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9712 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.98 · 95% CI 0.38 to 2.53
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0910 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.31 · 95% CI 1.22 to 8.98
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.68 · 95% CI 2.01 to 16.06
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8466 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.91 · 95% CI 0.35 to 2.39
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1409 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.03 · 95% CI 0.79 to 5.21
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1212 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.08 · 95% CI 0.82 to 5.25
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4269 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.48 · 95% CI 0.56 to 3.88
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5454 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.34 · 95% CI 0.52 to 3.49
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0595 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.62 · 95% CI 0.96 to 7.15
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0041 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.58 · 95% CI 1.62 to 12.98
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6121 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.77 · 95% CI 0.28 to 2.13
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2329 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.80 · 95% CI 0.68 to 4.75
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0891 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.28 · 95% CI 0.88 to 5.90
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6857 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.55 · 95% CI 0.03 to 9.97
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.7291 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.56 · 95% CI 0.12 to 19.71
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.8951 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.82 · 95% CI 0.05 to 14.41
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6865 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.66 · 95% CI 0.14 to 19.74
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.9132 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.17 · 95% CI 0.07 to 20.24
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.7982 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.38 · 95% CI 0.12 to 16.59
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9029 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.17 · 95% CI 0.09 to 15.57
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.7971 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.69 · 95% CI 0.04 to 11.94
SecondaryNumber of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 111010000
Week 212057034
Week 313398249
Week 4124611368
Week 53231010366
Week 616311133512
Week 715513116614
Week 827715125614
Week 9371112153712
Week 104769163815
Week 1137713177813
Week 128710111451210
Week 1300010001
Week 1400000000
Week 1500000000
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7899 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.67 · 95% CI 0.04 to 12.34
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.9186 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.86 · 95% CI 0.05 to 14.73
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5303 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.19 · 95% CI 0.19 to 25.46
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1149 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.85 · 95% CI 0.65 to 52.66
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0442 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.07 · 95% CI 1.06 to 77.71
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2851 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.53 · 95% CI 0.35 to 35.68
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2073 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.22 · 95% CI 0.45 to 39.48
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2700 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.68 · 95% CI 0.36 to 37.16
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2982 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.41 · 95% CI 0.34 to 34.27
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0204 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.30 · 95% CI 1.47 to 102.6
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0270 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.10 · 95% CI 1.31 to 93.74
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5224 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.19 to 25.68
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1635 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.92 · 95% CI 0.52 to 46.35
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0266 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.97 · 95% CI 1.32 to 91.15
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4299 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.69 · 95% CI 0.23 to 31.21
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1667 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.87 · 95% CI 0.52 to 45.84
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0592 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.11 · 95% CI 0.92 to 71.35
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0070 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 18.28 · 95% CI 2.21 to 151.2
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2594 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.79 · 95% CI 0.37 to 38.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0589 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.14 · 95% CI 0.92 to 71.67
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0338 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.08 · 95% CI 1.19 to 85.20
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7756 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.76 · 95% CI 0.12 to 4.88
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9246 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.08 · 95% CI 0.20 to 5.74
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0177 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.42 · 95% CI 1.34 to 21.93
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0178 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.38 · 95% CI 1.34 to 21.65
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8564 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.17 · 95% CI 0.22 to 6.20
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2202 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.52 · 95% CI 0.58 to 11.00
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2498 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.55 to 10.25
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0576 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.22 · 95% CI 0.93 to 72.29
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3065 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.34 · 95% CI 0.33 to 33.59
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0056 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 19.90 · 95% CI 2.40 to 165.1
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0027 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 25.05 · 95% CI 3.05 to 205.5
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2762 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.61 · 95% CI 0.36 to 36.51
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0851 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.93 · 95% CI 0.77 to 62.69
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0081 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 17.02 · 95% CI 2.09 to 138.7
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0995 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.37 · 95% CI 0.70 to 57.62
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1184 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.76 · 95% CI 0.64 to 51.80
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0023 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 26.54 · 95% CI 3.23 to 218.3
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0062 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 19.09 · 95% CI 2.31 to 157.9
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0695 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.49 · 95% CI 0.85 to 65.87
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0520 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.64 · 95% CI 0.98 to 75.98
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0036 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 22.30 · 95% CI 2.75 to 180.6
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0676 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.66 · 95% CI 0.89 to 24.23
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0903 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.14 · 95% CI 0.80 to 21.38
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0007 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 15.46 · 95% CI 3.18 to 75.14
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0032 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.94 · 95% CI 2.22 to 53.77
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2031 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.04 · 95% CI 0.55 to 16.85
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0972 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.13 · 95% CI 0.77 to 22.10
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0027 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.04 · 95% CI 2.30 to 53.06
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1306 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.06 · 95% CI 0.72 to 13.02
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0248 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.83 · 95% CI 1.22 to 19.10
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0054 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.14 · 95% CI 1.79 to 28.53
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0010 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.01 · 95% CI 2.55 to 39.36
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8271 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.21 · 95% CI 0.23 to 6.45
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1089 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.27 · 95% CI 0.77 to 13.95
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0138 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.58 · 95% CI 1.42 to 21.93
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1987 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.40 · 95% CI 0.63 to 9.15
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3984 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.80 · 95% CI 0.46 to 7.02
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0402 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.92 · 95% CI 1.06 to 14.45
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0010 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.05 · 95% CI 2.32 to 27.95
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8287 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.84 · 95% CI 0.17 to 4.08
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1083 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.93 · 95% CI 0.79 to 10.92
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0043 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.03 · 95% CI 1.76 to 20.66
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1126 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.23 · 95% CI 0.76 to 13.79
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1479 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.90 · 95% CI 0.69 to 12.30
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0010 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.49 · 95% CI 2.59 to 42.46
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.01 · 95% CI 3.31 to 51.14
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1483 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.91 · 95% CI 0.68 to 12.41
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0557 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.03 · 95% CI 0.97 to 16.84
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0072 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.47 · 95% CI 1.66 to 25.28
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9715 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.32 to 3.24
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4720 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.49 · 95% CI 0.50 to 4.39
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1262 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.35 · 95% CI 0.79 to 7.05
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0396 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.07 · 95% CI 1.05 to 8.92
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5137 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.66 · 95% CI 0.19 to 2.29
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1370 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.25 · 95% CI 0.77 to 6.58
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5526 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.39 · 95% CI 0.47 to 4.07
SecondaryNumber of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1621252728142325
Week 21531313232252927
Week 31831313333303329
Week 42329313232293231
Week 52330342931323530
Week 62529313130283432
Week 72629333030313229
Week 82831333228303332
Week 92730333231283229
Week 102531292631293531
Week 112531312530313431
Week 122231292729263231
Week 131222181418191616
Week 14111916914181418
Week 15131212812141213
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0012 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.75 · 95% CI 1.99 to 16.62
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.86 · 95% CI 3.06 to 25.68
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.55 · 95% CI 3.94 to 33.85
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.55 · 95% CI 4.55 to 40.38
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0555 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.90 · 95% CI 0.98 to 8.61
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.98 · 95% CI 2.75 to 23.18
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.07 · 95% CI 2.81 to 23.19
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0012 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.55 · 95% CI 1.82 to 11.39
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0005 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.25 · 95% CI 2.06 to 13.43
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.62 · 95% CI 2.20 to 14.39
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.42 · 95% CI 2.99 to 23.74
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0277 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.74 · 95% CI 1.12 to 6.70
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0022 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.15 · 95% CI 1.66 to 10.32
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0314 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.06 · 95% CI 1.26 to 7.41
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0041 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.92 · 95% CI 1.54 to 9.97
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0028 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.19 · 95% CI 1.64 to 10.74
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.96 · 95% CI 1.90 to 12.98
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.79 · 95% CI 2.86 to 26.99
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0036 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.09 · 95% CI 1.59 to 10.57
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0018 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.52 · 95% CI 1.75 to 11.67
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0243 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.76 · 95% CI 1.14 to 6.68
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0770 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.33 · 95% CI 0.91 to 5.96
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0451 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.61 · 95% CI 1.02 to 6.69
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0165 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.36 · 95% CI 1.25 to 9.04
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0037 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.28 · 95% CI 1.72 to 16.23
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0812 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.29 · 95% CI 0.90 to 5.82
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0577 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.46 · 95% CI 0.97 to 6.22
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0706 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.33 · 95% CI 0.93 to 5.85
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0404 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.70 · 95% CI 1.04 to 7.00
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0054 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.30 · 95% CI 1.54 to 11.99
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0186 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.37 · 95% CI 1.22 to 9.27
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0023 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.58 · 95% CI 1.96 to 22.14
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0118 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.63 · 95% CI 1.33 to 9.93
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0020 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.57 · 95% CI 1.88 to 16.53
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0430 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.71 · 95% CI 1.03 to 7.14
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2197 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.81 · 95% CI 0.70 to 4.66
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1341 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.08 · 95% CI 0.80 to 5.42
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0196 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.69 · 95% CI 1.23 to 11.05
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0121 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.79 · 95% CI 1.41 to 16.26
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1511 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.06 · 95% CI 0.77 to 5.56
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0068 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.94 · 95% CI 1.55 to 15.68
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0741 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.49 · 95% CI 0.91 to 6.79
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2772 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.70 · 95% CI 0.65 to 4.43
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0705 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 0.92 to 7.02
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0220 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.88 · 95% CI 1.22 to 12.39
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0196 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.33 · 95% CI 1.27 to 14.82
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0433 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.09 · 95% CI 1.03 to 9.24
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0355 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.15 · 95% CI 1.08 to 9.20
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.3238 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.63 · 95% CI 0.62 to 4.28
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3208 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.68 · 95% CI 0.60 to 4.68
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2281 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.90 · 95% CI 0.67 to 5.40
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0566 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.18 · 95% CI 0.97 to 10.46
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1491 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.39 · 95% CI 0.73 to 7.78
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1477 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.32 · 95% CI 0.74 to 7.23
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0532 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.24 · 95% CI 0.98 to 10.64
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1616 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.73 to 6.76
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4320 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.50 · 95% CI 0.55 to 4.11
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2231 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.90 · 95% CI 0.68 to 5.35
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0347 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.88 · 95% CI 1.10 to 13.64
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0291 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.59 · 95% CI 1.17 to 18.07
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2805 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.82 · 95% CI 0.61 to 5.38
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0602 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.10 · 95% CI 0.95 to 10.11
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5087 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.41 · 95% CI 0.51 to 3.88
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1224 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.26 · 95% CI 0.80 to 6.38
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2280 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.85 · 95% CI 0.68 to 5.02
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1835 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.07 · 95% CI 0.71 to 6.02
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0107 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.85 · 95% CI 1.51 to 22.69
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0576 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.94 · 95% CI 0.97 to 8.96
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0047 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.68 · 95% CI 2.00 to 46.77
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0569 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.89 · 95% CI 0.97 to 8.64
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1078 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.35 · 95% CI 0.83 to 6.68
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0772 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 0.90 to 7.47
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1311 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.36 · 95% CI 0.77 to 7.22
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.01255 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.64 · 95% CI 1.45 to 21.96
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0128 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.97 · 95% CI 1.41 to 17.54
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0079 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.32 · 95% CI 1.62 to 24.63
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0572 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.90 · 95% CI 0.97 to 8.67
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0284 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.33 · 95% CI 1.14 to 9.79
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0705 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.58 · 95% CI 0.92 to 7.22
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0136 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.81 · 95% CI 1.38 to 16.77
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0043 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.96 · 95% CI 2.06 to 48.29
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0760 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.66 · 95% CI 0.90 to 7.83
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0059 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.75 · 95% CI 1.65 to 20.00
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0143 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.22 · 95% CI 1.33 to 13.35
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2779 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.82 · 95% CI 0.62 to 5.35
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7559 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.18 · 95% CI 0.41 to 3.41
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.9050 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.07 · 95% CI 0.35 to 3.23
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.2163 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.05 · 95% CI 0.66 to 6.38
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1713 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.24 · 95% CI 0.70 to 7.14
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.3981 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.63 · 95% CI 0.52 to 5.09
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.9692 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.35 to 2.96
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2978 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.77 · 95% CI 0.60 to 5.22
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8525 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.11 · 95% CI 0.38 to 3.18
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.5028 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.67 · 95% CI 0.21 to 2.13
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.4594 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.53 · 95% CI 0.50 to 4.73
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1124 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.56 · 95% CI 0.80 to 8.17
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.3415 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.75 · 95% CI 0.55 to 5.58
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.3635 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.65 · 95% CI 0.56 to 4.83
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5716 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.73 · 95% CI 0.24 to 2.20
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5028 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.69 · 95% CI 0.23 to 2.05
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3982 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.60 · 95% CI 0.18 to 1.98
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.93 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.93 · 95% CI 0.30 to 2.87
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2364 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.12 · 95% CI 0.61 to 7.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.7095 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.25 · 95% CI 0.39 to 4.04
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.6011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.75 · 95% CI 0.26 to 2.20
SecondaryNumber of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 121114212261117
Week 2918252725152022
Week 31122272828212425
Week 41320292530252825
Week 51620302529252826
Week 61821292728233026
Week 71823322528252825
Week 81926312628212626
Week 92126292729252826
Week 101826282329232925
Week 112127302428263028
Week 122024272427252826
Week 13517911815712
Week 1491087310710
Week 1579841878
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0181 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.78 · 95% CI 1.39 to 33.10
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0039 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.97 · 95% CI 2.10 to 47.48
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 21.20 · 95% CI 4.51 to 99.65
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 23.97 · 95% CI 5.09 to 112.9
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1766 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.17 · 95% CI 0.59 to 16.87
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0116 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.68 · 95% CI 1.58 to 37.43
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0013 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.74 · 95% CI 2.71 to 59.81
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0359 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.82 · 95% CI 1.07 to 7.43
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.80 · 95% CI 2.20 to 15.33
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.13 · 95% CI 2.68 to 18.98
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.84 · 95% CI 2.53 to 18.46
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1540 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.04 · 95% CI 0.76 to 5.47
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0065 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.84 · 95% CI 1.46 to 10.12
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0052 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.90 · 95% CI 1.50 to 10.14
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0064 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.68 · 95% CI 1.44 to 9.39
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.86 · 95% CI 2.26 to 15.21
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.42 · 95% CI 2.47 to 16.69
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.21 · 95% CI 3.01 to 22.42
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0171 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.12 · 95% CI 1.22 to 7.97
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0020 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.38 · 95% CI 1.71 to 11.18
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.97 · 95% CI 1.58 to 9.99
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0399 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.63 · 95% CI 1.05 to 6.59
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.76 · 95% CI 2.23 to 14.84
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0031 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.05 · 95% CI 1.60 to 10.23
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.82 · 95% CI 3.41 to 28.28
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0036 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.96 · 95% CI 1.57 to 10.01
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.79 · 95% CI 1.89 to 12.11
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0091 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.33 · 95% CI 1.35 to 8.21
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2043 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.78 · 95% CI 0.73 to 4.34
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0012 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.70 · 95% CI 1.84 to 12.01
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0058 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.77 · 95% CI 1.47 to 9.70
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.07 · 95% CI 2.73 to 23.83
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0221 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.88 · 95% CI 1.16 to 7.12
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.00 · 95% CI 1.58 to 10.13
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0123 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.22 · 95% CI 1.29 to 8.04
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3291 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.56 · 95% CI 0.64 to 3.78
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0118 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.27 · 95% CI 1.30 to 8.21
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0058 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.93 · 95% CI 1.49 to 10.40
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0012 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.98 · 95% CI 2.03 to 17.65
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1043 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.13 · 95% CI 0.85 to 5.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.01 · 95% CI 1.85 to 13.54
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0658 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.33 · 95% CI 0.95 to 5.73
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1253 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.02 · 95% CI 0.82 to 4.98
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0013 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.01 · 95% CI 1.88 to 13.34
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0096 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.66 · 95% CI 1.37 to 9.75
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0012 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.06 · 95% CI 2.04 to 17.96
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0344 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.75 · 95% CI 1.08 to 7.02
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0045 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.07 · 95% CI 1.55 to 10.72
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0810 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.24 · 95% CI 0.91 to 5.55
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0761 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.29 · 95% CI 0.92 to 5.70
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0078 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.66 · 95% CI 1.41 to 9.51
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0253 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.99 · 95% CI 1.15 to 7.82
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0017 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.23 · 95% CI 1.99 to 19.55
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3512 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.55 · 95% CI 0.62 to 3.87
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0352 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.77 · 95% CI 1.07 to 7.13
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0704 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.36 · 95% CI 0.93 to 5.97
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1651 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.94 · 95% CI 0.76 to 4.93
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0964 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.21 · 95% CI 0.87 to 5.62
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0276 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.12 · 95% CI 1.13 to 8.59
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0060 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.99 · 95% CI 1.58 to 15.70
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1556 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.03 · 95% CI 0.76 to 5.39
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0202 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.33 · 95% CI 1.21 to 9.18
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2063 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.83 · 95% CI 0.72 to 4.67
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0383 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.70 · 95% CI 1.06 to 6.92
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0118 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.46 · 95% CI 1.32 to 9.10
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0314 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.96 · 95% CI 1.10 to 7.97
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0010 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.80 · 95% CI 2.17 to 21.34
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0956 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.24 · 95% CI 0.87 to 5.80
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0027 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.80 · 95% CI 1.72 to 13.40
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0660 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.94 to 6.14
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0853 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.32 · 95% CI 0.89 to 6.05
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0159 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.49 · 95% CI 1.26 to 9.62
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0303 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.27 · 95% CI 1.12 to 9.53
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0071 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.84 · 95% CI 1.54 to 15.28
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0621 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 0.95 to 7.09
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0081 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.20 · 95% CI 1.45 to 12.15
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0533 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 0.99 to 7.09
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2666 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.66 to 4.42
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0754 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.44 · 95% CI 0.91 to 6.52
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0313 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.27 · 95% CI 1.11 to 9.64
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0056 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.76 · 95% CI 1.67 to 19.88
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0736 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.58 · 95% CI 0.91 to 7.28
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0184 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.51 · 95% CI 1.24 to 10.00
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1187 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.18 · 95% CI 0.82 to 5.81
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0299 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.80 · 95% CI 1.14 to 12.69
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5989 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.40 · 95% CI 0.40 to 4.89
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1337 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.61 · 95% CI 0.74 to 9.14
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.4605 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.62 · 95% CI 0.45 to 5.89
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0188 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.48 · 95% CI 1.28 to 15.65
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.5854 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.44 · 95% CI 0.39 to 5.42
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1768 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.32 · 95% CI 0.68 to 7.86
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8426 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.89 · 95% CI 0.29 to 2.78
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3017 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.54 · 95% CI 0.17 to 1.73
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.5958 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.72 · 95% CI 0.21 to 2.43
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0515 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.23 · 95% CI 0.05 to 1.01
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.9734 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.98 · 95% CI 0.31 to 3.11
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.7969 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.85 · 95% CI 0.25 to 2.93
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.6637 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.78 · 95% CI 0.25 to 2.40
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4921 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.53 · 95% CI 0.45 to 5.15
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8910 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.09 · 95% CI 0.33 to 3.64
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.5881 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.68 · 95% CI 0.16 to 2.78
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0523 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.11 · 95% CI 0.01 to 1.02
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4646 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.60 · 95% CI 0.46 to 5.61
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.5806 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.43 · 95% CI 0.40 to 5.14
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.9220 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.94 · 95% CI 0.28 to 3.12
SecondaryNumber of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 11451012246
Week 2381318217714
Week 351215232391418
Week 4812182322121418
Week 5812182024131319
Week 61013212225121421
Week 7912222126121721
Week 81417222227121922
Week 91617222427122021
Week 101418192028161822
Week 111518202026162121
Week 121418191824161922
Week 1315392832
Week 1414341531
Week 1502330141
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1933 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.45 · 95% CI 0.47 to 42.25
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1240 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.61 · 95% CI 0.62 to 50.44
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0140 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.16 · 95% CI 1.71 to 117.2
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0075 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 17.50 · 95% CI 2.15 to 142.7
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5853 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.98 · 95% CI 0.17 to 22.96
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1596 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.00 · 95% CI 0.53 to 47.05
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0908 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.48 · 95% CI 0.74 to 56.51
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1318 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.97 · 95% CI 0.72 to 12.19
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0093 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.99 · 95% CI 1.56 to 23.04
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.13 · 95% CI 2.69 to 38.22
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 15.63 · 95% CI 4.11 to 59.40
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2054 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.53 · 95% CI 0.60 to 10.64
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1592 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.80 · 95% CI 0.67 to 11.72
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0070 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.31 · 95% CI 1.66 to 24.07
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0392 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.39 · 95% CI 1.06 to 10.85
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0096 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.49 · 95% CI 1.44 to 13.96
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.11 · 95% CI 3.28 to 31.16
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.76 · 95% CI 3.75 to 36.90
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2217 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.11 · 95% CI 0.64 to 7.03
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0131 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.26 · 95% CI 1.36 to 13.38
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0031 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.39 · 95% CI 1.76 to 16.46
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1485 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.15 · 95% CI 0.76 to 6.10
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0128 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.54 · 95% CI 1.31 to 9.56
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.50 · 95% CI 2.37 to 17.81
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.42 · 95% CI 2.32 to 17.77
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2354 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.87 · 95% CI 0.67 to 5.26
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0894 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.87 to 6.65
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0201 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.23 · 95% CI 1.20 to 8.67
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1614 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.10 · 95% CI 0.74 to 5.94
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0123 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.57 · 95% CI 1.32 to 9.66
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.08 · 95% CI 2.17 to 17.03
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.82 · 95% CI 3.40 to 28.36
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1609 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.08 · 95% CI 0.75 to 5.81
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0930 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.42 · 95% CI 0.86 to 6.79
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0063 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.02 · 95% CI 1.48 to 10.91
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2621 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.76 · 95% CI 0.65 to 4.74
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0092 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.55 · 95% CI 1.37 to 9.21
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0007 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.69 · 95% CI 2.09 to 15.48
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.85 · 95% CI 3.08 to 25.43
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4259 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.50 · 95% CI 0.55 to 4.08
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1334 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.13 · 95% CI 0.79 to 5.74
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0120 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.39 · 95% CI 1.31 to 8.77
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2443 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.84 · 95% CI 0.66 to 5.10
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0022 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.60 · 95% CI 1.73 to 12.25
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.60 · 95% CI 2.35 to 18.58
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.17 · 95% CI 4.05 to 36.63
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3101 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.70 · 95% CI 0.61 to 4.71
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0116 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.65 · 95% CI 1.34 to 10.00
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0045 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.15 · 95% CI 1.56 to 11.05
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3505 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.55 · 95% CI 0.62 to 3.88
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0739 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.28 · 95% CI 0.92 to 5.62
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0163 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.19 · 95% CI 1.24 to 8.20
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.49 · 95% CI 2.81 to 25.64
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8358 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.90 · 95% CI 0.35 to 2.35
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.18 · 95% CI 0.86 to 5.52
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0484 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.53 · 95% CI 1.01 to 6.34
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6492 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.24 · 95% CI 0.50 to 3.08
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2230 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.71 to 4.27
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0126 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.43 · 95% CI 1.30 to 9.02
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0014 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.56 · 95% CI 1.94 to 15.98
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4713 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.70 · 95% CI 0.27 to 1.83
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1397 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.02 · 95% CI 0.79 to 5.12
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2272 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.75 · 95% CI 0.71 to 4.34
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2024 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.83 · 95% CI 0.72 to 4.64
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1716 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.90 · 95% CI 0.76 to 4.79
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0199 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.20 · 95% CI 1.20 to 8.51
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.45 · 95% CI 2.80 to 25.54
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4243 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.47 · 95% CI 0.57 to 3.77
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1507 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.99 · 95% CI 0.78 to 5.09
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0449 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 1.02 to 6.60
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2759 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.68 · 95% CI 0.66 to 4.24
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1700 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.90 · 95% CI 0.76 to 4.78
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0153 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.47 · 95% CI 1.27 to 9.51
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.04 · 95% CI 2.08 to 17.53
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6228 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.27 · 95% CI 0.50 to 3.23
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0460 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.62 · 95% CI 1.02 to 6.76
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1215 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.07 · 95% CI 0.82 to 5.23
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2470 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.75 · 95% CI 0.68 to 4.48
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2072 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.83 · 95% CI 0.72 to 4.66
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0621 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.57 · 95% CI 0.95 to 6.94
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0016 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.67 · 95% CI 1.93 to 16.69
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4372 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.47 · 95% CI 0.56 to 3.84
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1100 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.18 · 95% CI 0.84 to 5.66
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0533 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 0.99 to 6.59
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1769 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.68 · 95% CI 0.50 to 44.00
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4942 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.26 · 95% CI 0.22 to 23.53
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0214 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.82 · 95% CI 1.46 to 112.7
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.6013 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.93 · 95% CI 0.16 to 22.99
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0537 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.60 · 95% CI 0.97 to 76.58
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2662 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.80 · 95% CI 0.36 to 39.91
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.7431 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.51 · 95% CI 0.13 to 17.84
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2829 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.53 · 95% CI 0.35 to 35.22
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5311 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.12 · 95% CI 0.20 to 22.29
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1857 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.71 · 95% CI 0.47 to 46.83
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.9879 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.06 to 17.50
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1853 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.57 · 95% CI 0.48 to 43.19
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2170 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.43 · 95% CI 0.42 to 46.93
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.8354 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.74 · 95% CI 0.04 to 12.62
SecondaryNumber of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 111033010
Week 2123710046
Week 31569124612
Week 41381014489
Week 54581015678
Week 6181012165615
Week 71710141691015
Week 8491216166915
Week 95912151851215
Week 10791116196917
Week 115911151910915
Week 129812141691413
Week 1301261311
Week 1411220210
Week 1501230110
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9671 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.94 · 95% CI 0.06 to 16.04
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3289 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.16 · 95% CI 0.31 to 31.87
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.3157 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.26 · 95% CI 0.32 to 32.71
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.991 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.00 · 95% CI 0.06 to 16.83
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5139 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.26 · 95% CI 0.20 to 26.12
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3079 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.32 · 95% CI 0.33 to 33.45
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0469 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.83 · 95% CI 1.03 to 75.68
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0134 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.39 · 95% CI 1.74 to 119.1
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1606 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.98 · 95% CI 0.53 to 46.90
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0854 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.69 · 95% CI 0.77 to 58.35
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1082 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.07 · 95% CI 0.67 to 54.72
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0737 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.22 · 95% CI 0.83 to 63.04
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0217 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.98 · 95% CI 1.44 to 99.74
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0058 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 19.24 · 95% CI 2.36 to 157.1
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1924 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.44 · 95% CI 0.47 to 41.87
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0680 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.54 · 95% CI 0.86 to 66.00
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0095 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 15.95 · 95% CI 1.97 to 129.4
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2690 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.68 · 95% CI 0.36 to 37.21
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0321 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.28 · 95% CI 1.22 to 86.53
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0131 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.48 · 95% CI 1.75 to 119.7
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0025 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 25.22 · 95% CI 3.11 to 204.6
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1788 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.65 · 95% CI 0.49 to 43.72
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0320 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.33 · 95% CI 1.22 to 87.31
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0251 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.24 · 95% CI 1.35 to 93.33
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6154 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.43 · 95% CI 0.35 to 5.83
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1906 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.65 to 8.63
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0450 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.67 · 95% CI 1.03 to 13.07
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0017 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.19 · 95% CI 2.10 to 24.66
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3939 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.80 · 95% CI 0.47 to 6.97
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2869 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.06 · 95% CI 0.55 to 7.74
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1817 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.66 to 8.80
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0256 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.41 · 95% CI 1.35 to 96.77
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0153 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.65 · 95% CI 1.65 to 112.8
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0042 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 21.76 · 95% CI 2.64 to 179.2
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0008 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 35.75 · 95% CI 4.39 to 291.5
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0967 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.45 · 95% CI 0.71 to 58.21
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0564 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.30 · 95% CI 0.94 to 72.95
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0030 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 23.63 · 95% CI 2.93 to 190.5
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0384 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.72 · 95% CI 1.13 to 83.68
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0153 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.65 · 95% CI 1.65 to 112.9
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 30.55 · 95% CI 3.72 to 250.6
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0008 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 35.99 · 95% CI 4.41 to 293.5
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0192 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.67 · 95% CI 1.51 to 106.1
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0089 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 16.92 · 95% CI 2.03 to 141.0
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0025 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 24.96 · 95% CI 3.09 to 201.6
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0910 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.03 · 95% CI 0.84 to 10.94
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0296 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.96 · 95% CI 1.15 to 13.67
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.23 · 95% CI 2.38 to 28.44
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0007 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.54 · 95% CI 2.46 to 29.63
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4152 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.76 · 95% CI 0.45 to 6.86
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0700 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.29 · 95% CI 0.91 to 11.93
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0048 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.83 · 95% CI 1.71 to 19.84
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1497 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.44 · 95% CI 0.72 to 8.23
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0608 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.05 · 95% CI 0.95 to 9.77
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0028 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.99 · 95% CI 1.85 to 19.34
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0005 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.84 · 95% CI 2.45 to 25.13
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8393 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.15 · 95% CI 0.30 to 4.39
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0215 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.01 · 95% CI 1.23 to 13.10
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0112 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.42 · 95% CI 1.40 to 13.94
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3498 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.55 to 5.29
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1981 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.05 · 95% CI 0.69 to 6.08
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0029 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.28 · 95% CI 1.76 to 15.78
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.95 · 95% CI 2.03 to 17.40
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.9511 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.96 · 95% CI 0.29 to 3.23
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.3241 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.76 · 95% CI 0.57 to 5.45
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0111 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.90 · 95% CI 1.36 to 11.16
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1375 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.51 · 95% CI 0.74 to 8.48
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0670 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.02 · 95% CI 0.93 to 9.83
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0009 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.57 · 95% CI 2.29 to 25.04
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.42 · 95% CI 2.91 to 30.49
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0982 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.75 · 95% CI 0.83 to 9.14
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1233 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 0.77 to 8.80
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0091 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.63 · 95% CI 1.46 to 14.64
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9620 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.03 · 95% CI 0.34 to 3.10
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3527 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.63 · 95% CI 0.58 to 4.59
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0394 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.04 · 95% CI 1.06 to 8.76
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0224 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.36 · 95% CI 1.19 to 9.53
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.7891 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.16 · 95% CI 0.39 to 3.44
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0851 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.48 · 95% CI 0.88 to 6.99
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2885 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.63 to 4.83
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8611 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.78 · 95% CI 0.05 to 13.30
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7549 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.48 · 95% CI 0.13 to 17.42
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.5658 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.07 · 95% CI 0.17 to 24.66
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6319 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.83 · 95% CI 0.15 to 21.86
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.9526 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.09 · 95% CI 0.06 to 18.96
SecondaryNumber of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 12027323533233432
Week 22834323833323633
Week 32933353735343539
Week 43031343535334039
Week 53334383334363836
Week 63336373333333739
Week 73234363233323738
Week 83435363432333737
Week 93334373333323737
Week 103434322933333636
Week 113433342731333636
Week 123134312831313535
Week 131730262222212528
Week 141722261621202125
Week 151818201220121622
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2251 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.71 to 4.26
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0084 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.57 · 95% CI 1.39 to 9.20
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0007 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.71 · 95% CI 2.09 to 15.62
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.11 · 95% CI 1.87 to 14.00
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6976 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.20 · 95% CI 0.48 to 2.95
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0021 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.57 · 95% CI 1.73 to 12.05
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0171 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.06 · 95% CI 1.22 to 7.68
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2224 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.86 · 95% CI 0.69 to 5.04
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2716 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.65 to 4.69
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0112 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.49 · 95% CI 1.41 to 14.32
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0461 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.08 · 95% CI 1.02 to 9.31
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3463 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.63 · 95% CI 0.59 to 4.47
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0419 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.05 · 95% CI 1.04 to 8.92
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2977 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.68 · 95% CI 0.63 to 4.46
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2300 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.87 · 95% CI 0.67 to 5.21
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0655 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.83 · 95% CI 0.94 to 8.58
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0245 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.79 · 95% CI 1.19 to 12.11
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0129 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.62 · 95% CI 1.44 to 21.93
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1259 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.79 to 7.15
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.40 · 95% CI 0.84 to 6.82
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0167 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.48 · 95% CI 1.31 to 15.33
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5232 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.40 · 95% CI 0.50 to 3.95
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2055 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.00 · 95% CI 0.68 to 5.82
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0658 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.00 · 95% CI 0.93 to 9.64
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0136 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.34 · 95% CI 1.51 to 35.75
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3238 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.59 to 5.00
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0118 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.86 · 95% CI 1.48 to 23.21
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0163 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.29 · 95% CI 1.36 to 20.62
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6363 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.32 · 95% CI 0.42 to 4.18
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0722 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.68 · 95% CI 0.89 to 15.25
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.35 · 95% CI 0.63 to 8.73
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0337 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.15 · 95% CI 1.20 to 86.09
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2207 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.25 · 95% CI 0.61 to 8.24
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0849 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.50 · 95% CI 0.84 to 14.57
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0844 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.47 · 95% CI 0.84 to 14.24
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2383 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.15 · 95% CI 0.60 to 7.65
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1653 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 0.68 to 9.58
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1836 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.48 · 95% CI 0.65 to 9.48
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0529 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.30 · 95% CI 0.97 to 70.80
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3197 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.95 · 95% CI 0.52 to 7.27
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0376 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.88 · 95% CI 1.11 to 31.25
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0343 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.08 · 95% CI 1.19 to 85.64
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4435 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.58 · 95% CI 0.49 to 5.09
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1805 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.34 · 95% CI 0.67 to 8.13
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0857 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.54 · 95% CI 0.84 to 14.95
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0316 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.50 · 95% CI 1.23 to 89.63
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3471 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.81 · 95% CI 0.52 to 6.27
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0313 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.15 · 95% CI 1.18 to 32.09
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0208 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.49 · 95% CI 1.47 to 106.3
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8669 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.11 · 95% CI 0.31 to 3.97
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6592 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.34 · 95% CI 0.37 to 4.89
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2923 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.23 · 95% CI 0.50 to 9.98
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1145 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.78 · 95% CI 0.65 to 51.04
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4470 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.77 · 95% CI 0.40 to 7.78
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0753 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.31 · 95% CI 0.82 to 65.41
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0829 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.85 · 95% CI 0.78 to 60.24
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9978 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.00 · 95% CI 0.28 to 3.59
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4571 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.68 · 95% CI 0.43 to 6.65
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3681 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.99 · 95% CI 0.44 to 8.94
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1038 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.12 · 95% CI 0.69 to 54.38
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4639 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.39 to 7.72
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0770 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.15 · 95% CI 0.81 to 63.27
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9838 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.01 · 95% CI 0.26 to 4.01
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6995 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.77 · 95% CI 0.21 to 2.86
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.8808 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.12 · 95% CI 0.26 to 4.71
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1570 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.94 · 95% CI 0.54 to 45.13
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3742 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.19 · 95% CI 0.39 to 12.26
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1436 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.24 · 95% CI 0.57 to 48.26
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1277 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.57 · 95% CI 0.61 to 50.77
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6689 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.75 · 95% CI 0.20 to 2.81
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.20 · 95% CI 0.29 to 4.95
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.9591 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.96 · 95% CI 0.23 to 4.05
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.3364 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.33 · 95% CI 0.42 to 13.06
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3698 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.20 · 95% CI 0.39 to 12.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1587 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.92 · 95% CI 0.54 to 45.01
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1300 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.50 · 95% CI 0.61 to 50.06
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4152 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.81 · 95% CI 0.43 to 7.53
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9645 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.97 · 95% CI 0.27 to 3.50
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3884 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.95 · 95% CI 0.43 to 8.96
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2670 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.62 · 95% CI 0.48 to 14.41
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0861 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.91 · 95% CI 0.76 to 62.90
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0774 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.21 · 95% CI 0.80 to 64.66
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0389 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.73 · 95% CI 1.08 to 20.65
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3695 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.81 · 95% CI 0.50 to 6.57
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3501 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.95 · 95% CI 0.48 to 7.89
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.2021 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.49 · 95% CI 0.61 to 10.14
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6201 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.42 · 95% CI 0.36 to 5.62
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0235 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.71 · 95% CI 1.42 to 132.0
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0929 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.43 · 95% CI 0.81 to 14.48
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9820 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.99 · 95% CI 0.29 to 3.33
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4956 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.55 · 95% CI 0.44 to 5.41
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.5708 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.70 · 95% CI 0.20 to 2.44
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1985 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 0.61 to 10.61
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8368 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.15 · 95% CI 0.31 to 4.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1397 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.18 · 95% CI 0.68 to 14.76
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0366 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.88 · 95% CI 0.52 to 6.85
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7968 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.84 · 95% CI 0.23 to 3.05
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9074 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.08 · 95% CI 0.30 to 3.81
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1987 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.41 · 95% CI 0.10 to 1.60
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.2040 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.58 · 95% CI 0.60 to 11.18
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3318 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.51 · 95% CI 0.13 to 1.99
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.7437 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.26 · 95% CI 0.31 to 5.10
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.6848 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.30 · 95% CI 0.36 to 4.71
SecondaryNumber of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 11423293228183129
Week 21930303632283331
Week 32431303634293432
Week 42630323434293534
Week 52931363333343533
Week 62829333132303638
Week 73031343032313738
Week 83132343229313734
Week 93032333232313634
Week 102932292931313634
Week 113031302730323634
Week 122831312728303433
Week 131624202118201926
Week 141518211517171823
Week 151715181213111417
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1114 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.12 · 95% CI 0.84 to 5.32
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0013 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.69 · 95% CI 1.83 to 12.04
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.01 · 95% CI 2.65 to 18.54
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0010 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.96 · 95% CI 1.91 to 12.89
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6384 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.25 · 95% CI 0.49 to 3.22
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.77 · 95% CI 2.23 to 14.93
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0025 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.15 · 95% CI 1.65 to 10.45
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0279 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.82 · 95% CI 1.12 to 7.12
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0114 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.36 · 95% CI 1.31 to 8.61
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.55 · 95% CI 2.66 to 21.45
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0005 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.41 · 95% CI 2.25 to 18.26
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0695 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.93 to 6.02
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.83 · 95% CI 1.83 to 12.77
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0120 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.28 · 95% CI 1.30 to 8.28
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.662 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.49 · 95% CI 0.94 to 6.57
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.85 to 5.80
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0023 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.44 · 95% CI 1.83 to 16.18
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.33 · 95% CI 2.15 to 25.02
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2380 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.78 · 95% CI 0.68 to 4.66
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0120 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.61 · 95% CI 1.33 to 9.81
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0910 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.25 · 95% CI 0.88 to 5.77
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1926 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.93 · 95% CI 0.72 to 5.18
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1017 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.29 · 95% CI 0.85 to 6.15
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0153 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.85 · 95% CI 1.29 to 11.45
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.52 · 95% CI 1.95 to 28.98
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4539 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.44 · 95% CI 0.55 to 3.76
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0327 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.03 · 95% CI 1.10 to 8.40
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0555 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.67 · 95% CI 0.98 to 7.30
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3505 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.64 · 95% CI 0.58 to 4.67
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0265 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.92 · 95% CI 1.17 to 13.11
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0174 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.77 · 95% CI 1.32 to 17.32
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0075 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.95 · 95% CI 1.80 to 44.61
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1228 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.46 · 95% CI 0.78 to 7.68
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0431 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.28 · 95% CI 1.04 to 10.38
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0851 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.70 · 95% CI 0.87 to 8.35
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4726 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.45 · 95% CI 0.53 to 3.99
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1289 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.29 · 95% CI 0.79 to 6.67
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0400 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.39 · 95% CI 1.06 to 10.84
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0097 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.22 · 95% CI 1.67 to 40.55
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2260 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.97 · 95% CI 0.66 to 5.94
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0031 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.63 · 95% CI 2.07 to 35.96
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0043 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.16 · 95% CI 2.07 to 49.90
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5571 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.38 · 95% CI 0.47 to 4.04
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1911 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.13 · 95% CI 0.69 to 6.59
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1101 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.74 · 95% CI 0.80 to 9.41
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0199 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.86 · 95% CI 1.36 to 34.74
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2600 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.96 · 95% CI 0.61 to 6.33
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0090 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.93 · 95% CI 1.73 to 46.19
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0089 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 17.22 · 95% CI 2.04 to 145.2
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8966 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.07 · 95% CI 0.36 to 3.19
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5031 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.47 · 95% CI 0.48 to 4.51
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2603 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.03 · 95% CI 0.59 to 6.92
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.2447 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.16 · 95% CI 0.59 to 7.88
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4239 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.64 · 95% CI 0.49 to 5.55
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0240 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.72 · 95% CI 1.38 to 99.35
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1457 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 0.72 to 9.41
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9000 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.08 · 95% CI 0.34 to 3.38
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7644 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.19 · 95% CI 0.39 to 3.64
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2245 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.29 · 95% CI 0.60 to 8.67
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0475 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.28 · 95% CI 1.02 to 27.40
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2569 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.15 · 95% CI 0.57 to 8.07
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0412 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.32 · 95% CI 1.09 to 79.44
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1201 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.84 · 95% CI 0.76 to 10.61
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3814 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.67 · 95% CI 0.53 to 5.23
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8549 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.11 · 95% CI 0.38 to 3.23
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1274 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.77 · 95% CI 0.75 to 10.24
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0703 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.67 · 95% CI 0.90 to 15.01
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1821 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.66 to 8.76
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0187 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.96 · 95% CI 1.53 to 109.5
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0458 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.18 · 95% CI 1.03 to 17.00
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6806 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.27 · 95% CI 0.41 to 3.89
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8090 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.15 · 95% CI 0.38 to 3.45
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2352 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.60 to 8.26
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1231 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.04 · 95% CI 0.74 to 12.50
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1445 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.86 · 95% CI 0.70 to 11.76
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0230 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.03 · 95% CI 1.41 to 102.7
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0801 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.51 · 95% CI 0.86 to 14.36
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4152 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.63 · 95% CI 0.50 to 5.32
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3845 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.70 · 95% CI 0.51 to 5.65
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1864 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.46 · 95% CI 0.65 to 9.39
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.01268 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.06 · 95% CI 0.73 to 12.86
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1600 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.80 · 95% CI 0.67 to 11.76
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0317 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.13 · 95% CI 1.17 to 32.11
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0709 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.73 · 95% CI 0.89 to 15.53
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4533 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.60 · 95% CI 0.47 to 5.41
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7053 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.80 · 95% CI 0.24 to 2.60
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3677 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.84 · 95% CI 0.49 to 6.99
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.7350 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.24 · 95% CI 0.35 to 4.40
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6443 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.37 · 95% CI 0.36 to 5.15
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.4865 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.58 · 95% CI 0.43 to 5.76
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1628 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.52 · 95% CI 0.69 to 9.27
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6935 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.79 · 95% CI 0.24 to 2.57
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9753 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.32 to 3.28
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.7407 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.81 · 95% CI 0.23 to 2.81
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.4929 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.55 · 95% CI 0.44 to 5.49
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8496 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.88 · 95% CI 0.25 to 3.15
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.3248 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.92 · 95% CI 0.52 to 7.05
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2589 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.03 · 95% CI 0.59 to 6.92
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3318 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.54 · 95% CI 0.16 to 1.87
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8536 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.89 · 95% CI 0.26 to 3.01
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2817 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.48 · 95% CI 0.12 to 1.84
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.4091 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.59 · 95% CI 0.17 to 2.07
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3147 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.50 · 95% CI 0.13 to 1.93
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.8547 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.89 · 95% CI 0.24 to 3.24
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5023 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.66 · 95% CI 0.20 to 2.19
SecondaryNumber of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1821212624162229
Week 21627293328252726
Week 31828273331263331
Week 42227283130263231
Week 52428313033283431
Week 62728273130263433
Week 72727323030263332
Week 82829323129283430
Week 92830313231283532
Week 102729272830303431
Week 112728282630303531
Week 122526282727273332
Week 131220161817181723
Week 141416171213161518
Week 15151413912101213
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0093 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.99 · 95% CI 1.41 to 11.35
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0035 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.66 · 95% CI 1.66 to 13.09
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.48 · 95% CI 3.01 to 23.90
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.57 · 95% CI 2.65 to 21.59
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1664 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.13 · 95% CI 0.73 to 6.22
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0012 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.39 · 95% CI 1.94 to 14.96
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.85 · 95% CI 3.49 to 27.86
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0334 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.73 · 95% CI 1.08 to 6.89
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.12 · 95% CI 1.60 to 10.62
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.55 · 95% CI 2.45 to 17.47
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0014 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.90 · 95% CI 1.85 to 12.98
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0872 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.26 · 95% CI 0.89 to 5.74
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0131 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.19 · 95% CI 1.28 to 7.98
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0386 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 1.05 to 6.43
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0191 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.11 · 95% CI 1.20 to 8.05
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0291 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.84 · 95% CI 1.11 to 7.26
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.09 · 95% CI 2.23 to 16.58
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.24 · 95% CI 2.49 to 21.02
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0992 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.86 to 5.72
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.66 · 95% CI 2.11 to 15.16
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0060 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.74 · 95% CI 1.46 to 9.59
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1472 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.01 · 95% CI 0.78 to 5.14
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1284 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.05 · 95% CI 0.81 to 5.15
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0117 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.55 · 95% CI 1.32 to 9.50
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0067 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.24 · 95% CI 1.49 to 12.03
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4088 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.47 · 95% CI 0.59 to 3.71
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0194 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.09 · 95% CI 1.20 to 7.96
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0423 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 1.03 to 6.73
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2151 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.86 · 95% CI 0.70 to 4.99
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0531 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.71 · 95% CI 0.99 to 7.42
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0118 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.11 · 95% CI 1.37 to 12.34
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 16.28 · 95% CI 3.29 to 80.46
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3698 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.57 · 95% CI 0.59 to 4.22
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0059 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.58 · 95% CI 1.55 to 13.53
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0241 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.32 · 95% CI 1.17 to 9.44
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5308 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.38 · 95% CI 0.50 to 3.77
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8603 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.09 · 95% CI 0.41 to 2.90
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0264 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.73 · 95% CI 1.17 to 11.95
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0188 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.60 · 95% CI 1.29 to 16.42
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.7642 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.17 · 95% CI 0.42 to 3.27
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0101 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.91 · 95% CI 1.46 to 16.53
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0572 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.88 · 95% CI 0.97 to 8.55
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7348 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.19 · 95% CI 0.44 to 3.20
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1397 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.20 · 95% CI 0.77 to 6.25
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0231 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.07 · 95% CI 1.21 to 13.64
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0196 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.54 · 95% CI 1.27 to 16.15
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.7703 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.16 · 95% CI 0.42 to 3.24
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0222 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.83 · 95% CI 1.21 to 12.12
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0668 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.77 · 95% CI 0.93 to 8.21
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7533 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.18 · 95% CI 0.43 to 3.22
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3325 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.67 · 95% CI 0.59 to 4.73
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0899 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.71 · 95% CI 0.86 to 8.57
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0642 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.31 · 95% CI 0.93 to 11.79
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5964 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.34 · 95% CI 0.46 to 3.89
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0224 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.43 · 95% CI 1.23 to 15.91
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.3139 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.72 · 95% CI 0.60 to 4.96
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6343 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.30 · 95% CI 0.45 to 3.76
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6557 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.27 · 95% CI 0.45 to 3.61
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0516 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.66 · 95% CI 0.99 to 13.51
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0400 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.38 · 95% CI 1.07 to 17.91
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5825 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.37 · 95% CI 0.44 to 4.24
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0152 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.46 · 95% CI 1.47 to 37.83
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1565 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.30 · 95% CI 0.73 to 7.30
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4932 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.45 · 95% CI 0.50 to 4.25
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8504 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.11 · 95% CI 0.39 to 3.12
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0759 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.07 · 95% CI 0.89 to 10.61
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0477 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.69 · 95% CI 1.01 to 13.46
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1448 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.47 · 95% CI 0.73 to 8.36
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0173 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.54 · 95% CI 1.35 to 22.71
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1101 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.57 · 95% CI 0.81 to 8.17
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6022 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.32 · 95% CI 0.46 to 3.78
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6128 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.31 · 95% CI 0.46 to 3.73
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.82 · 95% CI 0.82 to 9.68
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0255 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.95 · 95% CI 1.22 to 20.12
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1521 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.42 · 95% CI 0.72 to 8.10
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0071 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.37 · 95% CI 1.84 to 47.69
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1150 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.52 · 95% CI 0.80 to 7.93
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8101 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.14 · 95% CI 0.40 to 3.22
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4663 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.49 · 95% CI 0.51 to 4.33
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0453 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.80 · 95% CI 1.03 to 14.01
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0659 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.36 · 95% CI 0.92 to 12.21
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3117 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.83 · 95% CI 0.57 to 5.86
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0129 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.02 · 95% CI 1.46 to 24.73
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0303 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.12 · 95% CI 1.14 to 14.83
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2772 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.94 · 95% CI 0.59 to 6.42
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9432 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.96 · 95% CI 0.29 to 3.16
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2577 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.08 · 95% CI 0.59 to 7.36
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1496 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 0.71 to 9.12
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2874 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.05 · 95% CI 0.55 to 7.67
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1981 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.26 · 95% CI 0.65 to 7.78
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0531 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.35 · 95% CI 0.98 to 11.43
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5858 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.72 · 95% CI 0.22 to 2.35
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5122 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.68 · 95% CI 0.21 to 2.16
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3415 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.55 · 95% CI 0.16 to 1.89
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.8263 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.87 · 95% CI 0.25 to 2.98
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8085 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.86 · 95% CI 0.24 to 3.03
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.6745 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.30 · 95% CI 0.38 to 4.43
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.9019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.08 · 95% CI 0.34 to 3.45
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4425 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.62 · 95% CI 0.18 to 2.10
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3106 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.54 · 95% CI 0.17 to 1.77
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0912 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.32 · 95% CI 0.08 to 1.20
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.5681 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.70 · 95% CI 0.20 to 2.41
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.4261 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.58 · 95% CI 0.15 to 2.21
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.7514 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.82 · 95% CI 0.24 to 2.82
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2712 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.52 · 95% CI 0.16 to 1.67
SecondaryNumber of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1517192221131820
Week 21425242724212326
Week 31625252927252927
Week 41724262528243127
Week 52024262628263228
Week 62224253027253030
Week 72227272728242830
Week 82226262826233130
Week 92625262828233230
Week 102226232529253230
Week 112427252427273330
Week 122323262226243129
Week 13918131414171317
Week 14101512109161314
Week 15111198791112
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0103 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.89 · 95% CI 1.46 to 16.40
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.19 · 95% CI 2.20 to 23.48
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.06 · 95% CI 3.41 to 35.86
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.48 · 95% CI 3.18 to 34.55
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1571 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.46 · 95% CI 0.71 to 8.55
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0010 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.14 · 95% CI 2.21 to 23.04
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0008 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.35 · 95% CI 2.29 to 23.61
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0342 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.78 · 95% CI 1.08 to 7.18
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0231 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.98 · 95% CI 1.16 to 7.66
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0032 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.12 · 95% CI 1.60 to 10.55
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0059 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.89 · 95% CI 1.48 to 10.22
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2471 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.76 · 95% CI 0.68 to 4.59
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0381 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.66 · 95% CI 1.05 to 6.70
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0113 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.34 · 95% CI 1.31 to 8.48
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0486 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.56 · 95% CI 1.01 to 6.52
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0350 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.71 · 95% CI 1.07 to 6.87
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0027 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.24 · 95% CI 1.65 to 10.90
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0020 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.68 · 95% CI 1.76 to 12.47
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0686 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.94 to 6.19
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.02 · 95% CI 1.58 to 10.21
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0222 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.90 · 95% CI 1.16 to 7.22
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0876 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.28 · 95% CI 0.89 to 5.84
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0345 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.72 · 95% CI 1.08 to 6.88
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0319 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.76 · 95% CI 1.09 to 6.99
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0013 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.27 · 95% CI 1.92 to 14.47
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1751 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.91 · 95% CI 0.75 to 4.87
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.46 · 95% CI 1.73 to 11.50
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0284 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.79 · 95% CI 1.11 to 6.97
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2650 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.72 · 95% CI 0.66 to 4.45
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1238 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.10 · 95% CI 0.82 to 5.38
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0219 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.22 · 95% CI 1.18 to 8.74
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0022 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.46 · 95% CI 1.84 to 16.16
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2230 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.82 · 95% CI 0.69 to 4.77
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0018 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.05 · 95% CI 1.83 to 13.97
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0205 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.17 · 95% CI 1.19 to 8.42
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4628 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.44 · 95% CI 0.54 to 3.81
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.51 · 95% CI 0.58 to 3.92
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0031 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.39 · 95% CI 1.76 to 16.47
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0115 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.15 · 95% CI 1.38 to 12.50
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2513 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.81 · 95% CI 0.66 to 4.98
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0099 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.94 · 95% CI 1.39 to 11.14
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0242 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.19 · 95% CI 1.16 to 8.74
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1518 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.07 · 95% CI 0.77 to 5.60
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1811 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.95 · 95% CI 0.73 to 5.17
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0150 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.88 · 95% CI 1.30 to 11.55
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0046 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.28 · 95% CI 1.67 to 16.68
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3788 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.58 · 95% CI 0.57 to 4.34
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0424 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.82 · 95% CI 1.04 to 7.70
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0139 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.69 · 95% CI 1.30 to 10.43
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3057 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.67 · 95% CI 0.63 to 4.42
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3717 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.55 · 95% CI 0.59 to 4.02
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0252 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.32 · 95% CI 1.16 to 9.50
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0235 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.56 · 95% CI 1.19 to 10.69
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6580 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.25 · 95% CI 0.46 to 3.39
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0061 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.58 · 95% CI 1.54 to 13.62
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0149 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.70 · 95% CI 1.29 to 10.61
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9282 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.95 · 95% CI 0.35 to 2.62
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7902 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.87 · 95% CI 0.33 to 2.35
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1603 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.73 to 6.74
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1144 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 0.80 to 8.14
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5903 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.75 · 95% CI 0.26 to 2.13
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0290 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.89 · 95% CI 1.15 to 13.16
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1721 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.12 · 95% CI 0.72 to 6.26
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2439 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.83 · 95% CI 0.66 to 5.09
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7402 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.18 · 95% CI 0.44 to 3.19
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0422 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.17 · 95% CI 1.04 to 9.63
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0061 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.44 · 95% CI 1.62 to 18.27
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3191 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.59 to 4.92
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0037 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.91 · 95% CI 1.78 to 19.66
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0139 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.02 · 95% CI 1.33 to 12.20
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3757 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.59 · 95% CI 0.57 to 4.42
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7087 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.21 · 95% CI 0.45 to 3.28
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1083 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.53 · 95% CI 0.81 to 7.88
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0473 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.21 · 95% CI 1.01 to 10.14
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2481 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.89 · 95% CI 0.64 to 5.60
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0066 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.84 · 95% CI 1.64 to 20.89
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0466 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.06 · 95% CI 1.02 to 9.18
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8769 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.92 · 95% CI 0.34 to 2.53
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5448 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.37 · 95% CI 0.49 to 3.82
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.4125 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.57 · 95% CI 0.53 to 4.64
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0500 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.36 · 95% CI 1.00 to 11.30
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6167 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.32 · 95% CI 0.45 to 3.87
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0233 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.00 · 95% CI 1.21 to 13.26
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0803 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.68 · 95% CI 0.89 to 8.09
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1274 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 0.76 to 9.18
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9445 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.05 · 95% CI 0.29 to 3.71
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.4204 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.69 · 95% CI 0.47 to 6.03
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1315 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.78 · 95% CI 0.74 to 10.49
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0944 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.24 · 95% CI 0.82 to 12.87
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2801 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.99 · 95% CI 0.57 to 6.89
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1524 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.44 · 95% CI 0.72 to 8.30
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6129 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.38 · 95% CI 0.40 to 4.75
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4617 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.63 · 95% CI 0.18 to 2.18
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.6519 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.74 · 95% CI 0.20 to 2.70
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.8011 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.84 · 95% CI 0.22 to 3.18
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3254 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.95 · 95% CI 0.51 to 7.41
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2730 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.00 · 95% CI 0.58 to 6.94
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.6601 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.31 · 95% CI 0.39 to 4.41
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6588 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.74 · 95% CI 0.20 to 2.76
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3257 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.52 · 95% CI 0.14 to 1.92
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2229 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.42 · 95% CI 0.10 to 1.69
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.2425 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.43 · 95% CI 0.10 to 1.77
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.9672 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.97 · 95% CI 0.23 to 4.11
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.5838 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.43 · 95% CI 0.40 to 5.09
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.9361 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.95 · 95% CI 0.28 to 3.24
SecondaryNumber of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 12233323536283432
Week 23036333736363833
Week 33133363636373739
Week 43134343436364039
Week 53234393235373935
Week 63336373233343738
Week 73335363134343738
Week 83536363233353737
Week 93335373133343737
Week 103435322833343635
Week 113435342632343636
Week 123135312731323535
Week 131729272124242227
Week 141723261720232225
Week 151819221419141721
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0429 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 1.03 to 6.55
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0296 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.81 · 95% CI 1.11 to 7.12
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0032 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.48 · 95% CI 1.65 to 12.13
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.11 · 95% CI 2.31 to 21.90
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2073 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.80 · 95% CI 0.72 to 4.47
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0096 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.54 · 95% CI 1.36 to 9.20
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0462 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.52 · 95% CI 1.02 to 6.27
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1387 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.26 · 95% CI 0.77 to 6.63
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3130 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.60 to 4.84
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0392 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.32 · 95% CI 1.06 to 10.40
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0135 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.70 · 95% CI 1.43 to 22.71
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0840 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.85 · 95% CI 0.87 to 9.36
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0163 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.47 · 95% CI 1.32 to 15.17
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5056 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.41 · 95% CI 0.52 to 3.84
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3358 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.69 · 95% CI 0.58 to 4.90
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0696 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.05 · 95% CI 0.91 to 10.18
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0794 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.80 · 95% CI 0.89 to 8.82
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0149 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.32 · 95% CI 1.48 to 36.28
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0377 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.37 · 95% CI 1.09 to 17.59
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0454 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.32 · 95% CI 1.03 to 10.77
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0390 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.77 · 95% CI 1.07 to 13.26
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1947 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.12 · 95% CI 0.68 to 6.64
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2913 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.79 · 95% CI 0.61 to 5.25
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1665 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.21 · 95% CI 0.72 to 6.82
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0157 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.41 · 95% CI 1.63 to 110.3
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0846 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.01 · 95% CI 0.86 to 10.49
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0171 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.42 · 95% CI 1.35 to 21.75
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0262 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.71 · 95% CI 1.20 to 18.49
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2858 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.88 · 95% CI 0.59 to 5.95
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0155 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.65 · 95% CI 1.47 to 39.72
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1249 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.66 · 95% CI 0.76 to 9.31
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0616 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.85 · 95% CI 0.94 to 15.82
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0126 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.32 · 95% CI 1.58 to 43.90
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0853 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.10 · 95% CI 0.85 to 11.23
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1562 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.56 · 95% CI 0.70 to 9.35
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1297 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.83 · 95% CI 0.74 to 10.91
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.34 · 95% CI 0.64 to 8.55
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0495 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.60 · 95% CI 1.00 to 73.70
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1553 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.86 · 95% CI 0.67 to 12.20
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0199 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.67 · 95% CI 1.38 to 42.67
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0472 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.28 · 95% CI 1.02 to 27.34
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3736 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.75 · 95% CI 0.51 to 5.98
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2628 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.06 · 95% CI 0.58 to 7.26
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1998 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.43 · 95% CI 0.63 to 9.39
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1507 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.89 · 95% CI 0.68 to 12.28
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0385 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.92 · 95% CI 1.10 to 31.94
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0299 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.85 · 95% CI 1.26 to 93.28
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.8034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.19 · 95% CI 0.30 to 4.74
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8532 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.14 · 95% CI 0.29 to 4.42
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.8823 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.11 · 95% CI 0.28 to 4.41
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1651 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.79 · 95% CI 0.52 to 43.76
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1048 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.36 · 95% CI 0.68 to 59.55
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1168 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.87 · 95% CI 0.64 to 53.53
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6936 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.31 · 95% CI 0.35 to 4.95
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4315 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.74 · 95% CI 0.44 to 6.90
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.7936 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.19 · 95% CI 0.31 to 4.53
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0990 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.30 · 95% CI 0.71 to 56.03
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1128 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.86 · 95% CI 0.66 to 52.21
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0732 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.36 · 95% CI 0.83 to 65.38
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6559 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.39 · 95% CI 0.33 to 5.91
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7333 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.80 · 95% CI 0.21 to 2.96
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.9266 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.94 · 95% CI 0.24 to 3.74
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1518 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.04 · 95% CI 0.55 to 46.13
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1714 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.69 · 95% CI 0.51 to 42.91
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1299 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.60 · 95% CI 0.60 to 51.95
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2495 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.75 · 95% CI 0.49 to 15.44
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7065 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.32 · 95% CI 0.31 to 5.60
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7504 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.26 · 95% CI 0.30 to 5.24
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.7862 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.83 · 95% CI 0.21 to 3.29
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1550 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.98 · 95% CI 0.54 to 45.59
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1706 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.70 · 95% CI 0.51 to 42.96
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1415 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.31 · 95% CI 0.57 to 49.11
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1241 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.67 · 95% CI 0.62 to 51.74
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2169 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 0.57 to 12.29
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9982 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.00 · 95% CI 0.28 to 3.60
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.5364 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.57 · 95% CI 0.38 to 6.54
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1210 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.68 · 95% CI 0.63 to 51.07
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0726 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.65 · 95% CI 0.83 to 70.58
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0749 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.34 · 95% CI 0.82 to 65.81
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0530 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.01 · 95% CI 0.98 to 16.35
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2134 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.32 · 95% CI 0.62 to 8.72
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3688 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.88 · 95% CI 0.48 to 7.41
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0563 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.61 · 95% CI 0.96 to 22.11
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0935 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.94 · 95% CI 0.79 to 19.52
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0901 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.71 · 95% CI 0.81 to 16.93
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1366 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.84 · 95% CI 0.72 to 11.26
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7876 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.19 · 95% CI 0.34 to 4.08
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4658 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.59 · 95% CI 0.45 to 5.59
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.8707 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.90 · 95% CI 0.25 to 3.20
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.3584 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.89 · 95% CI 0.49 to 7.36
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1455 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.13 · 95% CI 0.67 to 14.57
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0661 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.07 · 95% CI 0.90 to 28.66
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.3034 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.97 · 95% CI 0.54 to 7.17
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.9901 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.01 · 95% CI 0.28 to 3.60
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5070 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.55 · 95% CI 0.42 to 5.68
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.7927 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.83 · 95% CI 0.21 to 3.26
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.4426 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.44 to 6.69
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.8925 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.91 · 95% CI 0.23 to 3.56
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.4285 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.79 · 95% CI 0.42 to 7.52
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.9000 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.08 · 95% CI 0.31 to 3.72
SecondaryNumber of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 11525303033233328
Week 22233323534323530
Week 32532313435333733
Week 42632323335333734
Week 53134363134363733
Week 63033333033333637
Week 73132332933323437
Week 83233333131333532
Week 93032333133333434
Week 102833302833343634
Week 113032312632343633
Week 122832312631313433
Week 131625222021222126
Week 141521211418191922
Week 151817181215131617
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0602 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.96 to 6.06
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0010 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.88 · 95% CI 1.89 to 12.57
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.24 · 95% CI 2.03 to 13.51
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.07 · 95% CI 3.23 to 25.45
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1259 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.06 · 95% CI 0.82 to 5.22
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.05 · 95% CI 2.65 to 18.71
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0070 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.51 · 95% CI 1.41 to 8.76
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0193 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.15 · 95% CI 1.20 to 8.23
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0148 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.34 · 95% CI 1.27 to 8.81
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0018 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.05 · 95% CI 1.83 to 13.94
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0007 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.27 · 95% CI 2.32 to 22.78
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0246 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.11 · 95% CI 1.16 to 8.35
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0016 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.22 · 95% CI 1.87 to 14.60
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0825 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.25 · 95% CI 0.90 to 5.62
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0542 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.66 · 95% CI 0.98 to 7.20
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0837 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.38 · 95% CI 0.89 to 6.33
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0131 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.67 · 95% CI 1.31 to 10.26
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0012 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.34 · 95% CI 2.41 to 36.19
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0359 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.10 · 95% CI 1.08 to 8.93
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.86 · 95% CI 1.91 to 17.92
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0715 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.43 · 95% CI 0.93 to 6.38
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0465 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.89 · 95% CI 1.02 to 8.20
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0839 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.89 to 6.53
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0191 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.56 · 95% CI 1.23 to 10.28
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0019 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.11 · 95% CI 2.52 to 58.22
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0593 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.76 · 95% CI 0.96 to 7.90
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0048 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.95 · 95% CI 1.63 to 15.04
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0494 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.75 · 95% CI 1.00 to 7.57
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1887 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.15 · 95% CI 0.69 to 6.70
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0717 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.06 · 95% CI 0.91 to 10.7
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1419 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.43 · 95% CI 0.74 to 7.92
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0141 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.37 · 95% CI 1.71 to 120.6
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0775 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.19 · 95% CI 0.88 to 11.54
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0283 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.35 · 95% CI 1.17 to 16.19
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1767 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.21 · 95% CI 0.70 to 6.96
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1675 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.20 · 95% CI 0.72 to 6.72
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2717 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.84 · 95% CI 0.62 to 5.49
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1367 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.40 · 95% CI 0.76 to 7.64
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0162 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.53 · 95% CI 1.62 to 113.0
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0765 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.23 · 95% CI 0.88 to 11.78
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0061 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.80 · 95% CI 1.79 to 33.87
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0181 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.40 · 95% CI 1.33 to 21.85
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3925 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.63 · 95% CI 0.53 to 4.99
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3740 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.66 · 95% CI 0.54 to 5.12
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1753 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.33 · 95% CI 0.69 to 7.93
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0195 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 12.85 · 95% CI 1.51 to 109.5
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1932 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.29 · 95% CI 0.66 to 8.02
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0537 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.55 · 95% CI 0.98 to 12.86
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0144 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.72 · 95% CI 1.50 to 39.66
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6660 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.29 · 95% CI 0.41 to 4.09
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7923 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.16 · 95% CI 0.37 to 3.62
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3796 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.73 · 95% CI 0.51 to 5.90
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0874 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.20 · 95% CI 0.81 to 21.73
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1925 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 0.62 to 10.96
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0651 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.99 · 95% CI 0.92 to 17.38
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5361 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.46 · 95% CI 0.44 to 4.81
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6258 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.33 · 95% CI 0.42 to 4.17
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.6275 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.32 · 95% CI 0.43 to 4.06
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2212 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.21 · 95% CI 0.62 to 7.90
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0280 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 11.13 · 95% CI 1.30 to 95.49
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0589 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.88 · 95% CI 0.94 to 25.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0799 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.63 · 95% CI 0.86 to 15.39
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1112 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.91 · 95% CI 0.78 to 10.87
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0959 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.76 · 95% CI 0.84 to 9.11
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3886 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.62 · 95% CI 0.54 to 4.85
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0864 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.00 · 95% CI 0.85 to 10.52
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0145 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.22 · 95% CI 1.69 to 119.5
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0180 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.08 · 95% CI 1.56 to 110.0
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0080 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 18.53 · 95% CI 2.14 to 160.6
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0236 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.07 · 95% CI 1.24 to 20.65
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4303 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.59 · 0.4303% CI 0.50 to 5.07
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5529 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.41 · 95% CI 0.45 to 4.39
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3268 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.87 · 95% CI 0.53 to 6.55
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0343 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.02 · 95% CI 1.19 to 84.66
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0391 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.45 · 95% CI 1.12 to 79.82
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0187 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 13.31 · 95% CI 1.54 to 115.1
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1475 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.60 · 95% CI 0.71 to 9.47
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2161 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.19 · 95% CI 0.63 to 7.55
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3478 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.79 · 95% CI 0.53 to 6.04
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2269 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.22 · 95% CI 0.61 to 8.14
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0683 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.66 · 95% CI 0.89 to 24.35
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0228 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.11 · 95% CI 1.31 to 38.49
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0620 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.95 · 95% CI 0.93 to 16.72
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2251 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.18 · 95% CI 0.62 to 7.67
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7908 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.18 · 95% CI 0.35 to 3.99
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3735 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.84 · 95% CI 0.48 to 7.06
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1856 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.49 · 95% CI 0.64 to 9.64
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.01798 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.67 · 95% CI 0.64 to 11.20
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1101 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.19 · 95% CI 0.77 to 13.22
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1060 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.99 · 95% CI 0.79 to 11.31
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5258 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.47 · 95% CI 0.45 to 4.86
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8746 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.10 · 95% CI 0.34 to 3.50
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.7434 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.82 · 95% CI 0.24 to 2.77
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.3211 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.90 · 95% CI 0.53 to 6.80
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5330 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.51 · 95% CI 0.41 to 5.48
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1119 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.00 · 95% CI 0.77 to 11.64
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.3540 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.76 · 95% CI 0.53 to 5.85
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5076 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.65 · 95% CI 0.19 to 2.29
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5801 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.71 · 95% CI 0.21 to 2.41
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2785 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.48 · 95% CI 0.13 to 1.82
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.5656 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.69 · 95% CI 0.19 to 2.45
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6445 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.73 · 95% CI 0.19 to 2.81
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.7363 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.27 · 95% CI 0.32 to 4.99
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.3455 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.56 · 95% CI 0.17 to 1.86
SecondaryNumber of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 11125232626192627
Week 21630293232262926
Week 32031293133283631
Week 42328292931313330
Week 52729312834333531
Week 62831292931303432
Week 72831322832303231
Week 82933323030313430
Week 92831303133313432
Week 102731272631323531
Week 112731282431333530
Week 122529282529293131
Week 131323181719201821
Week 141419161116181517
Week 151515121014131113
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0037 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.30 · 95% CI 1.60 to 11.54
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0057 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.95 · 95% CI 1.49 to 10.48
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.03 · 95% CI 2.26 to 16.13
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.42 · 95% CI 2.37 to 17.39
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1410 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.11 · 95% CI 0.78 to 5.73
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.85 · 95% CI 2.20 to 15.55
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.50 · 95% CI 2.08 to 14.54
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0037 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.09 · 95% CI 1.58 to 10.57
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0026 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.31 · 95% CI 1.67 to 11.16
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.26 · 95% CI 2.63 to 16.60
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.40 · 95% CI 3.23 to 27.34
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0431 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 1.03 to 6.76
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0020 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.40 · 95% CI 1.72 to 11.29
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0291 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.76 · 95% CI 1.11 to 6.86
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0063 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.96 · 95% CI 1.48 to 10.61
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0202 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.11 · 95% CI 1.19 to 8.11
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0044 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.10 · 95% CI 1.55 to 10.84
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.21 · 95% CI 2.89 to 29.38
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0706 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.43 · 95% CI 0.93 to 6.37
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.20 · 95% CI 2.79 to 24.08
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0146 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.24 · 95% CI 1.26 to 8.32
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0816 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.90 to 6.24
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0930 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.25 · 95% CI 0.87 to 5.81
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.365 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.81 · 95% CI 1.07 to 7.39
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0042 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.93 · 95% CI 1.65 to 14.73
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0488 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.73 · 95% CI 1.01 to 7.41
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0075 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.85 · 95% CI 1.43 to 10.36
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0984 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.20 · 95% CI 0.86 to 5.59
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2226 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.89 · 95% CI 0.68 to 5.29
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1467 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.16 · 95% CI 0.76 to 6.08
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0705 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.74 · 95% CI 0.92 to 8.19
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0025 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 26.62 · 95% CI 3.16 to 223.9
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0757 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.75 · 95% CI 0.90 to 8.40
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0045 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.66 · 95% CI 1.71 to 18.74
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0771 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.63 · 95% CI 0.90 to 7.67
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1856 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.03 · 95% CI 0.71 to 5.81
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5973 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.31 · 95% CI 0.48 to 3.54
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0935 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.57 · 95% CI 0.85 to 7.77
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0157 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.52 · 95% CI 1.38 to 22.10
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1963 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.08 · 95% CI 0.68 to 6.32
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0085 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.31 · 95% CI 1.53 to 18.43
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1433 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.21 · 95% CI 0.76 to 6.38
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1577 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.17 · 95% CI 0.74 to 6.37
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1608 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.16 · 95% CI 0.74 to 6.34
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0693 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.96 · 95% CI 0.92 to 9.53
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0063 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.57 · 95% CI 1.89 to 48.39
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1637 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.25 · 95% CI 0.72 to 7.05
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0326 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.57 · 95% CI 1.11 to 11.47
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1455 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.24 · 95% CI 0.76 to 6.67
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1951 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.08 · 95% CI 0.69 to 6.32
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4097 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.56 · 95% CI 0.54 to 4.53
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1554 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.29 · 95% CI 0.73 to 7.22
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0440 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.22 · 95% CI 1.04 to 17.14
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1928 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.23 · 95% CI 0.67 to 7.47
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0222 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.67 · 95% CI 1.25 to 17.47
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.4075 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.58 · 95% CI 0.54 to 4.65
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3659 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.65 · 95% CI 0.56 to 4.93
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7878 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.15 · 95% CI 0.41 to 3.24
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0635 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.26 · 95% CI 0.94 to 11.38
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0137 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 14.62 · 95% CI 1.73 to 123.3
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1069 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.91 · 95% CI 0.79 to 10.62
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0186 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.60 · 95% CI 1.33 to 23.47
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1434 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.75 to 7.56
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1670 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.20 · 95% CI 0.72 to 6.75
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7810 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.16 · 95% CI 0.41 to 3.28
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1682 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.27 · 95% CI 0.71 to 7.26
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0215 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.22 · 95% CI 1.28 to 21.39
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0306 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.75 · 95% CI 1.16 to 19.52
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0059 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.10 · 95% CI 1.92 to 52.29
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1004 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.64 · 95% CI 0.83 to 8.43
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1837 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.11 · 95% CI 0.70 to 6.36
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.5929 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.33 · 95% CI 0.47 to 3.75
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2588 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.93 · 95% CI 0.62 to 6.07
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0129 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.69 · 95% CI 1.54 to 38.41
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0168 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.12 · 95% CI 1.42 to 35.61
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0058 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 9.95 · 95% CI 1.94 to 50.97
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1934 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.08 · 95% CI 0.69 to 6.26
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2181 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.01 · 95% CI 0.66 to 6.12
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4116 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.58 · 95% CI 0.53 to 4.71
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0938 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.84 · 95% CI 0.84 to 9.66
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0125 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.02 · 95% CI 1.57 to 41.08
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0761 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.29 · 95% CI 0.88 to 12.23
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0305 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.02 · 95% CI 1.14 to 14.16
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0501 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.42 · 95% CI 1.00 to 11.68
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1212 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.61 · 95% CI 0.78 to 8.77
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.8332 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.13 · 95% CI 0.35 to 3.68
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.4285 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.66 · 95% CI 0.48 to 5.76
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0954 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.98 · 95% CI 0.83 to 10.74
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1110 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.98 · 95% CI 0.78 to 11.38
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.1642 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.44 · 95% CI 0.69 to 8.55
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1976 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.19 · 95% CI 0.66 to 7.24
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5761 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.40 · 95% CI 0.43 to 4.58
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4540 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.64 · 95% CI 0.20 to 2.04
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3732 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.57 · 95% CI 0.17 to 1.96
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.4665 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.59 · 95% CI 0.46 to 5.50
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.5634 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.46 · 95% CI 0.41 to 5.25
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.4297 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.65 · 95% CI 0.48 to 5.70
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.9789 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.98 · 95% CI 0.31 to 3.14
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.7357 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.81 · 95% CI 0.24 to 2.70
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1977 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.46 · 95% CI 0.14 to 1.50
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3203 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.52 · 95% CI 0.14 to 1.88
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.9739 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.02 · 95% CI 0.30 to 3.44
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.6714 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.33 · 95% CI 0.36 to 4.97
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.6375 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.75 · 95% CI 0.22 to 2.52
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.2980 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.54 · 95% CI 0.17 to 1.71
SecondaryNumber of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · participants
Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
participantsPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 1619222322141722
Week 21425272725242724
Week 31625272828253125
Week 41924282629253126
Week 52325282628293327
Week 62326282728273129
Week 72329292529273129
Week 82526282626273129
Week 92427292629273229
Week 102227262429293229
Week 112429272327303130
Week 122325272126273128
Week 13920151314201316
Week 14101713910171213
Week 159121087111012
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0044 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.35 · 95% CI 1.69 to 16.96
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0002 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 8.65 · 95% CI 2.79 to 26.83
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.82 · 95% CI 3.49 to 33.54
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = <0.0001 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 10.01 · 95% CI 3.20 to 31.29
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1266 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.51 · 95% CI 0.77 to 8.15
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0024 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.72 · 95% CI 1.85 to 17.66
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.93 · 95% CI 2.59 to 24.26
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0217 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.11 · 95% CI 1.18 to 8.17
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0021 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.63 · 95% CI 1.75 to 12.25
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0016 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.72 · 95% CI 1.80 to 12.37
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0018 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.80 · 95% CI 1.79 to 12.86
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0467 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.69 · 95% CI 1.01 to 7.14
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0016 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.70 · 95% CI 1.80 to 12.28
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0234 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.98 · 95% CI 1.16 to 7.65
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0294 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.88 · 95% CI 1.11 to 7.46
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0068 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.74 · 95% CI 1.44 to 9.73
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0025 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.35 · 95% CI 1.68 to 11.29
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0006 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.82 · 95% CI 2.13 to 15.92
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0572 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.53 · 95% CI 0.97 to 6.61
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0003 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.03 · 95% CI 2.28 to 15.97
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0460 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 1.02 to 6.38
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1406 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.03 · 95% CI 0.79 to 5.23
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0234 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.97 · 95% CI 1.16 to 7.63
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0302 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.82 · 95% CI 1.10 to 7.22
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0016 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.23 · 95% CI 1.87 to 14.63
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2105 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.82 · 95% CI 0.71 to 4.64
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0033 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.17 · 95% CI 1.61 to 10.81
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1087 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.10 · 95% CI 0.85 to 5.21
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.3600 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.56 · 95% CI 0.60 to 4.03
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1394 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.05 · 95% CI 0.79 to 5.32
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0522 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.70 · 95% CI 0.99 to 7.36
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0119 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.97 · 95% CI 1.63 to 11.61
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1474 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.07 · 95% CI 0.77 to 5.53
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0026 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.08 · 95% CI 1.76 to 14.67
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1263 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.11 · 95% CI 0.81 to 5.51
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2327 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.83 · 95% CI 0.68 to 4.95
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.1359 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.12 · 95% CI 0.79 to 5.70
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0258 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.35 · 95% CI 1.16 to 9.69
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0076 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.77 · 95% CI 1.51 to 15.04
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1088 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.36 · 95% CI 0.83 to 6.75
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0045 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.89 · 95% CI 1.64 to 14.62
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0493 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.74 · 95% CI 1.00 to 7.50
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0376 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.99 · 95% CI 1.06 to 8.41
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.0723 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.53 · 95% CI 0.92 to 6.94
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0396 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.11 · 95% CI 1.06 to 9.17
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0031 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 6.18 · 95% CI 1.85 to 20.67
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1044 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.41 · 95% CI 0.83 to 6.96
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0029 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.47 · 95% CI 1.78 to 16.75
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0364 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.01 · 95% CI 1.07 to 8.45
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.6396 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.26 · 95% CI 0.47 to 3.37
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4378 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.47 · 95% CI 0.55 to 3.91
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.2045 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.95 · 95% CI 0.70 to 5.44
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0958 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.54 · 95% CI 0.85 to 7.62
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.3210 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.70 · 95% CI 0.60 to 4.85
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0199 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.75 · 95% CI 1.23 to 11.39
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1219 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.26 · 95% CI 0.80 to 6.36
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.2975 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.72 · 95% CI 0.62 to 4.76
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2763 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.75 · 95% CI 0.64 to 4.80
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1235 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.33 · 95% CI 0.79 to 6.82
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0190 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.24 · 95% CI 1.27 to 14.19
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.2213 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.98 · 95% CI 0.66 to 5.93
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0050 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.88 · 95% CI 1.71 to 20.25
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1053 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.39 · 95% CI 0.83 to 6.85
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0991 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.39 · 95% CI 0.85 to 6.72
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.2056 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.93 · 95% CI 0.70 to 5.32
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.0407 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.17 · 95% CI 1.05 to 9.57
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0059 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.47 · 95% CI 1.63 to 18.30
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0230 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.85 · 95% CI 1.20 to 12.30
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0015 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.36 · 95% CI 2.14 to 25.29
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0248 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.45 · 95% CI 1.17 to 10.16
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1091 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.37 · 95% CI 0.82 to 6.83
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3054 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.61 to 4.75
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.1129 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.48 · 95% CI 0.81 to 7.61
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0432 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.28 · 95% CI 1.04 to 10.37
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0315 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.77 · 95% CI 1.13 to 12.60
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0147 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 4.26 · 95% CI 1.33 to 13.64
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.0405 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.18 · 95% CI 1.05 to 9.59
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.5238 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.40 · 95% CI 0.50 to 3.93
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.3060 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.73 · 95% CI 0.60 to 4.97
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.3747 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.64 · 95% CI 0.55 to 4.86
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.0443 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.49 · 95% CI 1.03 to 11.80
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1269 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.49 · 95% CI 0.77 to 8.06
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.0095 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 5.15 · 95% CI 1.49 to 17.13
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1254 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.34 · 95% CI 0.79 to 6.94
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.0402 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 3.66 · 95% CI 1.06 to 12.63
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.4547 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.59 · 95% CI 0.47 to 5.42
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.4008 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.71 · 95% CI 0.49 to 5.99
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.1535 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.55 · 95% CI 0.71 to 9.22
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.0055 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 7.19 · 95% CI 1.79 to 28.95
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2116 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.19 · 95% CI 0.64 to 7.50
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.1668 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.34 · 95% CI 0.70 to 7.83
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.1824 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.32 · 95% CI 0.67 to 7.98
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.7970 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.85 · 95% CI 0.25 to 2.90
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.7065 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.78 · 95% CI 0.21 to 2.85
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.9126 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.08 · 95% CI 0.29 to 3.93
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1282 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.82 · 95% CI 0.74 to 10.70
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2661 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.03 · 95% CI 0.58 to 7.04
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.7457 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.22 · 95% CI 0.36 to 4.09
  • Placebo vs Fezolinetant 15 mg BID · Regression, Logistic · p = 0.4095 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.73 · 95% CI 0.47 to 6.41
  • Placebo vs Fezolinetant 30 mg BID · Regression, Logistic · p = 0.9571 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.04 · 95% CI 0.28 to 3.77
  • Placebo vs Fezolinetant 60 mg BID · Regression, Logistic · p = 0.8827 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.90 · 95% CI 0.23 to 3.59
  • Placebo vs Fezolinetant 90 mg BID · Regression, Logistic · p = 0.5944 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 0.69 · 95% CI 0.17 to 2.74
  • Placebo vs Fezolinetant 30 mg QD · Regression, Logistic · p = 0.1647 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.74 · 95% CI 0.66 to 11.39
  • Placebo vs Fezolinetant 60 mg QD · Regression, Logistic · p = 0.2684 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 2.07 · 95% CI 0.57 to 7.48
  • Placebo vs Fezolinetant 120 mg QD · Regression, Logistic · p = 0.5338 (Odds ratio, corresponding 95% CI and p-value are based on a logistic regression with responder as the dependent variable and treatment group and smoking status as factors and baseline measurement (mean frequency of vasomotor symptoms) as a covariate.) · Odds ratio (or): 1.48 · 95% CI 0.43 to 5.07
SecondaryChange From Baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) at Weeks 4, 8, 12, and 15

The HFRDIS is a 10-item scale that measures a woman's perceptions of the degree to which VMS interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, and enjoying life); the tenth item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory, which assess the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which VMS had interfered with each item during the previous 2-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score is the average of individual item scores (sum of items/10).

Time frame:
Baseline and weeks 4, 8, 12, and 15
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) at Weeks 4, 8, 12, and 15
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 4-2.2 ± 0.34-3.3 ± 0.32-3.6 ± 0.33-3.8 ± 0.33-3.7 ± 0.35-2.5 ± 0.35-3.4 ± 0.32-3.5 ± 0.34
Week 8-2.7 ± 0.34-3.3 ± 0.33-3.6 ± 0.34-4.1 ± 0.35-4.2 ± 0.36-3.0 ± 0.36-3.3 ± 0.33-3.6 ± 0.35
Week 12-2.9 ± 0.33-3.6 ± 0.31-3.8 ± 0.33-4.3 ± 0.34-4.2 ± 0.35-3.3 ± 0.35-3.5 ± 0.32-3.9 ± 0.33
Week 15-2.4 ± 0.39-2.6 ± 0.37-2.2 ± 0.39-2.3 ± 0.40-1.9 ± 0.41-2.9 ± 0.42-2.4 ± 0.38-2.5 ± 0.40
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · Mixed model repeated measures (MMRM) · p = 0.0179 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.95 to -0.18
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0027 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -2.25 to -0.47
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -2.50 to -0.73
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0009 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.43 to -0.64
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5806 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.14 to 0.64
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0105 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.03 to -0.27
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0048 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -2.16 to -0.39
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1801 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.52 to 0.29
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0609 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.76 to 0.04
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0028 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -2.33 to -0.49
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0018 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.40 to -0.55
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5519 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.19 to 0.64
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1922 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.51 to 0.31
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0463 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.82 to -0.02
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1288 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.53 to 0.19
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0577 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.72 to 0.03
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0027 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -2.26 to -0.48
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0043 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · -1.3: -1.3 · 95% CI -2.20 to -0.41
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4089 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.27 to 0.52
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.2050 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.44 to 0.31
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0265 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.84 to -0.11
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.7617 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -1.20 to 0.88
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6061 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.3 · 95% CI -0.77 to 1.32
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.7997 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.93 to 1.21
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.3391 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.5 · 95% CI -0.55 to 1.60
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3934 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.55 to 0.61
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9750 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.00 · 95% CI -1.08 to 1.04
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.8830 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors and baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -1.13 to 0.97
SecondaryLeeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores at Weeks 4, 8, 12 and 15

The LSEQ is a 10-item self-rated questionnaire that assesses a participants aspects of sleep and early morning behavior. The questions are grouped into 4 chronological areas: ease of getting to sleep, perceived quality of sleep, ease of awaking from sleep, and integrity of early morning behavior following wakefulness. The LSEQ is a visual analog scale that requires respondents to place marks on a group of 10 cm lines. Lines extend between extremes like "more difficult than usual" and "easier than usual." Responses are measured using a 100 mm scale and are averaged to a score for each domain. Higher scores indicates better sleep and better early morning behavior.

Time frame:
Weeks 4, 8, 12, and 15
Reported as:
Least squares mean · Score on a scale
Leeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores at Weeks 4, 8, 12 and 15
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 4: Ease of Getting to Sleep40.7 ± 3.1843.1 ± 3.0644.6 ± 3.2536.7 ± 3.2541.7 ± 3.3843.1 ± 3.3540.3 ± 2.9844.7 ± 3.32
Week 4: Quality of Sleep38.7 ± 3.7540.4 ± 3.6436.1 ± 3.8132.8 ± 3.8442.0 ± 4.0036.7 ± 3.9838.6 ± 3.5342.4 ± 3.95
Week 4: Ease of Awaking From Sleep43.6 ± 3.3147.1 ± 3.1843.9 ± 3.3637.8 ± 3.3841.7 ± 3.5341.8 ± 3.5137.5 ± 3.1043.3 ± 3.48
Week 4: Integrity of Behavior Following Awaking41.2 ± 3.4042.0 ± 3.2341.5 ± 3.4432.4 ± 3.4438.0 ± 3.6143.3 ± 3.5841.8 ± 3.1641.3 ± 3.56
Week 8:Ease of Getting to Sleep40.3 ± 3.0939.2 ± 2.9641.5 ± 3.1035.6 ± 3.1838.3 ± 3.2841.7 ± 3.2443.6 ± 2.9843.7 ± 3.15
Week 8: Quality of Sleep41.1 ± 3.6336.3 ± 3.5239.5 ± 3.6233.6 ± 3.7538.6 ± 3.8636.9 ± 3.8337.7 ± 3.5438.2 ± 3.71
Week 8:Ease of Awaking From Sleep40.3 ± 3.3538.8 ± 3.2237.5 ± 3.3436.4 ± 3.4641.2 ± 3.5637.7 ± 3.5344.3 ± 3.2741.2 ± 3.43
Week 8: Integrity of Behavior Following Awake40.9 ± 3.4940.6 ± 3.3338.8 ± 3.4735.2 ± 3.5641.4 ± 3.6935.9 ± 3.6641.3 ± 3.3640.5 ± 3.55
Wek 12: Ease of Getting Sleep32.0 ± 3.3037.2 ± 3.0438.9 ± 3.4137.7 ± 3.4439.6 ± 3.6939.4 ± 3.7841.6 ± 3.1938.4 ± 3.39
Week 12: Quality of Sleep36.3 ± 3.7637.2 ± 3.4638.4 ± 3.8936.0 ± 3.9234.5 ± 4.2237.1 ± 4.3537.6 ± 3.6436.6 ± 3.88
Week 12: Ease of Awaking From Sleep37.3 ± 3.6837.1 ± 3.4135.9 ± 3.7737.4 ± 3.8237.8 ± 4.0637.1 ± 4.1541.9 ± 3.5740.9 ± 3.78
Week 12: Integrity of Behavior Following Awaking35.5 ± 3.8238.3 ± 3.5436.6 ± 3.9037.3 ± 3.9341.2 ± 4.1835.2 ± 4.2744.2 ± 3.6739.0 ± 3.92
Wek 15:Ease of Getting Sleep39.8 ± 3.6239.2 ± 3.2942.8 ± 3.5141.5 ± 3.5949.4 ± 3.9138.8 ± 3.8544.8 ± 3.4544.0 ± 3.64
Week 15: Quality of Sleep39.3 ± 4.5434.7 ± 4.1937.1 ± 4.3936.2 ± 4.5245.9 ± 4.9533.0 ± 4.8842.4 ± 4.3941.4 ± 4.60
Week 15: Ease of Awaking From Sleep33.9 ± 4.2034.9 ± 3.8837.1 ± 4.0836.1 ± 4.2145.4 ± 4.5735.6 ± 4.5149.4 ± 4.0845.0 ± 4.26
Week 15: Integrity of Behavior Following Awaking40.9 ± 4.1535.1 ± 3.8146.7 ± 4.0142.8 ± 4.1150.9 ± 4.4835.9 ± 4.4347.1 ± 3.9843.8 ± 4.19
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5872 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.3 · 95% CI -6.09 to 10.73
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.3779 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.8 · 95% CI -4.70 to 12.35
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3506 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -4.1 · 95% CI -12.61 to 4.49
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.8236 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.0 · 95% CI -7.66 to 9.62
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5949 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.3 · 95% CI -6.24 to 10.87
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9237 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.4 · 95% CI -8.65 to 7.85
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3599 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 4.0 · 95% CI -4.54 to 12.46
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.7422 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.7 · 95% CI -8.33 to 11.68
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6030 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.6 · 95% CI -12.67 to 7.37
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2478 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -6.0 · 95% CI -16.07 to 4.17
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.5295 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.3 · 95% CI -6.94 to 13.47
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.6938 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.0 · 95% CI -12.20 to 8.13
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9765 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.1 · 95% CI -9.93 to 9.63
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4771 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.7 · 95% CI -6.45 to 13.76
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.4256 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.5 · 95% CI -5.19 to 12.27
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.9559 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.2 · 95% CI -8.52 to 9.01
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2003 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -5.8 · 95% CI -14.60 to 3.07
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.6692 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.9 · 95% CI -10.86 to 6.98
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.6894 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.8 · 95% CI -10.68 to 7.08
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1627 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -6.1 · 95% CI -14.66 to 2.48
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9371 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.4 · 95% CI -9.18 to 8.47
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.8521 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.8 · 95% CI -8.07 to 9.77
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.9367 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.4 · 95% CI -8.62 to 9.35
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0551 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -8.8 · 95% CI -17.82 to 0.19
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.4936 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean differencce: -3.2 · 95% CI -12.32 to 5.96
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.6404 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.1 · 95% CI -6.89 to 11.17
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.8955 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.6 · 95% CI -8.17 to 9.34
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9776 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.1 · 95% CI -8.91 to 9.17
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.7852 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.1 · 95% CI -9.27 to 7.01
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.7812 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.2 · 95% CI -7.02 to 9.33
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2648 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -4.7 · 95% CI -13.07 to 3.61
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.6312 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.0 · 95% CI -10.41 to 6.32
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.7416 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.4 · 95% CI -6.89 to 9.67
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4254 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.3 · 95% CI -4.83 to 11.41
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4038 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.4 · 95% CI -4.66 to 11.54
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3270 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -4.8 · 95% CI -14.49 to 4.85
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.7333 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.7 · 95% CI -11.21 to 7.90
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1319 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -7.5 · 95% CI -17.36 to 2.28
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.6132 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.5 · 95% CI -12.38 to 7.32
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4024 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -4.2 · 95% CI -13.98 to 5.63
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4904 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -3.4 · 95% CI -12.97 to 6.23
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.5521 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.9 · 95% CI -12.48 to 6.69
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.7370 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.5 · 95% CI -10.38 to 7.35
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.5269 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.8 · 95% CI -11.62 to 5.96
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3937 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -3.9 · 95% CI -12.93 to 5.11
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.8460 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.9 · 95% CI -8.15 to 9.94
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5673 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.6 · 95% CI -11.62 to 6.38
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.3791 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 4.0 · 95% CI -4.88 to 12.79
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.8340 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.9 · 95% CI -7.86 to 9.73
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.9457 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.3 · 95% CI -9.51 to 8.88
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6570 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -2.1 · 95% CI -11.22 to 7.09
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2310 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -5.7 · 95% CI -15.00 to 3.64
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9066 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.6 · 95% CI -8.84 to 9.96
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2914 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean differnce: -5.0 · 95% CI -14.26 to 4.30
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9277 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.4 · 95% CI -8.73 to 9.57
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9367 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.4 · 95% CI -9.51 to 8.77
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.2407 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 5.1 · 95% CI -3.46 to 13.69
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1305 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 6.9 · 95% CI -2.06 to 15.89
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2152 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 5.7 · 95% CI -3.34 to 14.75
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.1099 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 7.6 · 95% CI -1.73 to 16.89
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1219 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 7.4 · 95% CI -1.99 to 16.75
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0316 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 9.6 · 95% CI 0.85 to 18.36
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1557 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 6.4 · 95% CI -2.44 to 15.16
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.8592 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.9 · 95% CI -8.91 to 10.67
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6891 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.1 · 95% CI -8.08 to 12.20
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9481 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.3 · 95% CI -10.59 to 9.92
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.7246 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.9 · 95% CI -12.46 to 8.68
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.8842 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.8 · 95% CI -9.94 to 11.53
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.8103 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.2 · 95% CI -8.74 to 11.17
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9631 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.2 · 95% CI -9.81 to 10.28
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.9788 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.1 · 95% CI -9.73 to 9.47
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.7875 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.4 · 95% CI -11.26 to 8.54
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9746 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.2 · 95% CI -9.85 to 10.17
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9092 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.6 · 95% CI -9.67 to 10.86
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.9745 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.2 · 95% CI -10.55 to 10.21
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.3458 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 4.7 · 95% CI -5.08 to 14.44
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4657 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean differnce: 3.6 · 95% CI -6.17 to 13.45
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5838 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.8 · 95% CI -7.20 to 12.76
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.8322 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.1 · 95% CI -9.18 to 11.39
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.7366 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.8 · 95% CI -8.59 to 12.13
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.2971 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 5.6 · 95% CI -4.99 to 16.28
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.9562 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.3 · 95% CI -10.96 to 10.37
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0926 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · 0.28: 8.7 · 95% CI -1.44 to 18.76
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4996 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.5 · 95% CI -6.70 to 13.70
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.8960 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -0.6 · 95% CI -9.99 to 8.75
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.5471 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.9 · 95% CI -6.68 to 12.58
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.7380 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.7 · 95% CI -8.06 to 11.36
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0644 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 9.6 · 95% CI -0.58 to 19.69
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.8475 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -1.0 · 95% CI -10.90 to 8.96
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.3044 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 5.0 · 95% CI -4.57 to 14.59
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.3895 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 4.2 · 95% CI -5.42 to 13.86
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.4551 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -4.5 · 95% CI -16.50 to 7.42
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.7182 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean differencce: -2.2 · 95% CI -14.21 to 9.81
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.6259 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -3.0 · 95% CI -15.26 to 9.20
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.3120 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 6.6 · 95% CI -6.22 to 19.40
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3297 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -6.3 · 95% CI -18.89 to 6.37
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.6130 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.1 · 95% CI -9.02 to 15.26
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.7292 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.2 · 95% CI -10.09 to 14.40
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.8695 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 0.9 · 95% CI -1.11 to 11.96
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.5800 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 3.1 · 95% CI -7.99 to 14.25
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.7024 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.2 · 95% CI -9.11 to 13.50
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0572 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 11.4 · 95% CI -0.35 to 23.23
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.7830 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 1.6 · 95% CI -10.04 to 13.31
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0074 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · 0.1: 15.4 · 95% CI 4.19 to 26.67
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0551 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 11.0 · 95% CI -0.24 to 22.32
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.2959 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -5.8 · 95% CI -16.63 to 5.08
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.2976 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 5.8 · 95% CI -5.14 to 16.74
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.7236 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.0 · 95% CI -9.07 to 13.05
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0884 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 10.1 · 95% CI -1.52 to 21.63
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3887 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: -5.0 · 95% CI -16.35 to 6.38
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.2671 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 6.2 · 95% CI -4.80 to 17.24
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.6076 (LSM, SE, CI, \& p-values come from an MMRM model with domain score as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement (BM) as a covariate, as well as interaction of treatment by week \& an interaction of BM by week.) · Lsmean difference: 2.9 · 95% CI -8.20 to 13.99
SecondaryChange From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8, 12, and 15

The GCS is a 21-item scale that provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item is rated by the participant according to its severity using a 4-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into 3 main independent symptom measures by summing up the individual item scores: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and VMS (items 19 to 20; score 0 to 6). Item 21 is a probe for sexual dysfunction. The total score can range from 0 to 63. Higher scores indicate worse symptoms.

Time frame:
Baseline and weeks 4, 8, 12, and 15
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8, 12, and 15
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 4: Psychological Symptoms-2.6 ± 0.70-3.8 ± 0.66-4.5 ± 0.69-5.0 ± 0.68-4.4 ± 0.71-3.7 ± 0.70-2.1 ± 0.65-4.9 ± 0.71
Week 4: Physical Symptoms-1.1 ± 0.38-1.1 ± 0.37-1.6 ± 0.38-1.1 ± 0.37-1.2 ± 0.39-1.4 ± 0.39-0.8 ± 0.36-1.9 ± 0.39
Week 4: VasomotorSymptoms Score-1.7 ± 0.27-2.1 ± 0.25-2.7 ± 0.26-3.3 ± 0.26-3.2 ± 0.27-2.2 ± 0.27-2.6 ± 0.25-2.9 ± 0.27
Week 4: Sexual Dysfunction Score-0.4 ± 0.13-0.7 ± 0.12-0.7 ± 0.13-0.9 ± 0.13-0.7 ± 0.13-0.3 ± 0.13-0.4 ± 0.12-0.6 ± 0.13
Week 4: Total Score-6.1 ± 1.17-7.8 ± 1.10-9.6 ± 1.16-10.4 ± 1.15-9.5 ± 1.19-7.6 ± 1.19-5.8 ± 1.10-10.3 ± 1.19
Week 8: Psychological Symptoms-3.3 ± 0.71-5.0 ± 0.69-4.7 ± 0.71-4.9 ± 0.73-4.5 ± 0.74-3.3 ± 0.73-2.8 ± 0.69-4.6 ± 0.73
Week 8: Physical Symptoms-1.1 ± 0.40-1.5 ± 0.39-1.3 ± 0.40-0.8 ± 0.40-1.6 ± 0.41-1.4 ± 0.41-0.9 ± 0.39-1.9 ± 0.40
Week 8: VasomotorSymptoms Score-1.9 ± 0.27-2.5 ± 0.26-3.0 ± 0.27-3.4 ± 0.28-3.5 ± 0.28-2.2 ± 0.28-2.9 ± 0.26-3.0 ± 0.28
Week 8: Sexual Dysfunction Score-0.4 ± 0.14-0.5 ± 0.13-0.8 ± 0.14-0.7 ± 0.14-0.6 ± 0.14-0.6 ± 0.14-0.3 ± 0.13-0.8 ± 0.14
Week 8: Total Score-6.9 ± 1.23-9.4 ± 1.18-9.9 ± 1.21-9.9 ± 1.25-10.1 ± 1.27-7.6 ± 1.26-7.0 ± 1.18-10.2 ± 1.24
Week 12: Psychological Symptoms-3.3 ± 0.73-5.0 ± 0.68-4.9 ± 0.73-4.8 ± 0.75-4.3 ± 0.77-4.4 ± 0.77-3.6 ± 0.70-4.9 ± 0.74
Week 12: Physical Symptoms Score-1.5 ± 0.38-2.1 ± 0.36-1.0 ± 0.39-1.3 ± 0.40-1.6 ± 0.41-1.7 ± 0.41-0.9 ± 0.37-1.9 ± 0.39
Week 12: Vasomotor Symptoms Score-2.1 ± 0.26-2.7 ± 0.24-3.1 ± 0.26-3.6 ± 0.26-3.6 ± 0.27-2.9 ± 0.27-2.8 ± 0.25-2.9 ± 0.26
Week 12: Sexual Dysfunction Score-0.5 ± 0.14-0.7 ± 0.13-1.1 ± 0.14-0.9 ± 0.15-0.8 ± 0.15-0.5 ± 0.15-0.5 ± 0.14-0.6 ± 0.14
Week 12: Total Score-7.6 ± 1.23-10.4 ± 1.15-10.1 ± 1.23-10.7 ± 1.25-10.3 ± 1.29-9.6 ± 1.29-7.8 ± 1.18-10.3 ± 1.24
Week 15: Psychological Symptoms Score ;-2.7 ± 0.82-4.6 ± 0.76-4.3 ± 0.79-2.7 ± 0.82-2.3 ± 0.83-4.4 ± 0.84-2.6 ± 0.79-4.1 ± 0.82
Week 15: Physical Symptoms Score-1.4 ± 0.43-1.7 ± 0.40-1.8 ± 0.42-1.0 ± 0.42-1.4 ± 0.43-1.4 ± 0.44-1.2 ± 0.41-2.1 ± 0.43
Week 15: Vasomotor Symptoms Score-1.4 ± 0.34-2.1 ± 0.32-1.6 ± 0.33-1.7 ± 0.34-1.9 ± 0.35-1.9 ± 0.35-1.8 ± 0.33-1.5 ± 0.34
Week 15: Sexual Dysfunction Score-0.5 ± 0.15-0.7 ± 0.14-0.6 ± 0.15-0.7 ± 0.15-0.5 ± 0.15-0.7 ± 0.16-0.6 ± 0.15-0.7 ± 0.15
Week 15: Total Score-6.3 ± 1.41-9.1 ± 1.31-8.3 ± 1.37-6.3 ± 1.41-6.0 ± 1.43-8.6 ± 1.44-6.3 ± 1.36-8.3 ± 1.41
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.2159 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -2.93 to 0.67
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0405 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.9 · 95% CI -3.70 to -0.08
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0115 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.4 · 95% CI -4.18 to -0.53
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0553 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.62 to 0.04
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2753 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -2.82 to 0.80
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.5140 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.6 · 95% CI -1.20 to 2.40
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0178 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.2 · 95% CI -4.03 to -0.38
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.9675 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -1.02 to 0.98
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.3122 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.52 to 0.49
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9977 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -1.00 to 1.00
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9312 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -1.05 to 0.97
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.6005 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.27 to 0.74
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.5284 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.3 · 95% CI -0.68 to 1.32
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1111 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.82 to 0.19
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1764 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.16 to 0.21
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0037 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.73 to -0.34
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -2.30 to -0.92
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.21 to -0.81
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1444 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.21 to 0.18
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0088 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.60 to -0.23
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0005 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -1.93 to -0.54
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0416 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.69 to -0.01
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0353 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.71 to -0.03
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0040 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.84 to -0.16
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0495 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.69 to -0.00
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.8665 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.31 to 0.37
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9303 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.35 to 0.32
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1039 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.62 to 0.06
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.2547 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -4.78 to 1.27
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0225 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -3.6 · 95% CI -6.60 to -0.50
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0058 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean differencce: -4.3 · 95% CI -7.38 to -1.26
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0301 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -3.4 · 95% CI -6.48 to -0.33
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3220 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -4.59 to 1.51
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.8782 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -2.80 to 3.27
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0069 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -4.2 · 95% CI -7.27 to -1.17
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0890 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.49 to 0.25
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1444 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -3.25 to 0.48
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1022 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.51 to 0.32
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.2342 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -3.07 to 0.75
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.9906 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -1.89 to 1.87
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.5770 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.5 · 95% CI -1.34 to 2.40
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1865 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -3.14 to 0.61
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.4575 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.45 to 0.65
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6016 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.33 to 0.77
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.7026 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.86 to 1.28
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.2971 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.64 to 0.50
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5491 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.38 to 0.74
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.7142 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.86 to 1.25
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1157 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.89 to 0.21
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1114 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.30 to 0.14
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0025 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.83 to -0.40
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.20 to -0.74
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5093 · Lsmean difference: -0.2 · 95% CI -0.96 to 0.48
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -2.33 to -0.86
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0090 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.67 to -0.24
  • Placebo vs Fezolinetant 120 mg QD · LSMean difference · p = 0.0024 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.84 to -0.40
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5497 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.47 to 0.25
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0276 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.76 to -0.04
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1274 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.65 to 0.08
  • Placebo vs Fezolinetant 90 mg BID · LSMean difference · p = 0.1865 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.61 to 0.12
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1857 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.61 to 0.12
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.8631 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.33 to 0.39
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0304 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.75 to -0.04
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1246 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -5.71 to 0.70
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0680 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -6.19 to 0.22
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0729 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -6.28 to 0.28
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0541 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -3.2 · 95% CI -6.49 to 0.06
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.6960 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -3.87 to 2.59
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9725 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -3.27 to 3.15
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0419 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -3.3 · 95% CI -6.53 to -0.12
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0794 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.57 to 0.20
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1153 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -3.47 to 0.38
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1334 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · -1.5: -1.5 · 95% CI -3.47 to 0.46
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.3457 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -2.93 to 1.03
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2607 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -3.07 to 0.83
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.7816 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -2.18 to 1.64
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0955 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -3.54 to 0.29
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.2582 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.57 to 0.42
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.3448 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.5 · 95% CI -0.53 to 1.52
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.6587 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.81 to 1.28
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.8299 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -1.16 to 0.93
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.8129 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -1.17 to 0.92
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.2130 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.6 · 95% CI -0.37 to 1.66
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4131 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.42 to 0.59
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1273 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.20 to 0.15
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0046 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.69 to -0.31
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.19 to -0.80
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.19 to -0.78
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.0333 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.45 to -0.06
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0423 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.39 to -0.02
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0208 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.49 to -0.12
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3435 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.55 to 0.19
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -0.98 to -0.22
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0408 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.79 to -0.02
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0911 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean differencce: -0.3 · 95% CI -0.73 to 0.05
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.7891 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.44 to 0.33
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9973 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.38 to 0.38
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.6377 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · -0.1: -0.1 · 95% CI -0.47 to 0.29
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0862 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.8 · 95% CI -5.95 to 0.40
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1305 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.5 · 95% CI -5.74 to 0.74
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0707 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -3.0 · 95% CI -6.34 to 0.26
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.1232 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -5.92 to 0.71
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2530 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.9 · 95% CI -5.18 to 1.37
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9133 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -3.40 to 3.04
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1078 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.6 · 95% CI -5.85 to 0.58
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0719 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean differencce: -1.9 · 95% CI -4.07 to 0.18
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1298 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -3.80 to 0.49
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9532 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -2.26 to 2.13
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.7510 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.4 · 95% CI -1.84 to 2.55
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1120 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.8 · 95% CI -3.95 to 0.42
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9781 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -2.13 to 2.19
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2060 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -1.4 · 95% CI -3.57 to 0.77
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5332 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.46 to 0.76
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.4599 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.54 to 0.70
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.4752 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.4 · 95% CI -0.72 to 1.55
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9051 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -1.21 to 1.07
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.9937 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -1.14 to 1.15
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.6956 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.91 to 1.35
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2302 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.81 to 0.44
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1544 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.55 to 0.25
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.6847 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -1.10 to 0.72
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.5520 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.20 to 0.64
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.3632 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.36 to 0.50
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2828 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.43 to 0.42
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4702 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.24 to 0.58
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.8262 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -1.02 to 0.81
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3152 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.60 to 0.19
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.4399 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.56 to 0.24
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1898 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.67 to 0.13
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9791 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.40 to 0.41
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3178 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.61 to 0.20
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4174 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.57 to 0.24
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2490 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.63 to 0.16
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1233 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.9 · 95% CI -6.57 to 0.79
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.2858 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -5.76 to 1.70
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.9716 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -3.87 to 3.73
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9072 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -3.58 to 4.03
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2334 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.3 · 95% CI -6.07 to 1.49
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9859 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -3.79 to 3.72
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2870 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \&TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& an interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -5.77 to 1.72
SecondaryChange From Baseline in Menopause-Specific Quality of Life (MENQoL) at Weeks 4, 8, 12, and 15

The MENQoL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of 1 of 4 domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1 to 3), psychosocial (items 4 to 10), physical (items 11 to 26), and sexual (items 27 to 29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a 0 (not bothersome) to 6 (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a "1" and endorsement a "2," plus the number of the particular rating, so that the possible score on any item ranges from 1 to 8. Higher scores indicate that menopause symptoms are more bothersome.

Time frame:
Baseline and weeks 4, 8, 12, and 15
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Menopause-Specific Quality of Life (MENQoL) at Weeks 4, 8, 12, and 15
Score on a scalePlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Week 4: Vasomotor Mean Score-1.8 ± 0.32-2.4 ± 0.30-3.0 ± 0.32-3.4 ± 0.31-3.6 ± 0.32-1.9 ± 0.32-2.4 ± 0.30-2.8 ± 0.32
Week 4:Psychological Mean Score-1.0 ± 0.21-1.2 ± 0.20-1.3 ± 0.21-1.3 ± 0.20-1.2 ± 0.21-0.8 ± 0.21-0.6 ± 0.20-1.0 ± 0.21
Week 4: Physical Mean Score-0.8 ± 0.18-1.2 ± 0.17-1.4 ± 0.18-1.1 ± 0.18-1.3 ± 0.19-1.1 ± 0.19-0.8 ± 0.17-1.3 ± 0.19
Week 4: Sexual Mean Score-0.7 ± 0.27-1.5 ± 0.25-1.8 ± 0.27-1.4 ± 0.26-1.2 ± 0.27-0.8 ± 0.28-0.7 ± 0.25-1.2 ± 0.27
Week 4: Overall Mean Score-0.9 ± 0.18-1.3 ± 0.17-1.6 ± 0.18-1.4 ± 0.17-1.5 ± 0.18-1.1 ± 0.18-0.9 ± 0.17-1.3 ± 0.18
Week 8: Vasomotor Mean Score-2.1 ± 0.31-2.6 ± 0.30-3.4 ± 0.31-3.8 ± 0.31-4.1 ± 0.32-2.5 ± 0.32-3.1 ± 0.30-3.4 ± 0.32
Week 8: Psychological Mean Score-1.2 ± 0.20-1.2 ± 0.19-1.3 ± 0.20-1.4 ± 0.20-1.3 ± 0.21-1.0 ± 0.20-1.0 ± 0.19-1.1 ± 0.20
Week 8: Physical Mean Score-1.0 ± 0.19-1.2 ± 0.18-1.5 ± 0.19-1.4 ± 0.19-1.5 ± 0.19-1.3 ± 0.19-1.0 ± 0.18-1.3 ± 0.19
Week 8: Sexual Mean Score-0.9 ± 0.26-1.0 ± 0.25-1.7 ± 0.26-1.2 ± 0.27-1.2 ± 0.27-1.3 ± 0.27-0.8 ± 0.25-1.2 ± 0.27
Week 8: Overall Mean Score-1.2 ± 0.18-1.3 ± 0.17-1.7 ± 0.18-1.6 ± 0.18-1.7 ± 0.18-1.4 ± 0.18-1.2 ± 0.17-1.5 ± 0.18
Week 12: Vasomotor Mean Score-2.3 ± 0.31-3.2 ± 0.29-3.5 ± 0.31-3.8 ± 0.31-4.4 ± 0.32-2.9 ± 0.32-3.3 ± 0.30-3.6 ± 0.31
Week 12: Psychological Mean Score-1.3 ± 0.20-1.3 ± 0.19-1.7 ± 0.20-1.5 ± 0.21-1.4 ± 0.22-1.0 ± 0.22-1.1 ± 0.20-1.2 ± 0.21
Week 12: Physical Mean Score-1.3 ± 0.19-1.4 ± 0.18-1.6 ± 0.19-1.4 ± 0.19-1.5 ± 0.20-1.4 ± 0.20-1.0 ± 0.18-1.4 ± 0.19
Week 12: Sexual Score-0.8 ± 0.29-0.9 ± 0.27-1.8 ± 0.29-1.4 ± 0.29-0.9 ± 0.30-1.4 ± 0.31-0.8 ± 0.28-1.3 ± 0.29
Week 12: Overall Mean Score-1.3 ± 0.18-1.5 ± 0.17-1.8 ± 0.18-1.7 ± 0.18-1.7 ± 0.19-1.5 ± 0.19-1.3 ± 0.17-1.6 ± 0.18
Week 15: Vasomotor Mean Score-1.8 ± 0.36-2.1 ± 0.34-1.7 ± 0.36-1.4 ± 0.37-1.7 ± 0.37-2.1 ± 0.38-2.2 ± 0.35-1.3 ± 0.37
Week 15: Psychological Mean Score-1.0 ± 0.23-1.0 ± 0.22-1.3 ± 0.23-1.1 ± 0.23-0.9 ± 0.24-1.2 ± 0.24-0.9 ± 0.22-1.0 ± 0.23
Week 15: Physical Mean Score-1.2 ± 0.20-1.3 ± 0.18-1.5 ± 0.19-0.9 ± 0.20-1.2 ± 0.20-1.4 ± 0.20-1.0 ± 0.19-1.2 ± 0.20
Week 15: Sexual Mean Score-0.6 ± 0.30-0.9 ± 0.28-1.5 ± 0.30-1.4 ± 0.30-0.6 ± 0.31-1.3 ± 0.32-0.6 ± 0.29-1.2 ± 0.30
Week 15: Overall Mean Score-1.1 ± 0.19-1.3 ± 0.18-1.5 ± 0.19-1.1 ± 0.19-1.2 ± 0.20-1.4 ± 0.21-1.0 ± 0.19-1.2 ± 0.20
Statistical analysis
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.1632 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.41 to 0.24
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0045 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.03 to -0.38
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0002 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.6 · 95% CI -2.43 to -0.77
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.9 · 95% CI -2.70 to -1.02
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.8569 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.91 to 0.76
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1110 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.49 to 0.15
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0187 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.83 to -0.17
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.4972 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.73 to 0.36
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.2568 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.86 to 0.23
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2609 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.86 to 0.23
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.4148 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.78 to 0.32
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5575 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.38 to 0.71
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.1671 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.4 · 95% CI -0.16 to 0.92
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9462 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.57 to 0.53
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0699 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.91 to 0.04
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0056 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.15 to -0.20
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1117 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.86 to 0.09
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0265 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.02 to -0.06
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1119 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.86 to 0.09
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.7607 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.54 to 0.40
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0437 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.97 to -0.01
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0211 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.51 to -0.12
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0017 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.1 · 95% CI -1.82 to -0.42
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0598 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.37 to 0.03
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.1573 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.5 · 95% CI -1.21 to 0.20
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.7257 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.83 to 0.58
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9324 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.72 to 0.66
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2172 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.14 to 0.26
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0742 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.88 to 0.04
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0035 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.16 to -0.23
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0266 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.99 to -0.06
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0124 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.06 to -0.13
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4367 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.65 to 0.28
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9318 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.48 to 0.44
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0714 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.89 to 0.04
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.2027 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.35 to 0.29
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0013 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -2.16 to -0.53
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.7 · 95% CI -2.53 to -0.87
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -2.83 to -1.16
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3791 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.19 to 0.45
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0211 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.78 to -0.15
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0021 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.3 · 95% CI -2.10 to -0.47
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.8890 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.55 to 0.48
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.5568 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.67 to 0.36
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3989 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.75 to 0.30
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.6094 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.66 to 0.39
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5229 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.35 to 0.69
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4409 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.31 to 0.72
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.8062 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.45 to 0.58
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.3663 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.71 to 0.26
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0424 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.99 to -0.02
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1597 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.85 to 0.14
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0595 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.97 to 0.02
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2162 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differnce: -0.3 · 95% CI -0.80 to 0.18
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9833 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.49 to 0.48
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2034 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.81 to 0.17
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.9576 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.70 to 0.67
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0410 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.7 · 95% CI -1.40 to -0.03
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3961 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.00 to 0.40
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.5012 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.94 to 0.46
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2592 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -1.10 to 0.30
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.6141 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.51 to 0.86
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.4390 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.95 to 0.41
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.4521 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.64 to 0.29
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0257 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.99 to -0.06
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0564 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.93 to 0.01
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.0293 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.99 to -0.05
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3742 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.68 to 0.26
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9106 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.49 to 0.44
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1844 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.78 to 0.15
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.0287 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.69 to -0.09
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0028 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.2 · 95% CI -2.05 to -0.43
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0004 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.5 · 95% CI -2.32 to -0.67
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = <0.0001 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -2.0 · 95% CI -2.87 to -1.22
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1826 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.38 to 0.26
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.0178 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -1.0 · 95% CI -1.79 to -0.17
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.0025 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differnce: -1.2 · 95% CI -2.06 to -0.44
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.9163 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.55 to 0.50
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1597 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.92 to 0.15
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.4871 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.74 to 0.35
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.5401 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.72 to 0.38
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.3788 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.30 to 0.79
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4541 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · 0.28: 0.2 · 95% CI -0.33 to 0.74
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9233 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.51 to 0.56
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.6043 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.61 to 0.35
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1781 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.82 to 0.15
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.5221 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.66 to 0.34
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.4744 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.68 to 0.32
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5167 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.66 to 0.33
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.3441 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.25 to 0.72
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.5362 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.64 to 0.33
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.9349 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.78 to 0.71
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0084 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -1.0 · 95% CI -1.78 to -0.26
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1212 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.38 to 0.16
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.7709 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.89 to 0.66
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1667 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.33 to 0.23
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9213 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.72 to 0.79
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2315 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.21 to 0.29
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.4731 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.63 to 0.29
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0310 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -0.98 to -0.05
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.1320 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.84 to 0.11
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.1212 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.85 to 0.10
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5689 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.62 to 0.34
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.7340 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · 0.1: 0.1 · 95% CI -0.39 to 0.55
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2704 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.73 to 0.20
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5610 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.24 to 0.67
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.7966 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.83 to 1.09
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.3965 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.4 · 95% CI -0.56 to 1.40
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.8189 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.87 to 1.10
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5693 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.27 to 0.70
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.5217 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -1.29 to 0.65
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.2988 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.5 · 95% CI -0.46 to 1.48
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.7957 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.69 to 0.53
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.2540 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.4 · 95% CI -0.97 to 0.26
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.6956 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.75 to 0.50
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.8694 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.57 to 0.68
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.5047 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.84 to 0.41
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.7515 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.52 to 0.71
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.7818 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.70 to 0.53
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5770 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.65 to 0.36
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1893 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.85 to 0.17
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.2997 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.3 · 95% CI -0.25 to 0.79
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.7529 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.60 to 0.44
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.4173 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.2 · 95% CI -0.73 to 0.31
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.4944 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.2 · 95% CI -0.34 to 0.69
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9231 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.0 · 95% CI -0.54 to 0.49
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5112 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean differencce: -0.3 · 95% CI -1.04 to 0.52
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.0300 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.9 · 95% CI -1.66 to -0.09
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.0634 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.8 · 95% CI -1.57 to 0.04
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9406 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.78 to 0.84
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.1168 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.6 · 95% CI -1.46 to 0.16
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.9937 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.0 · 95% CI -0.79 to 0.80
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.1858 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.5 · 95% CI -1.32 to 0.26
  • Placebo vs Fezolinetant 15 mg BID · MMRM · p = 0.5765 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.1 · 95% CI -0.65 to 0.36
  • Placebo vs Fezolinetant 30 mg BID · MMRM · p = 0.1848 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.86 to 0.17
  • Placebo vs Fezolinetant 60 mg BID · MMRM · p = 0.7299 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.43 to 0.61
  • Placebo vs Fezolinetant 90 mg BID · MMRM · p = 0.9415 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.54 to 0.50
  • Placebo vs Fezolinetant 30 mg QD · MMRM · p = 0.2742 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.3 · 95% CI -0.82 to 0.23
  • Placebo vs Fezolinetant 60 mg QD · MMRM · p = 0.6946 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: 0.1 · 95% CI -0.41 to 0.62
  • Placebo vs Fezolinetant 120 mg QD · MMRM · p = 0.9442 (LSM, SE, CI, \& p-values come from an MMRM model with CFB as dependent variable \& TG, visit \& smoking status as factors \& baseline measurement as a covariate, as well as interaction of treatment by week \& interaction of baseline measurement by week.) · Lsmean difference: -0.0 · 95% CI -0.53 to 0.50
SecondaryChange Over Time From Baseline in Plasma Concentrations of Luteinizing Hormone (LH) at Week 12

Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.

Time frame:
Baseline and week 12
Reported as:
Mean · International unit per liter (IU/L)
Change Over Time From Baseline in Plasma Concentrations of Luteinizing Hormone (LH) at Week 12
International unit per liter (IU/L)PlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Change Over Time From Baseline in Plasma Concentrations of Luteinizing Hormone (LH) at Week 12-1.14 ± 8.00-1.28 ± 8.53-3.28 ± 8.93-7.30 ± 15.49-10.86 ± 12.64-3.69 ± 11.21-3.97 ± 9.55-8.62 ± 11.95
SecondaryChange Over Time From Baseline in Plasma Concentrations of Follicle-Stimulating Hormone (FSH) at Week 12

Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.

Time frame:
Baseline and week 12
Reported as:
Mean · IU/L
Change Over Time From Baseline in Plasma Concentrations of Follicle-Stimulating Hormone (FSH) at Week 12
IU/LPlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Change Over Time From Baseline in Plasma Concentrations of Follicle-Stimulating Hormone (FSH) at Week 12-0.91 ± 9.79-1.52 ± 12.88-1.00 ± 13.51-6.49 ± 25.58-9.43 ± 17.40-0.98 ± 26.90-0.07 ± 8.97-9.94 ± 16.96
SecondaryChange Over Time From Baseline in Plasma Concentrations of Estradiol (E2) at Week 12

Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration. The analysis value for Estradiol was imputed as 73.4/2 = 36.7 when result was \< 73.4.

Time frame:
Baseline and week 12
Reported as:
Mean · picomole per milliliter (pmol/L)
Change Over Time From Baseline in Plasma Concentrations of Estradiol (E2) at Week 12
picomole per milliliter (pmol/L)PlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Change Over Time From Baseline in Plasma Concentrations of Estradiol (E2) at Week 121.49 ± 7.41-1.29 ± 53.5820.47 ± 93.3710.15 ± 96.52-4.85 ± 56.56-15.99 ± 213.04-32.08 ± 198.541.32 ± 5.68
SecondaryChange Over Time From Baseline in Plasma Concentrations of Sex Hormone-Binding Globulin (SHBG) at Week 12

Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.

Time frame:
Baseline and week 12
Reported as:
Mean · Nanomole per liter (nmol/L)
Change Over Time From Baseline in Plasma Concentrations of Sex Hormone-Binding Globulin (SHBG) at Week 12
Nanomole per liter (nmol/L)PlaceboFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Change Over Time From Baseline in Plasma Concentrations of Sex Hormone-Binding Globulin (SHBG) at Week 121.877 ± 12.2700.720 ± 14.2204.867 ± 10.4921.621 ± 16.3296.643 ± 11.1072.350 ± 17.8520.143 ± 8.7410.583 ± 14.283

Adverse events

Collected over From date of informed consent until end of the study (up to 15 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo BID0/43 (0%)0/43 (0%)5/43 (11.6%)
Fezolinetant 15 mg BID0/45 (0%)0/45 (0%)9/45 (20%)
Fezolinetant 30 mg BID0/43 (0%)0/43 (0%)7/43 (16.3%)
Fezolinetant 60 mg BID0/45 (0%)0/45 (0%)11/45 (24.4%)
Fezolinetant 90 mg BID0/44 (0%)0/44 (0%)11/44 (25%)
Fezolinetant 30 mg QD0/43 (0%)0/43 (0%)12/43 (27.9%)
Fezolinetant 60 mg QD0/45 (0%)1/45 (2.2%)14/45 (31.1%)
Fezolinetant 120 mg QD0/44 (0%)0/44 (0%)11/44 (25%)
Most frequent serious events
Most frequent serious events
EventPlacebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/430/450/430/450/440/431/450/44
Most frequent other events
Most frequent other events
EventPlacebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QD
HeadacheNervous system disorders2/433/452/432/451/446/433/454/44
NauseaGastrointestinal disorders1/431/453/433/451/442/433/452/44
Upper respiratory tract infectionInfections and infestations1/432/451/431/451/443/431/451/44
Urinary tract infectionInfections and infestations1/432/451/432/452/442/432/453/44
Viral upper respiratory tract infectionInfections and infestations0/432/451/431/453/440/430/450/44
DiarrhoeaGastrointestinal disorders1/430/451/432/452/441/433/450/44
FatigueGeneral disorders0/431/451/431/452/440/433/451/44
SinusitisInfections and infestations0/430/450/433/450/441/432/450/44
CoughRespiratory, thoracic and mediastinal disorders0/431/450/431/450/440/433/450/44

Baseline characteristics

The safety analysis set (SAF) consisted of all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
Mean54.8 ± 5.553.7 ± 5.053.9 ± 3.854.6 ± 5.054.9 ± 4.052.7 ± 3.855.0 ± 4.956.8 ± 4.454.6 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
Female4345434544434544352
Male000000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
Hispanic or Latino15169131017129101
Not Hispanic or Latino2829343234263335251
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
American Indian or Alaska Native100001002
Asian200100003
Native Hawaiian or Other Pacific Islander000000000
Black or African American1081215811101387
White3037312836313430257
More than one race000000000
Unknown or Not Reported000100113
Frequency of Moderate and Severe Vasomotor Symptoms per 24h
Frequency of Moderate and Severe Vasomotor Symptoms per 24h(VMS per day)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
Mean9.71 ± 3.5311.12 ± 7.139.85 ± 4.629.48 ± 3.979.32 ± 3.5911.18 ± 6.449.42 ± 2.709.65 ± 3.739.97 ± 4.71
Severity of Moderate and Severe Vasomotor Symptoms per 24h
Severity of Moderate and Severe Vasomotor Symptoms per 24h(Score on a scale)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
Mean2.46 ± 0.312.45 ± 0.272.43 ± 0.312.45 ± 0.312.38 ± 0.302.43 ± 0.302.40 ± 0.262.49 ± 0.322.44 ± 0.30
Frequency of Mild, Moderate, and Severe Vasomotor Symptoms per 24h
Frequency of Mild, Moderate, and Severe Vasomotor Symptoms per 24h(VMS per day)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
Mean9.96 ± 3.4911.63 ± 7.1010.33 ± 4.8810.14 ± 4.229.85 ± 4.3111.72 ± 6.6610.15 ± 2.8610.15 ± 3.7810.5 ± 4.88
Severity of Mild, Moderate, and Severe Vasomotor Symptoms per 24h
Severity of Mild, Moderate, and Severe Vasomotor Symptoms per 24h(Score on a scale)Placebo BIDFezolinetant 15 mg BIDFezolinetant 30 mg BIDFezolinetant 60 mg BIDFezolinetant 90 mg BIDFezolinetant 30 mg QDFezolinetant 60 mg QDFezolinetant 120 mg QDTotal
Mean2.43 ± 0.322.38 ± 0.292.37 ± 0.332.38 ± 0.362.33 ± 0.332.38 ± 0.342.31 ± 0.312.43 ± 0.372.38 ± 0.33
08

Study locations

51 sites
  • Research Site
    Anniston, Alabama 36207, United States
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Phoenix, Arizona 85023, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Oceanside, California 92056, United States
  • Research Site
    Panorama City, California 91402, United States
  • Research Site 052
    Sacramento, California 95821, United States
  • Research Site 058
    Sacramento, California 95821, United States
  • Research Site
    San Diego, California 92114, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Valley Village, California 91607, United States
  • Research Site
    Denver, Colorado 80209, United States
  • Research Site
    Milford, Connecticut 06460, United States
  • Research Site
    Crystal River, Florida 34429, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Jupiter, Florida 33458, United States
  • Research Site
    Lake Worth, Florida 33461, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Ormond Beach, Florida 32174, United States
  • Research Site
    Port Saint Lucie, Florida 34952, United States
  • Research Site
    Atlanta, Georgia 30312, United States
  • Research Site
    Norcross, Georgia 30092, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Champaign, Illinois 61820, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    Elkridge, Maryland 21075, United States
  • Research Site
    Watertown, Massachusetts 02472, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Norfolk, Nebraska 68701, United States
  • Research Site
    Las Vegas, Nevada 89123, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Williamsville, New York 14221, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Cleveland, Ohio 44122, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Clarksville, Tennessee 37040, United States
  • Research Site
    Kingsport, Tennessee 37660, United States
  • Research Site
    Houston, Texas 77058, United States
  • Research Site
    Hurst, Texas 76054, United States
  • Research Site
    Lampasas, Texas 76550, United States
  • Research Site
    Plano, Texas 75093, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Riverton, Utah 84065, United States
  • Research Site
    Charlottesville, Virginia 22911, United States
  • Research Site
    Vienna, Virginia 22182, United States
  • Research Site
    Seattle, Washington 98105, United States
  • Research Site
    Spokane, Washington 99207, United States
09

References and documents

Publications

  • Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020 Apr;27(4):382-392. doi: 10.1097/GME.0000000000001510. PubMed 32102086 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Sep 2018, 14 months.

Results were first posted in Sep 2021, 3 years after primary completion. A results delay was requested in Sep 2019.

Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2017
First posted
Jun 19, 2017
StartActual
Jul 19, 2017
Primary completionActual
Sep 19, 2018
CompletionActual
Sep 19, 2018
Results delay requested
Sep 4, 2019
Results first posted
Sep 29, 2021
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03192176
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
Jul 19, 2017
Primary completion
Sep 19, 2018
Completion
Sep 19, 2018
Results posted
Sep 29, 2021
Last update
Nov 26, 2024

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion